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Ágrip 
Sóri (e. psoriasis) er langvinnur ónæmismiðlaður bólgusjúkdómur í húð með sterkan 
erfðafræðilegan bakgrunn og veruleg neikvæð áhrif á lífgæði sjúklinga. Streptókokka 
hálsbólgur geta framkallað eða valdið versnun á einkennum hjá sumum sjúklingum, og 
nokkrar rannsóknir benda til þess að sóri geti batnað eftir hálskirtlatöku.  
Markmið rannsóknarinnar var að meta áhrif hálskirtlatöku á skellusóra með tilliti til 
klínískra, sálfélagslegra og ónæmisfræðilegra þátta ásamt því að kanna nánar tengslin milli 
hálsbólgu og sóra. 
Í upphafi var gerð slembiröðuð framskyggn samanburðarrannsókn þar sem 29 
sambærilegum sjúklingum með skellusóra, og sögu um versnun í tengslum við hálsbólgur, 
var skipt í tvo hópa. Annar hópurinn fór í hálskirtlatöku (n = 15) en hinn var 
viðmiðunarhópur (n = 14). Sjúklingarnir voru metnir með reglulegu millibili í 24 mánuði af 
lækni sem var blindaður með tilliti til hópaskiptingar. Síðar var 13 sjúklingum bætt við 
hálskirtlatökuhópinn en eftirfylgni þeirra var ekki blinduð og því voru gögn þeirra aðskilin 
upprunalega hálskirtlatökuhópnum. Breytingar á útbreiðslu og virkni sóra voru klínískt 
metnar með PASI skori (Psoriasis Area and Severity Index) og heilsutengd lífsgæði voru 
metin með Psoriasis Disability Index (PDI skali) og Psoriasis Life Stress Inventory (PLSI 
skali). Jafnframt var tíðni húðsækinna T eitilfrumna sem virkjast bæði af peptíðum 
streptókokka, og samsvarandi peptíðum sem eru yfirtjáð í sóraskellum (víxlvirkar T 
eitilfrumur) metin í blóði og hálskirtlum. HLA-Cw*0602 arfgerð var greind hjá öllum 
sjúklingum. Að lokum svöruðu 275 sórasjúklingar afturskyggnum spurningalista, en 
markmið hans var að meta hlutfall sórasjúklinga sem finna fyrir versnun á húðeinkennum við 
hálsbólgur.  
Hálskirtlatökuhópurinn sýndi marktækan viðvarandi bata samanborið við 
viðmiðunarhóp (p < 0.001). Meðal PASI skor hjá 13 af 15 (87%) sjúklinga lækkaði um 30% 
til 90% og nálægt 60% af sjúklingum náðu PASI 50 (50% lækkun á PASI skori). Sjúklingar 
greindu frá auknum lífsgæðum (p = 0.037) og minni sóra tengdri streitu (p < 0.002) eftir 
aðgerðina og marktæk fylgni var milli klínísks bata og aukinna lífgæða (r = 0.297, p = 0.008) 
og minni streitu tengdri sóra (r = 0.310, p = 0.005). Auk þess var sterk marktæk fylgni milli 
klínísks bata og fækkunar á víxlvirkum húðsæknum Tc17 (CD8+IL-17+, r = 0.560, p < 
0.001), Th17 (CD4+IL-17+, r = 0.452, p < 0.003) og Tc1 (CD8+IFN-γ+, r = 0.594, p < 
0.001) frumum. Engar samsvarandi klínískar, sálfélagslegar eða ónæmisfræðilegar breytingar 
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sáust meðal sjúklinga viðmiðunarhóps. Arfhreinir HLA-Cw*0602 sjúklingar sýndu marktækt 
meiri bata eftir hálskirtlatöku, bæði í formi klínískra einkenna (p < 0.001) og lífsgæða (p < 
0.001), samanborið við arfblendna og neikvæða HLA-Cw*0602 sjúklinga. Þannig höfðu allir 
arfhreinir HLA-Cw*0602 sjúklingar náð PASI 75 eftir 6 mánuði og PASI 90 eftir 12 mánuði. 
Að auki höfðu arfhreinir sjúklingar marktækt oftar fengið streptókokka hálsbólgur um ævina 
(p = 0.038), og þeir röktu oftar upphaf sóraútbrota sinna til hálsbólgu (p = 0.007). Afturvirki 
spurningalistinn leiddi í ljós að 42% sjúklinga með skellusóra höfðu fundið fyrir versun á 
húðeinkennum tengdum hálsbólgum. Að auki höfðu 72% af sjúklingum með skellusóra, sem 
höfðu greinst með streptókokkasýkingu í hálsi, fundið fyrir versnun á sóra. 
Þessar niðurstöður benda til náinna tengsla milli streptokokka sýkinga í hálsi og 
skellusóra, og að hálskirtlataka geti haft góð áhrif á bæði húðeinkenni og lífsgæði í undirhópi 
sórasjúklinga, sérstaklega hjá þeim sem eru HLA-Cw*0602 arfhreinir.  
 
 
Lykilorð: Sóri, hálskirtlataka, streptókokka sýking í hálskirtlum, heilsutengd lífsgæði, HLA-
Cw*0602. 
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Abstract 
Psoriasis is a chronic immune-mediated inflammatory skin disease with a strong genetic 
background and profound effects on psychosocial wellbeing. Streptococcal throat infections 
are known to trigger or exacerbate psoriasis in some patients, and several studies support the 
benefit of tonsillectomy.  
The aim of the study was to evaluate the clinical, psychosocial and immunological 
effects tonsillectomy has on plaque psoriasis and to define further the association between 
throat infections and the onset or exacerbation of psoriasis. 
Initially a prospective randomized controlled trial was conducted where 29 comparable 
patients with plaque psoriasis and a history of sore throat-associated psoriasis exacerbation 
were randomly selected to tonsillectomy (n = 15) or control (n = 14) groups. The patients 
were monitored for 24 months by the same observer, who was unaware of patients’ tonsil 
status. Later, 13 additional patients with plaque psoriasis were assigned to the tonsillectomy 
group, but analysed separately as their follow-up was not observer-blinded. The patients 
were evaluated clinically using the Psoriasis Area and Severity Index (PASI) and health-
related quality of life (HRQoL) and psoriasis-related stress were assessed with the Psoriasis 
Disability Index (PDI) and the Psoriasis Life Stress Inventory (PLSI). Immunological 
assessment consisted of enumeration of M/K peptide-reactive (responsive to homologous 
streptococcal M-proteins or skin keratin peptides) skin-homing T cells in tonsils and blood. 
All patients were genotyped for HLA-Cw*0602. Finally, a retrospective study-specific 
questionnaire, which sampled 275 patients with psoriasis, was used to estimate the 
proportion of patients with psoriasis with sore throat-associated psoriasis exacerbations. 
The tonsillectomy group showed a significant clinical improvement compared with the 
controls (p < 0.001). Mean PASI scores decreased by 30% to 90% for 13 out of 15 (87%) 
tonsillectomized patients and up to 60% of patients reached a PASI 50 response (50% 
reduction in PASI score). HRQoL and stress associated with psoriasis also improved 
significantly in the tonsillectomy group compared with the control group (p = 0.037 and p = 
0.002, respectively) with a significant positive correlation between clinical improvement and 
improved HRQoL (r = 0.297, p = 0.008) and psoriasis-related stress (r = 0.310, p = 0.005). 
Furthermore, there was a close correlation between the extent of clinical improvement and 
decrease in the frequency of circulating M/K peptide-reactive skin-homing Tc17 (CD8+IL-
17+, r = 0.560, p < 0.001), Th17 (CD4+IL-17+, r = 0.452, p < 0.003) and Tc1 (CD8+IFNγ+, 
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r = 0.594, p < 0.001) cells. No corresponding clinical, psychosocial or immunologic changes 
were observed among the controls. Patients who were homozygous for the HLA-Cw*0602 
allele improved significantly more after tonsillectomy, both clinically (p < 0.001) and in 
terms of improved HRQoL (p < 0.001) compared with heterozygous and HLA-Cw*0602-
negative patients. Thus, all HLA-Cw*0602 homozygotes achieved PASI 75 by month 6 and 
PASI 90 by month 12. Moreover, the homozygous patients had significantly more frequent 
streptococcal throat infections per lifetime (p = 0.038), and could more often trace the onset 
of their psoriasis to a sore throat (p = 0.007) than the heterozygous and HLA-Cw*0602-
negative patients. The retrospective study revealed that 42% of patients with plaque psoriasis 
have sore throat-associated psoriasis aggravations, and 72% of patients with plaque psoriasis 
with a confirmed streptococcal throat infection reported associated psoriasis exacerbation.  
These findings collectively suggest a closer association between streptococcal throat 
infections and plaque psoriasis than previously reported and that tonsillectomy can have a 
beneficial effect on both skin lesions and quality of life in a subset of patients with psoriasis, 
especially those that are homozygous HLA-Cw*0602 carriers.  
 
 
Keywords: Psoriasis, tonsillectomy, streptococcal throat infection, health-related quality of 
life, HLA-Cw*0602.  
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1  Introduction 
Psoriasis is a chronic immune-mediated inflammatory skin disease and probably the most 
prevalent autoimmune disease in humans.1,2 Psoriasis was first recognized as a specific 
cutaneous entity in 1808 by the English dermatologist Robert Willan,3 although its first 
description appeared in the 1st century AD, in a book by the roman scholar Celsus.4 In recent 
years, breakthrough advances have been made in understanding psoriasis, in terms of 
genetics, immunological mechanisms and environmental factors, of which all play a role in 
the pathogenesis of psoriasis. Although these advances have generated highly effective 
treatment options, a permanent cure for psoriasis is not yet available. Many fundamental 
questions remain unanswered about the aetiology and pathogenesis of psoriasis. The disease 
is a major burden on health care systems and the society in general and is a significant health 
burden to patients with a high degree of morbidity and reduced quality of life.5  
This thesis focuses on the effect of tonsillectomy on chronic plaque psoriasis and 
subsequent clinical, psychosocial and immunological changes. The association between 
psoriasis and β-haemolytic streptococci is also explored. The thesis summarizes the current 
literature on this subject and describes research performed from 2007-2012 in Reykjavik, 
Iceland resulting in new insights into psoriasis.  
1.1   Psoriasis 
1.1.1 Epidemiology 
Psoriasis is a common disease with a 2-3% worldwide prevalence.6,7 There is considerable 
geographic variation and prevalence in different populations is shown to vary from 0% to 
8.5%.7 Caucasians have a higher prevalence than other ethnic groups, and there is a certain 
trend of increased frequency of psoriasis in populations located farther from the equator.8-10 
It is likely that both genetic as well as environmental factors cause these variations. Hence, 
the prevalence of psoriasis in Sweden is 2%, 4.8-8.5% in Norway and 2.8% in the Faroe 
Islands7,9 but is currently unknown in Iceland. 
Psoriasis may appear at any age and has an equal distribution in both sexes.11 Studies 
have shown a bimodal distribution of age of onset, between 15 and 25 years and 50 and 60 
years.12  
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1.1.2   Clinical features 
Psoriasis varies highly in morphology, distribution, course and severity. As a 
papulosquamous disease, it is generally characterized by scaling papules and plaques. 
Psoriasis is usually divided into several phenotypes.  
1.1.2.1 Chronic plaque psoriasis 
Plaque psoriasis or psoriasis vulgaris is the most prevalent clinical phenotype and accounts 
for about 90% of all cases.13 It is characterized by sharply demarcated erythematous raised 
plaques with overlying silvery scale. The plaques are usually symmetrically distributed and 
commonly located on the scalp, lower back and extensor surfaces of the elbows and knees 
but any part of the skin can be involved. Plaque psoriasis is a heterogeneous phenotype and 
suggestions have been made for further subdivision. However, consensus is lacking on how 
subtyping should be performed. Based on the location of the plaques, plaque psoriasis can 
be divided into the following clinical subtypes (Figure 1): (1) Scalp psoriasis; (2) Nail 
psoriasis, occurring in 40-50% of plaque psoriasis, especially in patients with coexisting 
psoriasis joint disease.14 These include pitting, red spots in the lunula, leukonychia (white 
spots), onycholysis (separation of the nail from the nail bed) and subungal hyperkeratosis 
(thickening of the nail due to scaling);13 (3) Inverse psoriasis, involving the intertriginous 
areas such as the inguinal, genital, intergluteal, axillary and inframammary folds. The 
plaques are thin, well demarcated, shiny and usually without scaling; (4) Palmar and/or 
plantar psoriasis in weight-bearing areas of the soles and the center of the palms; (5) 
Sebopsoriasis, which is similar to seborrhoeic dermatitis and has a predilection for sebum-
rich areas of the body, scalp, eyebrows, nasolabial creases and chest. Plaque psoriasis can 
also be divided according to size or thickness of lesions (small vs. large, thin vs. thick 
plaque psoriasis) or stability of lesions (stable vs. unstable, dynamic or eruptive plaque 
psoriasis).13 In 1985 Henseler and Christophers15 classified plaque psoriasis into 2 distinct 
subtypes: (1) Type I, characterized by an early-onset (age at onset 40 years or less), 
frequently a positive family history of psoriasis, and carriage of the human leukocyte 
antigen (HLA)-Cw*0602 allele. Type I is more often associated with upper respiratory 
infections,16 and accounts for about 75% of patients; (2) Type II plaque psoriasis, a late-
onset disease (>40 years), with a distinct peak at 50-60 years, less often associated with 
carriage of the HLA-Cw*0602 allele and less frequently a family history of psoriasis.15 
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Figure 1. Chronic plaque psoriasis  
Photographs were obtained from subjects of this study, and reproduced with permission.  
1.1.1.1 Guttate psoriasis 
Guttate psoriasis is the second most common phenotype.17 Guttate derives from the Latin 
word gutta (a drop), but the clinical presentation is most often an acute eruption of 
numerous small (2-10 mm) drop-like erythematous scaly papules. Lesions are usually 
distributed on the trunk and proximal extremities and are more common in children and 
young adults. Guttate psoriasis is generally self-limiting within 3-4 months of onset, may 
intermittently recur, and in 33-68% of cases progress to plaque psoriasis.18,19 Patients with 
plaque psoriasis can also get guttate psoriasis flares.18  
A throat infection with beta (β)-haemolytic streptococci often precedes guttate psoriasis 
by 2-3 weeks.20-23 Streptococcal perianal infections have also been linked to the onset of 
guttate psoriasis.24 Case reports have linked the onset of guttate psoriasis with varicella,25 
and treatment with tumor necrosis factor-alpha (TNF-α) inhibitor therapy.26 In 75-100% of 
guttate psoriasis cases, patients carry HLA-Cw*0602.27,28 
1.1.1.2 Erythrodermic and pustular psoriasis  
Erythrodermic and generalized pustular psoriasis (GPP) are severe and rare variants of 
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psoriasis. Erythrodermic psoriasis presents with generalized erythema and fine scaling, 
covering the entire body, and may be precipitated by infections, drugs, withdrawal of oral 
corticosteroids and excessive alcohol intake. GPP often presents acute or subacute with 
widespread erythema and small superficial pustules. Both these psoriasis phenotypes are 
potentially life threatening.29,30 GPP may be a distinct entity from psoriasis but can occur 
concomitantly.31 
1.1.1.3 Palmoplantar pustulosis 
Palmoplantar pustulosis (PPP) is a painful chronic inflammatory condition that presents 
with sterile pustules on a scaly erythematous background, restricted to the palms and/or 
soles. It predominantly affects females in their 5th to 6th decade of life. Smoking as well as 
the use of TNF-α inhibitors is linked to the onset of PPP.32,33 PPP belongs to the pustular 
dermatoses,34,35 and does not share the same epidemiological, clinical and genetic profile as 
psoriasis.13,34,36 However, PPP coexists with plaque psoriasis in 20% of cases. PPP and 
plaque psoriasis possibly share common trigger factors. Streptococcal throat infections can 
cause exacerbation of both entities and studies indicate improvement of PPP after 
tonsillectomy.37-39  
1.1.2 Comorbidities 
Psoriasis is primarily a disease of the skin but accumulating data have indicated that patients 
with psoriasis have an increased risk of various other chronic and serious health conditions, 
known as comorbidities.40 Psoriasis can therefore be regarded as a multisystem chronic 
inflammatory disease associated with rheumatologic, cardiovascular, autoimmune, as well as 
psychiatric problems.41 Patients with early onset severe psoriasis have a significantly reduced 
life expectancy compared with the general population and patients with mild psoriasis, due to 
a higher risk for multiple comorbid diseses.42 Psoriasis comorbidities can be associated with 
psoriasis by shared genetic variants, activation of common inflammatory pathomechanisms 
or simply related to the persistence and chronic inflammation of the disease.43-45 Psoriatic 
arthritis (PsA) is, like psoriasis, considered a T cell driven inflammatory disease,6 present in 
6-48% of patients with psoriasis.46,47 Psoriatic arthritis usually develops several years after 
onset of skin lesions but up to 20% of patients get arthritis symptoms before any skin 
disease.48 Comorbidities also linked to psoriasis include depression,49 malignancy,50 
autoimmune disorders,51 type 2 diabetes,52 metabolic syndrome44,52 and cardiovascular 
diseases.53 
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1.1.3 Assessing psoriasis outcomes and quality of life 
The severity of psoriasis skin lesions can be assessed by several validated approaches, the 
Psoriasis Area and Severity Index (PASI), Physicians Global Assessment and the Body 
Surface Area.54 The commonly used PASI score combines the affected body surface area 
with severity of lesions into a single score, ranging from 0 (no psoriasis) to 72 (maximal).55 
The PASI score is quite reliable, especially when the same researcher does the scoring. 
However, routine clinical assessments such as the PASI do not address the psychosocial 
impact that psoriasis has on patients’ lives.  
Health-related quality of life (HRQoL) is an important patient-reported outcome used to 
assess psoriasis. HRQoL measures patients well-being with respect to health, in terms of 
physical, emotional, social and functional aspects.5 Although clinical improvements tend to 
correlate with improved HRQoL, studies indicate no direct correlation between HRQoL and 
PASI scores,56 and improvement of HRQoL is a major goal of psoriasis management. 
Several methods are available to measure HRQoL in psoriasis.57 These include generic 
questionnaires, disease-specific questionnaires such as the Dermatology Life Quality Index 
(DLQI),58 and psoriasis-specific questionnaires like the Psoriasis Disability Index (PDI)59 
and the Psoriasis Life Stress Inventory (PLSI).60  
Psoriasis is a chronic disease that has a significant negative impact on patients 
HRQoL.61 The visible nature of psoriasis can be strongly disabling and often associated with 
embarrassment, low self-esteem, psychological distress, stigmatization and limitation in 
skin-exposing activities.5,62 This may affect patients with psoriasis to the extent comparable 
to the effects of major medical diseases such as heart diseases, diabetes, depression and 
cancer.63 The National Psoriasis Foundation reported that 75% of patients with psoriasis, 
experience a moderate to large negative impact on quality of life.64 Despite major advances, 
psoriasis is still incurable and remains a major health burden to patients and the society.  
1.1.4 Histology  
Although psoriasis is primarily a clinical diagnosis, there are distinct histopathological 
features that can help diagnostically, especially when the clinical presentation is atypical. 
There is a rapid turn-over of the epidermis in psoriasis skin, as a result of increased 
proliferation and altered differentiation of keratinocytes.65 This causes thickening 
(acanthosis) of the skin and elongation of the epidermal rete ridges (downward projections of 
the epidermis which interlock with the papillary dermis), in combination with an 
inflammatory infiltrate in the dermis. The abnormal differentiation of keratinocytes in the 
upper epidermis leads to retention of nuclei in the stratum corneum (parakeratosis) and the 
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end result is scaling at the surface of the psoriatic plaques.66 Psoriatic keratinocytes express 
markers of proliferation such as keratins 6, 16 and 17 in the suprabasal layers of the 
epidermis in both involved and uninvolved skin.67,68 Inflammatory infiltrates are present in 
both dermis and epidermis. The dermal infiltrates consist of cluster of differentiation (CD) 
4+ and CD8+ T lymphocytes (T cells), antigen-presenting cells (APCs), including 
plasmacytoid dendritic cells (pDC) and dermal dendritic cells (DDc), macrophages, 
neutrophils and mast cells. In the epidermis CD8+ T cells predominate with Langerhans cells 
and neutrophils may form microabcesses in the stratum corneum (Munro microabcess) or the 
stratum spinosum (Kogoj microabcess).69 The redness of a plaque is due to increased 
formation, elongation and dilation of capillaries in the papillary dermis (angiogenesis), 
leading to a tortuous and fragile capillary network, close to the surface of the skin.66  
1.1.5 Genetics 
Psoriasis is a multifactorial complex genetic disease,70 indicating that multiple genetic 
determinants may be needed to generate the disease phenotypes in the presence of specific 
environmental conditions. Family and twin studies have demonstrated that psoriasis has a 
strong genetic basis and that a positive family history predisposes to a higher risk of 
psoriasis. Thus, the risk of developing psoriasis is 50% if both parents are affected and 16% 
if one of the parents has psoriasis.71 Twin studies in the USA and Denmark have shown a 
concordance rate of up to 70% for monozygotic twins and 20% for dizygotic twins.72,73 
However, in an Australian study the concordance rate of identical twins was 35% and 12% 
for dizygotic twins.74 This range of discordance in the monozygotic twins with psoriasis 
further suggests that the psoriasis phenotype is a complex interplay between genetic and 
environmental factors. Numerous pedigree studies have been carried out to elucidate further 
the genetic transmission of psoriasis.75-77 For instance, the unique segregation analysis by 
Lomholt on the prevalence of psoriasis in all 10,000 inhabitants of the Faroe Islands 
highlighted a multifactorial inheritance with a complex polygenic-environmental interplay.76 
In recent years, substantial progress has been made to identify the genetic components of 
psoriasis and genome-wide association studies (GWAS) have identified over 60 
susceptibility loci associated with psoriasis.78-82 However, the identities of many of the 
candidate genes remain unclear. Most genes implicated in psoriasis are involved in the 
adaptive or innate immune system as well as skin barrier function.83   
The psoriasis susceptibility locus 1 (PSORS1) is the most consistently reported genetic 
region with the strongest association with psoriasis.84 PSORS1 lies within a segment of the 
   
23 
major histocompatibility complex (MHC) on chromosome 6.84 The MHC is a chromosomal 
region that encodes for human leukocyte antigens (HLA), which are complexes expressed on 
the surface of all nucleated human cells with the function of presenting peptide antigens to T 
cells. In the MHC region are 3 different gene clusters, class I, II and III, and the class I genes 
encode for HLA-A, HLA-B and HLA-C. Class I HLA molecules form complexes with β2-
microglobulin and intracellular-derived peptides (antigens) from self-proteins or viruses and 
are recognized by CD8+ T cells or natural killer (NK) cells. Class II molecules present 
extracellular peptides. The likely causal gene within PSORS1 is HLA-Cw*0602, which 
encodes for the HLA class I molecule HLA-Cw6. HLA-Cw*0602 is associated with psoriasis 
in different populations, making it the prime psoriasis susceptibility allele.85-87 Interestingly, 
over 60% of patients with psoriasis carry 1 or 2 HLA-Cw*0602 alleles, whereas the 
frequency in general population is 10-15%.85,88 HLA-Cw*0602 accounts for 50% of psoriasis 
heritability,89-91 and heterozygous individuals (carrying 1 HLA-Cw*0602 allele) have a 10-
fold increased risk of developing psoriasis,28,92 whereas HLA-Cw*0602 homozygosity has a 
20-fold risk of psoriasis.92 Endoplasmic reticulum aminopeptidase (ERAP) 1 and 2 are genes 
associated with psoriasis that code for enzymes that trim peptides before they are loaded onto 
MHC I molecules and presented at the cells surface. The ERAP genes have been shown to 
interact with HLA-Cw*0602 and ERAP1 only confers susceptibility to psoriasis in 
individuals carrying the HLA-Cw*0602.90 This further reinforces the role of antigen 
presentation and subsequent T cell activation in the pathogenesis of psoriasis. 
Studies indicate that clinical subtypes of psoriasis might have different genetic 
backgrounds.93 HLA-Cw*0602 has been associated with guttate and eruptive plaque 
psoriasis,27,94-97 early onset psoriasis,15,27,96-99 familial psoriasis97 and female gender100 (Table 
1). Furthermore, frequent streptococcal throat infections or carriage96,101 and streptococcal-
associated psoriasis exacerbation27,96 have been linked to HLA-Cw*0602. HLA-Cw*0602 has 
also been associated with a risk for a higher incidence of Koebner phenomenon,27,96,97 and a 
more severe disease.27,96,97 Response to psoriasis treatment is also associated with different 
genotypes. Thus has HLA-Cw*0602 been linked to a more favourable response to UV light,27 
and 2 recent trials have shown that HLA-Cw*0602 predicts a better clinical response to the 
interleukin-12/23 inhibitor ustekinumab.102,103 Moreover, patients with early onset psoriasis 
respond better to etanercept than late onset psoriasis.104 Late onset psoriasis, usually HLA-
Cw*0602-negative, seems to be a milder and more stable disease and respond more often to 
topical agents.105 To a large extent, have HLA-Cw*0602-negative patients been shown to 
have more frequent psoriasis nail changes and a higher prevalence of PsA.23,96   
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Table 1. Some features of HLA-Cw*0602-positive and negative patients 
 HLA-Cw*0602-positive HLA-Cw*0602-negative 
Psoriasis phenotype Guttate and eruptive plaque Plaque 
Disease onset Early (≤ 40 years) Late (>40 years) 
Clinical symptoms Koebner phenomenon Psoriasis nail changes 
Clinical course More severe, often requiring  2nd
 
and 3rd
 
line treatments 
Less severe, responds more often 
to topical treatment 
Streptococcal association 
More often streptococcal carriage, throat 
infections and streptococcal-associated 
psoriasis exacerbation 
Currently unknown 
Familial psoriasis Higher frequency within families More often sporadic 
Response to treatment Better response to UV light, ustekinumab    and etanercept Currently unknown 
  
 A number of non-MHC genes have been implicated in psoriasis, some modify innate 
and adaptive immune responses, and others are involved in skin barrier function. A detailed 
discussion of psoriasis genetics is out of the scope of this thesis, however, many of these 
genes highlight the importance of abnormal T cell activation in psoriasis pathogenesis. 
Among these genes are those that involve regulatory cytokines and cytokine receptors in the 
interleukin (IL)-23/IL-17 axis such as the IL12B, IL23A and IL23R genes,91,106 as are genes 
involved in cytokine signal transduction pathways like the tyrosine kinase 2 (TYK2), 
TRAF3IP2 and nuclear factor kappa BIA (NFKBIA) genes. Other reported psoriasis 
susceptibility genes are involved in regulation of transcriptional factors such as runt-related 
transcription factor 3 (RUNX3) and signal transducer and activator of transcription 3 
(STAT3).107 Genes involved in skin barrier dysfunction include the late cornified envelope 
(LCE) genes,108 which incidentally have epistatic interactions with HLA-Cw*0602 and 
ERAP1.109 
1.1.6 Environmental risk factors 
Given that the highest reported concordance rate of psoriasis in monozygotic twins is 
70%,72,73 one can reasonably conclude that psoriasis is the result of interplay between 
genetic and environmental factors. A number of environmental stimuli have been identified 
that can both trigger the onset and cause aggravation of psoriasis (Figure 2). How these 
exogenous factors trigger or exacerbate psoriasis is not fully understood.  
 Throat infection with β-haemolytic streptococci is the most common infectious trigger 
for psoriasis (discussed in chapter 1.4). However, various other infections have been 
associated with psoriasis,110 These include Staphylococcus aureus,111 Helicobacter pylori,112 
Malassezia furfur,110 Hepatitis C virus113 and human immunodeficiency virus.110  
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Figure 2. Psoriasis environmental risk factors 
 Stress is a common psoriasis trigger and exacerbation factor.23,114 Often implicated are 
major stressful life events such as loss of a loved one, loss of a job or a divorce. However, 
even microstressors (daily hassle) can promote worsening of psoriasis.115 
Psoriasis may appear as a consequence of injury to unaffected skin, including physical, 
chemical, surgical or infective lesions. This is referred to clinically as the Koebner 
phenomenon and was first described by the German dermatologist Heinrich Köbner, in the 
18th century.116 With Koebner phenomenon the morphology of the psoriasis lesion is 
identical to the initiating injury and can be seen for example following mild skin scratches, 
venepuncture, tattoos, piercing and surgical scars.  
 Climate changes can affect psoriasis and generally, there is a higher prevalence of 
psoriasis in colder and less humid parts of the world.8 Many patients with psoriasis report 
that cold weather aggravates their psoriasis. Whether this is because of lack of sunlight and 
humidity has been debated. However, Lomholt reported that prolonged periods of low 
humidity could contribute to psoriasis exacerbation.76 Although sunlight and therapeutic 
phototherapy is beneficial to psoriasis, 5-20% of patients have photosensitive psoriasis,117 
where sun exposure and especially sunburn can cause exacerbation in their condition. This is 
more frequent in patients with a fair skin type, a history of photosensitivity, advanced age 
and psoriasis affecting hands.118  
A number of pharmacological agents have been linked with psoriasis aggravation, 
including beta-blockers, lithium, interferons and antimalarial drugs.119 Many other drugs 
have been implicated, such as angiotensin-converting enzyme inhibitors, angiotensin 
receptor blockers and terbinafin.120 
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Lifestyle can cause exacerbation of psoriasis. Smoking is a well-established trigger 
factor for PPP,121 but can also cause aggravation of  plaque psoriasis.122 Both smokers and 
former smokers have a greater risk of developing psoriasis than non-smokers,123 and 
cigarette smoking correlates with increased disease severity.124 Alcohol is another lifestyle 
factor that is implicated in the exacerbation of psoriasis.122 Patients who consume large 
quantities of alcohol tend to have a more severe psoriasis.124 Furthermore, patients with 
psoriasis have higher alcohol consumption and alcoholism is more prevalent.125,126   
It is postulated that hormones might trigger the onset of psoriasis, with peaks around 
puberty, postpartum and menopause. However psoriasis symptoms generally improve during 
pregnancy.12,127  
1.1.7   Brief summary of the immune system involved in psoriasis 
The immune system is traditionally divided into innate and adaptive arms. The innate 
immune system produces a fast acting, non-antigen specific response, which serves as a first 
line of defence against pathogens. The main components of the innate immune system are as 
follows: (1) Physical (epithelial surface) and chemical barriers (skin acidity, sebum); (2) 
Pattern-recognition receptors (PRRs) (toll-like receptors (TLR), nucleotide oligomerization 
domains (NOD)-like receptors and complement receptors); (3) Signaling molecules 
(cytokines, chemokines, antimicrobial peptides (AMPs)); (4) Epithelial cells lining the skin 
and mucosa; (5) Immune cells (mucosa-associated invariant T cells (MAIT), NK cells, 
dendritic cells (DCs), neutrophils and macrophages).128-131 PRRs are expressed by the cells 
of the innate system and detect conserved primitive molecular patterns (molecules) 
associated with bacteria and viruses. PRRs distinguish microbes from host cells, which can 
initiate an inflammatory cascade with the release of pro-inflammatory cytokines, chemokines 
and antimicrobial peptides. This is mediated by transcription factors such as nuclear factor 
(NF)-κB, and facilitates killing of microbes.132 If the innate immune system is unable to 
overcome the pathogen, or if the pathogen has been encountered before, the adaptive 
immune system is activated. 
The adaptive immune system is an antigen specific, second line defence system whereby 
protective immunological memory is generated. Adaptive immunity includes humoral 
immune response (antibodies) mediated by B lymphocytes (B cells) and cellular immune 
response mediated by T lymphocytes. DCs are crucial for activation of the adaptive immune 
system and thereby, link these 2 systems together. Thus, DCs in peripheral tissues are 
continuously sampling the microenvironment with their PRRs. Microbial proteins are 
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phagocytized and broken down inside the cell, before being expressed as short peptides 
bound to class II HLA molecules on the DC surface. The activated DCs migrate to the 
nearest draining lymph node, reside in the T cell area and present their peptide antigens to 
naïve T cells that can thereby be activated to become effector and memory T cells.133   
Following a first response to antigen, T cells expand clonally in the lymphoid tissues and 
become fully activated after 4-5 days. The activation involves: (1) signal 1, the T cell 
receptor (TCR) engagement; (2) signal 2, activation by co-stimulatory molecules and (3) 
signal 3, cytokine production, CD40L-CD40 or PRR binding. The resulting phenotype of T 
cells depends on the chemokines and cytokines that are present in the microenvironment 
during this priming event to direct an appropriate response. Microenvironmental factors also 
determine which tissue homing receptors the T cells express as activated T effectors cells. T1 
cells (type 1 helper (Th1) and cytotoxic (Tc1) T cells) secrete interferon gamma (IFN-γ) and 
TNF-α and usually express the cysteine-cysteine chemokine receptor (CCR) 5 and cysteine-
X-cysteine chemokine receptor (CXCR) 3. T17 cells (type 17 helper (Th17) and cytotoxic 
(Tc17) T cells) secrete IL-17 and express CCR6 and CCR4, and T22 cells (Th22 and Tc22) 
Table 2. Major cells involved in the pathogenesis of psoriasis  
A simplified summary of the major cells involved in psoriasis and their role 
Cells Role 
Myeloid dendritic cells 
(mDCs) 
Present antigens to T cells. Release TNF-α, iNOS, IL-12, IL-23, driving Th1 and T17 
differentiation 
Plasmacytoid dendritic 
cells (pDCs) Release IFN-α and -β that stimulate mDCs 
T cells Key cells in adaptive immune response. Recognize the antigen-MHC complex.  TCR, CD3+ 
T helper cells CD4+, interact with MHC II molecules. Involved in signal transduction and activation of other T-cells  
Th1 Induced by IL-12 and release IFN-γ and TNF-α. Involved in immune response against intracellular pathogens and autoimmunity 
Th17 Induced by IL-23, TGF-β, IL-6 and IL-21 and release IL-17 and IL-22. Involved in inflammation, defence against extracellular pathogens and autoimmunity 
Th22 Induced by IL-23, IL-6 and TGF-β, release IL-22. Involved in inflammation, induce keratinocyte acanthosis 
T cytotoxic cells,  
Tc1-Tc17-Tc22 
CD8+, interact with MHC I molecules. Induced by and secrete the same cytokines as 
Th1, Th17, Th22. Cytotoxic activity against intracellular pathogens 
Keratinocytes 
Key players in innate immunity, orchestrate innate and adaptive immune response. 
Recruit T cells to the skin and release CCL20, CXCL8, anti-microbial peptides, and 
pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, IL-23) 
Polymorphonuclear 
leukocytes (PMN) 
Effector cells of innate immunity. Show phagocytic properties against invading 
pathogens. Chemoattract other immune cells, release AMPs, proteases and IL-17 
Other cells involved  Natural killer T (NKT) cells, T regulatory cells, γδ T cells, mast cells, innate lymphoid cell etc. Function in psoriasis not fully understood 
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secrete IL-22 and express CCR4, CCR6 and CCR10.134,135 Expression of these chemokine 
receptors promotes homing of the cells to specific areas of inflammation. While primary 
responses and the generation of different subpopulations of effector and memory T cells 
mainly takes place in lymph nodes and other lymphoid tissues, lymphocyte homing is further 
nuanced by the expression of tissue-specific molecules. Thus, T cells that are destined to 
home to the skin express the cutaneous lymphocyte-associated antigen (CLA).136  
Once in the tissues, effector T cells, and tissue macrophages orchestrate an elimination 
of the pathogen and promote healing through complex interactions. Then most of the T cells 
are eliminated by apoptosis, but a few survive to become long-lived recirculating memory T 
cells or tissue resident memory T cells (Trm), that are thought to create a tissue-localized 
immunological memory. These cells have been suggested to play a role in the chronicity of 
immune-mediated inflammatory diseases and repeated viral infections of the skin such as 
herpes simplex virus.137 
1.1.8 Immunopathogenic mechanisms in psoriasis 
The pathogenesis of psoriasis is multifactorial, complex and not yet fully understood. It 
involves multiple cell types, their receptors and signaling molecules (short summary in Table 
2). Until the early 1980s, psoriasis was thought to be mostly an epidermal disease with 
aberrant proliferation of keratinocytes.138 However, the finding that cyclosporin A, an 
immunosuppressant drug, proved to be highly effective in psoriasis, revealed an important 
role for T cells in psoriasis.139,140  
For the past 3 decades, psoriasis has been regarded as an autoimmune disease where the 
T cells are key players.141-143 This is supported by several lines of research: (1) The presence 
of activated T cells in psoriasis lesions;144,145 (2) The efficacy of T cell targeted therapeutics 
in treating psoriasis;146,147 (3) Decrease in T cells with effective treatment;148,149 (4) Decrease 
in cytokines and cytokine receptors of T cells such as TNF-α, IFN-γ, IL-12/23, IL-17, IL-22, 
IL-23 with effective treatment;150,151 (5) Psoriasis has been induced152 or cured153 in patients 
with bone marrow transplants; (6) Severe combined immunodeficiency (SCID, without T 
and B cells) mice transplanted with uninvolved skin from patients with psoriasis, developed 
psoriasis after intradermal injections of activated T cells;154 (7) Inhibiting the entry of T cells 
into mouse epidermis prevents epidermal hyperplasia and psoriasis.155  
There is increasing evidence that the development of psoriasis involves dysregulated 
interactions between the epidermal keratinocytes and the innate and adaptive immune 
systems, impacted by environmental and genetic factors.156,157 Research in the last decade 
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has lead us to model of psoriasis pathogenesis that is described as the IL-23/Th17/IL-22 axis 
of psoriasis (Figure 3).158 In genetically predisposed individuals, the immune system can 
become activated by various triggers. The exact mechanisms in this induction phase are not 
yet understood for many environmental factors, such as streptococcal infections and it can be 
difficult to pinpoint the specific triggers in each and every individual.156 However, other 
triggers such as physical trauma might initiate the cascade by causing injured or stressed 
keratinocytes, which in turn release various antimicrobial peptides. Lande and Gilliet 
suggested a model of psoriasis initiation phase with the antimicrobial peptide leucine-leucine 
37 (LL-37) cathelicidin that forms complexes with self-DNA released from necrotic cells.159-
161 In this view, self-DNA is turned into a pro-inflammatory stimulus that breaks 
immunologic tolerance. The LL-37/self-DNA complexes bind to intracellular TLR9 on pDCs 
and LL-37/self-RNA complexes activate pDCs through TLR7 and thereby initiate the 
inflammatory cascade.162-164 Injured keratinocytes also produce high levels of cysteine-
cysteine chemokine ligand (CCL) 20, which attracts mDCs, neutrophils and T17 cells into 
psoriasis skin.165,166 Subsequently, mDCs are activated by the local inflammatory settings 
created in the skin by secretion of cytokines like IL-1β, IL-6 and TNF-α from stressed 
keratinocytes and by IFN-α and -β from the pDCs.166 In addition, the LL-37/RNA complex 
can activate mDCs via TLR8.156 The mDCs then migrate to the nearest draining lymph node 
where they drive the differentiation of naïve T cells to effector T cells; Th1 and Tc1 
stimulated by IL-12, Th17, Tc17, Th22 and Tc22 stimulated by IL-23. Despite years of 
research it still remains debatable what antigen is presented during the activation of these T 
cells in the lymph node. It has been proposed that LL-37, amongst a number of 
candidates,142,167 is an autoantigen in psoriasis, which drives both the activation of innate and 
adaptive inflammatory responses in psoriasis. The effector T cells migrate to inflamed skin, 
as they have become skin-homing T cells, expressing CLA. Activated mDCs secrete a 
plethora of cytokines including IL-12, which further stimulates Th1 and Tc1 cells to produce 
IFN-γ and TNF-α, and IL-1 and IL-23 which drive the expansion of Th17 and Tc17 cells, 
producing IL-17.  
Many of the T cell-derived cytokines work co-operatively driving keratinocyte 
activation: TNF-α and IL-17 strongly induce CCL20, recruiting T cells and induce neutrophil 
recruitment by stimulating cysteine-X-cysteine chemokine ligand (CXCL) 1, CXCL2 and 
CXCL8 release. Activated mDCs and to a limited extent keratinocytes secrete IL-23, which 
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Figure 3. The IL-23/Th17/IL-22 axis  
Trigger factors can cause injured keratinocytes (KCs) in the epidermis, which in turn activate plasmacytoid 
dendritic cells (pDCs) and myeloid dendritic cells through their Toll-like receptors (TLRs) and antimicrobial 
peptide LL37. CCL20 attracts mDCs and T17 cells. The activated mDCs stimulate expansion of T cells in the 
psoriatic lesion with cytokines; IL-12 (Th1, Tc1), IL-23 (T17, Th22, Tc22). The T cells produce cytokines that 
further stimulate the keratinocytes, IL-17 (T17), IFN-γ (Th1, Tc1), IL-22 (Th22, Tc22), thus a vicious 
inflammatory cycle is created. Reproduced with permission.156 Copyright Elsevier Inc. 
maintains the T17 and T22 cells and in return these cells produce a series of pro-
inflammatory cytokines, IL-17 and IL-22. This leads to synthesis of antimicrobial peptides 
and hyperproliferation of the keratinocytes that respond by producing more cytokines and 
chemokines.168,169 Thus, a vicious cycle of chronic inflammation is established. Trm remain 
in skin after resolution of psoriasis lesions with treatment, waiting to be reactivated. These 
cells produce IL-17 and IL-22 upon activation and might explain the reoccurrence of 
psoriasis at the same anatomic site.170  
1.2 The palatine tonsils 
The paired palatine tonsils are located in the lateral wall of the oropharynx, at the entrance to 
the gastrointestinal and upper respiratory tract. They are the first major barrier protecting us 
from invading pathogens, both airborne and alimentary.171 The tonsils are part of the 
mucosa-associated lymphoid tissues (MALT) and form a protective immunological ring 
(Waldeyer´s ring) with the nasopharyngeal tonsil (adenoids), the paired tubal tonsils and the 
lingual tonsils, although the function of the tonsils is similar to lymph nodes171,172 The 
palatine tonsils are covered with a stratified squamous epithelium that extends into deep 
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branched crypts, thereby giving rise to an enlarged surface area.172 The surface of the crypts 
is lined by reticulated epithelium, often only one cell thick.172 The reticulated crypt 
epithelium is ideal for productive antigen sampling with its unique cellular composition of 
epithelial cells, stromal cells, intraepithelial lymphocytes, dendritic cells, macrophages and 
neutrophils situated in close proximity. Under the epithelium are multiple lymphoid follicles 
with germinal centers surrounded by a connective tissue framework. The follicles are rich of 
B cells in different developmental stages, but the peripheral mantle zone, surrounding the 
germinal centers, is densely populated by T cells, with a relatively high CD4:CD8 T cell 
ratio.173 Recurrent infections with or without enlargement (hypertrophy) are the most 
common tonsil diseases, which can lead to removal of the tonsils by tonsillectomy. 
1.3   Streptococci 
The Streptococcus is a spherical Gram-positive bacterium. Some Streptococcus species are 
highly virulent and can cause infections. However, many are not pathogenic and form part of 
the healthy human microbiota of the skin, mouth, respiratory tract and intestine. Species of 
streptococci are classified based on their haemolytic properties: α-haemolytic streptococci 
cause partial haemolysis on blood agar by secreting hydrogen peroxide, whereas β-
haemolytic streptococci cause complete haemolysis by secreting streptolysin. The β-
haemolytic streptococci are further classified to 20 known Lancefield serotypes, groups A to 
V, according to their carbohydrate surface antigens. Group A β-haemolytic streptococci 
(GAS), especially Streptococcus pyogenes, are responsible for a wide range of invasive and 
non-invasive infections, and post-infectious immune-mediated disorders. GAS are the most 
common bacterial cause of acute pharyngitis, accounting for 5-10% of cases in adults and 
15-30% in children,174 but group C and G streptococci (GCS and GGS) can also cause 
pharyngitis.175 Autoimmune syndromes following GAS infections include acute rheumatic 
fever, rheumatic heart disease and post-streptococcal glomerulonephritis.176 The 
Streptococcus anginosus group belongs mostly to the non-β-haemolytic streptococci group 
but some anginosus strains carry a typable Lancefield group antigen, A, C, G or F.177 
Streptococcus anginosus often resides commensally in the human oral cavity but can give 
rise to pharyngitis.178  
Although traditionally an extracellular pathogen, the β-haemolytic streptococci are able 
to survive within macrophages179 and epithelial cells,180,181 which has been associated with 
persistent streptococcal carriage and recurrent infections.182,183 Streptococci possess 
virulence factors that help them penetrate host tissues and counteract the host’s immune 
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system, including M proteins, streptolysins and superantigens. The M proteins are a major 
streptococcal virulence factor and highly immunogenic. They are expressed on the surface of 
group A, C and G streptococci and are involved in adhesion to surfaces, cell invasion and 
interruption of host phagocytosis.180,184,185 Over 200 different M proteins types exist, and 
these are used to classify group A, C and G streptococci.186 Streptolysin O is an exotoxin 
released by β-haemolytic streptococci and antibodies to streptolysin O (ASO titres) can be 
measured to indicate a recent streptococcal infection. Streptococcal throat infections are most 
common in children between 5 and 15 years, often around puberty.175,187 Interestingly, the 
onset of psoriasis is often around puberty, especially guttate psoriasis. 
1.4   The involvement of streptococci in psoriasis 
The association between streptococcal throat infections and the onset of guttate psoriasis was 
first reported about 100 years ago,188 and has since then been confirmed in many studies. 
Patients with psoriasis have higher ASO titers than both controls and the general population, 
with patients with guttate psoriasis having the highest titers.20,21,189,190 Streptococcal throat 
infections precede guttate lesions by 1-3 weeks in 56%-97% of guttate cases,191 and guttate 
patients have a higher frequency of throat β-haemolytic streptococci compared with 
controls.192 Mallbris et al. reported that 84% of guttate patients had disease onset associated 
with a recent infection, of which 63% had a confirmed streptococcal throat infection. 
However, only 7% of patients with newly diagnosed plaque psoriasis had streptococcal 
pharyngitis. This difference can partly be explained by earlier medical attention for guttate 
psoriasis, due to the sudden onset and extensiveness, compared with a slower onset of plaque 
psoriasis.23 Recently it was reported that streptococcal extracts induce circulating memory 
CLA+ T cells, in guttate patients, to show a Th17 dominant response when co-cultured with 
epidermal cells. The response was especially prominent in HLA-Cw*0602-positive patients 
with a history of streptococcal-associated psoriasis exacerbation.193  
The association between streptococci and chronic plaque psoriasis is less well 
examined. Tervaert et al. reported that 20-30% of plaque patients had positive streptococcal 
throat cultures and raised ASO titers,194 and increased serum IgG levels against 
Streptococcus pyogenes have been reported in plaque patients.195 Furthermore, recurrent 
sore throats have been shown to be 3 times more common in patients with plaque psoriasis 
than age and sex matched controls.196 In line with this, Gudjonsson et al. followed over 200 
patients with plaques psoriasis and matched household controls over the course of a year. 
Almost 30% of the patients got sore throats compared with only 2.6% of the controls and β-
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haemolytic streptococci were 10 times more often cultured from patients’ tonsils.197 We 
have reported a 44% combined carrier rate for groups A, C and G streptococci in patients 
with plaque psoriasis and a history of sore throat-associated psoriasis exacerbation, which 
was significantly more compared with recurrently infected tonsils from patients without 
psoriasis.198  
It has been suggested that patients with psoriasis are more susceptible to streptococcal 
throat infections because of their genetic background. Carriage of HLA-Cw*0602 is 
associated with increased frequency of streptococcal throat carriage/infections96,101 and 
streptococcal-associated psoriasis exacerbations.27,101 Streptococci can induce the 
production of key psoriasis cytokines (IL-17, IL-22 and IFN-γ) in circulating CLA+ 
memory T cells cultured together with both lesional and nonlesional epidermal cell from 
psoriasis patients.199 These observations indicate that streptococci are involved in 
pathological mechanisms of psoriasis, such as keratinocyte activation and IL-17 production. 
Long-term antibiotic treatment for psoriasis has been reported. Two recent studies have 
shown the benefits of both intra muscular penicillin and oral azithromycin.200,201 However, 
other studies have not supported a beneficial effect of antibiotics on psoriasis.202-204 
Antibiotics can reduce the bacterial load in the tonsils, but there are reservoirs of intracellular 
streptococci in the tonsillar epithelial cells and macrophages,182 which can reactivate, 
recolonize and cause symptoms again. Tonsillectomy, on the other hand, should remove the 
entire pool of tonsil streptococci. Streptococcal throat infections have also been linked to 
exacerbation of PPP, especially α-haemolytic streptococci,205,206 and studies have shown that 
PPP can improve after tonsillectomy.37-39 
Proposed mechanisms for the association between psoriasis and streptococci include the 
following 3 hypotheses: (1) Superantigen induced immune response; (2) Molecular mimicry 
triggered T cell mediated autoimmune response; (3) Innate immune-mediated inflammatory 
response caused by peptidoglycans. Each of them will be explained in more detail in the next 
3 subchapters.  
1.4.1 Superantigen induced T cell activation 
Streptococcal superantigens (SAgs) are extracellular protein toxins that bypass conventional 
antigen processing. They bind directly to the MHC class II molecule and the TCRs variable 
region of the β chain (Vβ).207 Moreover, the superantigens can bind to more than 1 Vβ 
region. This leads to non-specific polyclonal T cell activation of a relatively large number of 
T cells, with massive release of pro-inflammatory cytokines, which can circumvent the 
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formation of an antigen-specific immune response.208 Superantigens and inflammatory 
mediators such as IL-12 released during a streptococcal pharyngitis can induce the 
expression of the skin-homing molecule CLA on effector T cells, facilitating their homing to 
the skin.209,210 The hypothesis of superantigen induced psoriasis is based on reports of Vβ 
restricted T cell proliferation in psoriasis skin, consistent with superantigen stimulation,211,212 
and selective expansion of Vβ2+ T cells, induced by the superantigen speC in guttate 
patients with a streptococcal throat infection.213 However, Vβ analysis of T cells in the blood 
of patients with plaque psoriasis has not supported a role of superantigens.214 Furthermore, 
numerous studies have demonstrated an oligoclonal T cell expansion in plaque lesions, 
indicating that the process is driven by specific antigen(s), rather than a superantigen-
mediated process (reviewed in142). 
1.4.2   Molecular mimicry 
Molecular mimicry is created when amino acid sequences of self-peptides are sufficiently 
similar to pathogen-derived peptides to give rise to cross-activation of autoreactive T cells. 
Once activated, the cross-reactive T cells can initiate an autoimmune reaction, leading to 
inflammation and tissue damage.215  
A number of studies have consistently indicated oligoclonal T cell expansion in psoriasis 
skin,216-221 suggesting a major role for antigen-specific T cells in psoriasis.142 Valdimarsson 
et al. proposed over 20 years ago that psoriasis might be initiated by a streptococcal 
tonsillitis and maintained by means of molecular mimicry between streptococcal and self-
antigens.141 A structural sequence homology between streptococcal M proteins and human 
keratins had then already been reported.222 Tonsils from patients with psoriasis have an 
increased number of skin-homing T cells compared with patients without psoriasis.198 T cells 
showing increased responses against streptococcal protein extracts and M proteins have been 
detected in the blood of patients with psoriasis but not in patients with atopic dermatitis or 
healthy controls.223-228 Furthermore, T cells from patients with psoriasis show increased 
responses to homologous peptides from M proteins and epidermal keratins 16 and 
17,224,229,230 that are highly upregulated in psoriasis skin.67 Moreover, when peripheral blood 
lymphocytes were stimulated with keratin peptides that share amino acid sequences with 
streptococcal M proteins, Johnston et al. found that the skin-homing CD8+ T cells and not 
the CD4+ T cells responded to these peptides. This was most pronounced in HLA-Cw*0602-
positive patients.224 In line with this, Prinz et al. isolated T cells with the same clonal T cell 
receptor Vβ gene rearrangements from tonsils and skin, indicating a mutual origin. These 
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patients had streptococcal-associated psoriasis exacerbations, and all experienced long-term 
remission after tonsillectomy.231 Collectively these findings indicate that psoriasis may be a 
consequence of cross-reactive T cells reacting with epitopes from streptococcal M-proteins 
in the tonsils and epidermal keratins in the skin, and thus be a molecular mimicry based 
autoimmune disease.141,142,232  
Homologies between human keratins and the streptococcal peptides RopA, RecF and 
FcR have been reported,233 and keratin peptides that react with antibodies against 
Streptococcus pyogenes, including keratin 6, ezrin, maspin, peroxiredoxin 2 and HSP27 have 
been identified.233 
1.4.3 Peptidoglycans 
The third hypothesis involves peptidoglycans (PGN), which are a major constituent of the 
cell wall of Gram-positive bacteria, including streptococci. They enable bacteria to resist 
osmosis234 and are recognized by peptidoglycan receptor proteins in tonsils, skin and gut, 
facilitating the killing of bacteria (reviewed by235,236). PGN are also recognized by TLRs and 
thereby initiate an immune response. It has been suggested that the innate immune system in 
psoriasis is continually stimulated by PGN within the skin and PGN containing cells (mostly 
macrophages) are found more frequently in close proximity to CD4+ T cells in lesional skin 
compared with normal or non-affected skin. PGN originating from tonsils have also been 
shown to trigger Th1 mediated response in psoriasis skin, and CD4+ T cells respond in an 
HLA-restricted way to peptides associated with PGN by producing IFN-γ.237,238 
1.5   Psoriasis and tonsillectomy 
Tonsillectomy is defined as the surgical excision of the palatine tonsils. The major 
indications for tonsillectomy are recurrent infections or obstruction caused by hypertrophic 
tonsils.239,240 Most patients have an uncomplicated post-operative course, but potential 
adverse events include postoperative bleeding, infection, laryngospasm and broncho-
spasm.241  
 The question of whether tonsillectomy is beneficial for psoriasis has long been disputed. 
Several studies have reported considerable clinical improvement of psoriasis after 
tonsillectomy and 3 reviews have recently summarized these studies.242-244 Rachakonda et al. 
concluded that 290 out of 410 (70%) patients with psoriasis improved after the procedure 
and that tonsillectomy may be beneficial in selected cases of therapy-resistant psoriasis with 
a tendency to chronic tonsillitis and associated psoriasis exacerbations.242 In the past 53 
years, 23 studies have been published on the effect of tonsillectomy on psoriasis (Table 3). 
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One of those is a prospective randomized controlled trial,245 which details are elaborated in 
the results and discussion sections of this thesis and in papers I and II.  
Three prospective controlled studies have been published on the effect of tonsillectomy 
on psoriasis.246-248 Ponomareva246 (1965) reported improvement in 8 out of 9 
tonsillectomized patients and Cepicka and Tielsch247 (1967) showed complete clearance in 
34 of 56 (61%) of tonsillectomized patients for 2-5 years, compared with 8 of 36 (22%) of 
controls. Nesterenko et al.248 (1972) reported improvement of 34 of 66 (52%) 
tonsillectomized patients, compared with 3 of 35 (9%) of controls. The authors of these 3 
studies did not provide information on clinical subtypes of psoriasis.  
Three prospective uncontrolled observational studies have been published.249-251 
Lukovskii et al.251 (1970) studied 57 patients with psoriasis and chronic tonsillitis where 51 
(89%) cleared or improved after tonsillectomy. Furthermore, 44% were still completely clear 
of psoriasis after 6-10 years. Kataura and Tsubota249 (1996) studied 35 patients with plaque 
psoriasis and reported that 49% of them improved following tonsillectomy. Interestingly, the 
procedure was more effective in women, where 84% of the women improved, compared with 
only 31% of the men. Furthermore, the tonsillectomy proved to be more effective in younger 
patients. The same year, Hone et al.250 (1996) studied a mixed group of patients with 
recalcitrant guttate (n=6) and plaque (n=7) psoriasis. All patients with guttate psoriasis 
improved, and 5 cleared completely. Four out of 7 patients with plaque psoriasis improved 
after the tonsillectomy, thereof 2 that became completely cleared of psoriasis. 
Three published studies are retrospective.252-254 Nyfors et al.252 (1976) reported 
improvement of in 72% of patients with psoriasis vulgaris refractory to topical treatments, 
with complete clearance in 24 out of 74 (32%) and a considerable improvement in 29 (39%). 
Interestingly, the authors also reported an improvement in patients without a history of sore 
throat-associated psoriasis exacerbation. However, the study was based on a retrospective 
questionnaire and thus subjected to recall bias. Ozawa et al.253 (1999) conducted a study on 
patients with generalized pustular psoriasis where 2 out of 12 tonsillectomized patients 
improved. Bucolo et al.254 (2013) recently published improvement of 5 plaque and 8 guttate 
patients with sore throat-associated psoriasis exacerbation. Six out of 8 patients with guttate 
psoriasis clinically improved with a PASI reduction ranging from 50-90%, lasting 6 months 
to 5 years. In 3 out of 5 of the patients with plaque psoriasis the PASI scores improved from 
50-100% and the improvement lasted 6 months to 12 months.  
Five case series have been published.255-259 Tytar et al.255 (1968) reported an 
improvement of 22 out of 29 (76%) patients with psoriasis, of which 13 (45%) completely 
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cleared. Bukharovich et al.256 (1971) reported a complete clearance of 14 patients with 
psoriasis and chronic tonsillitis. Fukunaga257 (1974) reported an improvement in 4 out of 5 
tonsillectomized patients, of which 3 completely cleared. Rosenberg et al.258 (1998) reported 
improvement of 14 patients, colonized by throat streptococci unresponsive of antibiotics, 
whereas 9 (65%) had complete clearance. Takahara et al.259 (2001) followed up 7 
tonsillectomized patients with psoriasis for 2–9 years. Three patients completely cleared and 
2 patients were 80% clear of psoriasis.  
Eight case reports are reported in the literature.21,231,260-265 Vovk and Testemitsanu260 
(1963) reported an improvement of psoriasis and psoriatic arthritis, aggravated by tonsillitis. 
Saita et al.262 (1979) described the complete clearance of 2 young sisters that developed 
guttate psoriasis 1 week after a sore throat. McMillin et al.264 (1999) reported a complete 
remission of 2 children with psoriasis and a history streptococcal throat infection. The group 
of Prinz231 (2006) reported 3 patients with therapy-resistant plaque psoriasis with guttate 
flares that were clear of psoriasis for 3 years after tonsillectomy. Interestingly, they reported 
the same T-cell receptor beta-chain variable region gene rearrangements within the skin and 
tonsils of these patients, suggesting a recirculation to the skin after activation in the tonsils. 
Simoes et al.265 (2015) recently reported a case of severe therapy-resistant plaque psoriasis 
with recurrent acute pharyngitis and associated psoriasis exacerbation. Lesions almost 
completely cleared within 4 months with PASI decreasing from 26.8 to 1, lasting at least 2 
years. 
All of the above studies suggest a beneficial effect of tonsillectomy on psoriasis, at least 
in selected patients. In summary, the 23 studies included 436 cases; 141 plaque, 20 guttate, 
12 GPP, and 263 unspecified psoriasis. Of those 436 cases, were 323 (74%) patients that 
improved after tonsillectomy; 99 (70%) with plaque psoriasis, 18 (90%) with guttate 
psoriasis, 2 (17%) with GPP and 192 (73%) of the unspecified psoriasis group. However, 
most of the data are based on case reports, case series and retrospective studies, without 
randomization and control groups, making it more difficult to draw concrete conclusions. 
Furthermore, many of the reports lack specification of psoriasis phenotype studied and in 
the older studies outcome measures are not standardized in terms of PASI scores or other 
psoriasis severity measures. Thus, a well-conducted randomized controlled trial on the 
effect of tonsillectomy on psoriasis was needed. 
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Table 3. Published studies on the effect of tonsillectomy on psoriasis 
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2 Aims 
The association between streptococcal throat infection and psoriasis prompted the following 
working hypothesis: As the palatine tonsils have the components required for sampling and 
presenting antigens to naïve lymphocytes, they might prime streptococcal antigen-specific T 
cells that subsequently migrate from the tonsils into the skin where they may recognize 
keratin antigens that share amino acid sequences with streptococcal peptides, resulting in 
eruption of guttate or worsening of plaque psoriasis. 
 
The overall aim of this thesis was to test this hypothesis, and to evaluate tonsillectomy as a 
treatment option for patients with chronic plaque psoriasis.  
 
First, we aimed to evaluate, in a prospective randomized controlled trial the clinical and 
immunological effect of tonsillectomy on plaque psoriasis, by assessing disease severity 
(PASI score), and frequency of circulating T cells that recognize antigen entities that are 
shared by streptococcal M proteins and skin (paper I). 
 
Second, we aimed to evaluate the psychological and social impact of tonsillectomy on plaque 
psoriasis by measuring health-related quality of life (paper II). 
 
Third, we aimed to estimate the proportion of patients who would most likely have the 
greatest benefit from tonsillectomy, by evaluating the frequency of sore throat and/or 
streptococcal-associated exacerbations in patients with plaque psoriasis and establishing 
whether HLA genotype can aid this identification (paper III and IV). 
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3 Materials and methods 
3.1   Study approval 
The National Bioethics Committee of Iceland (VSNb2006090015/03-15), the Data 
Protection Authority of Iceland and the Ethics Committee of Landspitali-The National 
University Hospital of Iceland approved the study. It was performed in compliance with the 
1964 Declaration of Helsinki and its later amendments. 
3.2   Study design 
A single center, 24-month, prospective, observer-blind, parallel, randomized controlled trial 
(RCT) was carried out to examine the clinical, psychosocial and immunological impact of 
tonsillectomy on patients with chronic plaque psoriasis (Paper I and II). A prospective case 
series was performed to explore if HLA-Cw*0602 carriage was associated with a favourable 
outcome after tonsillectomy (Paper III). Data were collected between November 2007 and 
January 2011, within the departments of Dermatology, Immunology and Otolaryngology-
Head and Neck Surgery at Landspitali-The National University Hospital of Iceland. A large 
retrospective case series was carried out from January 2011 to April 2011 to estimate the 
proportion of patients with psoriasis who have experienced exacerbation in association with 
sore throat, and might therefore be more likely to benefit from tonsillectomy (Paper IV). 
Data were collected at the dermatology outpatient center at Landspitali-The National 
University Hospital of Iceland, Hudlaeknastodin dermatology clinic, Kopavogur and the 
Blue Lagoon geothermal clinic, Grindavik. 
3.3   Participants and randomization 
Recruitment and screening of patients for the RCT took place from November 2007 to 
November 2008. Each patient gave written informed consent before initiation of study 
participation and 54 patients were screened. Most patients were referred by dermatologists 
(44%) or responded to advertisement (46%). A few patients heard about the study by other 
means (6%) and otolaryngologists referred 2 patients (4%). Key inclusion criteria are listed 
in Table 4. Before the patient recruitment began, the study supervisor created a sealed 
numerical allocation sequence, done with a simple randomization in a 1:1 ratio. Twenty-nine 
patients met all inclusion criteria and were randomly allocated into tonsillectomy (TX) and 
control groups by the allocation sequence. A numerical code was used to identify patients 
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and their specimens. All investigators except the study’s supervisor were unaware of the 
treatment allocation, which was concealed until the end of the study in order to reduce study 
bias. Moreover, the patients received strict instructions not to reveal their tonsil status during 
follow-up. Thirteen patients with plaque psoriasis and a history of sore throat-associated 
psoriasis aggravation were later added to the TX group, 8 new patients and 5 patients who 
had previously been controls in the RCT, but opted for tonsillectomy after the 24-month 
follow-up (paper III). Additional 374 patients with psoriasis were invited to participate in a 
retrospective case series study. After a 4-month study period, 275 patients were included, 
yielding a 73.5% response rate (paper IV).  
Table 4. Inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
Moderate to severe chronic plaque psoriasis 
diagnosed by a dermatologist 
Other psoriasis phenotypes (e.g. guttate, pustular, 
erythrodermic) 
Age ≥ 18 years Previous tonsillectomy 
History of psoriasis exacerbation in association with 
sore throat and/or streptococcal throat infection 
Unwillingness to stop psoriasis treatment at least 4 
weeks prior to study entry 
Psoriasis onset before 40 years of age Alcohol or drug abuse 
Signed informed consent Pregnancy or planned pregnancy within a year 
Consent to have tonsillectomy Participation in another clinical trial concurrently 
 
Significant underlying medical conditions increasing 
patients risk for anaesthesia and surgery, such as: 
Chronic heart diseases 
Chronic lung diseases 
Chronic kidney diseases 
Bleeding disorders 
3.4 Visit schedule 
Patients in the RCT were followed up at regular intervals for 24 months by the same 
investigator, who was unaware of patient’s tonsil status. The additional 13 patients were also 
followed up for 24 month, however unblinded. Detailed data was accumulated during 
screening: demographics, psoriasis features, association to various factors reported to 
exacerbate psoriasis and prior and concomitant psoriasis treatments (Figure 4). Health and 
medical history as well as alcohol and smoking habits were also noted. The severity of 
psoriasis was assessed and a brief physical examination, mainly heart and lung function, was 
performed as well as measurement of vital signs, height and weight. Patients included in the 
RCT then proceeded to a 4-week washout period, which included no antibiotics or psoriasis 
treatments other than moisturizers, before the baseline visit. The baseline visit included 
assessment of psoriasis clinical severity, health-related quality of life and psoriasis–related 
stress, heparinized venous blood sample and skin biopsy. Patients who had given permission 
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for photographic documentation were photographed and a bacterial throat swab was 
collected. Thereafter, the patients were asked to remain off all psoriasis treatments for 8 
weeks or until the first follow-up visit and subsequently they could be treated according to 
what they and their dermatologists felt indicated. The clinical follow-up was scheduled 2, 6, 
12, 18 and 24 months after the baseline visit and venous blood samples for immunological 
measurements were collected after 2, 12 and 24 months. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Flow chart of the study design  
PASI, Psoriasis Area and Severity Index; PDI, Psoriasis Disability Index; PLSI, Psoriasis Life Stress Inventory.  
Screening	  visit	   	   Inclusion	  criteria	  	  	   Collection	  of	  information	  
Informed	  consent	  	   Physical	  examination	  	  
PASI	  score	  
	  
Washout	   	   All	  psoriasis	  treatment	  prohibited	  
4	  weeks	   	  
	  
Baseline	  visit	   	   PASI	  score	  	   	   Blood	  sample	  
PDI	  &	  PLSI	  score	  	   	   Skin	  biopsy	  
Throat	  swab	   	   Photography	  
	  
Randomization	   	   Tonsillectomy,	  n	  =	  15	  
Control	  group,	  n	  =	  14	  
Treatment	  prohibited	  for	  8	  weeks	  
	  
Follow-­‐up	  visits	   	   PASI	  score	   	   Photography	  	  
24	  months	  	   	   PDI	  &	  PLSI	  score	   	   Monitoring	  of:	   	  	  	  	  	  	  	  
	   Blood	  samples	   	  	  	  	  	  	   	   Sore	  throats	  
Skin	  biopsy	  	   	  	  	  	  	  	  	   	   Treatments	  
Final	  visit	   	   Code	  unlocked	  	   	   End	  of	  study	  questionnaire	  
General	  discussion	   Otolaryngologist	  evaluation	  
	  
Controls	  offered	  tonsillectomy	  
Followed	  for	  24	  months	  
	  
Addition	  of	  8	  patients	  with	  plaque	  psoriasis	  (not	  in	  RCT)	  
Same	  inclusion	  criteria	  and	  clinical	  follow-­‐up	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 Follow-up questionnaires for assessment of health-related quality of life and psoriasis–
related stress were collected after 12 and 24 months. Patients were photographed at regular 
intervals and a skin biopsy was taken 6 months after the baseline visit. The use of psoriasis 
treatments during the follow-up period was closely monitored as well as the frequency of 
sore throats or streptococcal throat infections. At the end of the study, all tonsillectomized 
patients were examined for tonsillar remnants by an otolaryngologist and answered a study-
specific end-of-study questionnaire. Furthermore, patients who had been allocated to control 
group were offered tonsillectomy. 
3.5 Study end points and safety assessments 
The primary endpoints were as following: (1) Significant clinical improvements and a 
coinciding decrease in the frequency of blood T cells that recognize autoantigens in the skin 
after tonsillectomy; (2) Significant improvements in patient-reported outcomes (health-
related quality of life) after tonsillectomy; (3) Significant improvements in tonsillectomy 
outcomes of patients carrying HLA-Cw*0602. The key secondary endpoints included:  (1) 
Correlation of T cells that respond to homologous keratin and streptococcal peptides in 
tonsils and blood at the time of tonsillectomy; (2) Proportion of patients who achieve PASI 
50 (≥ 50% reduction in PASI from baseline), PASI 75 and PASI 90 responses; (3) 
Correlation between the change in clinical status (PASI scores) and health-related quality of 
life (PDI and PLSI scores).  
Post operative safety assessment following tonsillectomy, including evaluation of 
complications, was in the hands of the otolaryngologist who performed the procedures.  
3.6 Assessment of clinical symptoms  
The severity of psoriatic skin lesions was evaluated with the Psoriasis Area and Severity 
Index (PASI), which is a widely validated score for assessing the extent and severity of 
psoriasis.55 The score is based on 3 variables, erythema (E), infiltration (I) and desquamation 
(D), graded from 0 to 4 (none, slight, moderate, severe and very severe). The body is divided 
to 4 regions; head and neck (H), trunk (T), upper extremities (U) and lower extremities (L) 
and the area (A) covered by psoriasis in each region is calculated as a percentage of the total 
regional area. Each region is then weighted in the total score according to its percentage of 
the whole body; head and neck 10%, upper extremities 20%, trunk 30% and lower 
extremities 40%. Thus, the PASI score is calculated:  
PASI = 0.1(EH+IH+DH)AH+0.2(EU+IU+DU)AU+0.3(ET+IT+DT)AT+0.4(EL+IL+DL)AL 
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The PASI score may range from 0 to 72. However, scores over 10 generally represent severe 
psoriasis and scores under 10 a mild to moderate disease.  
3.7 Questionnaires 
3.7.1   Evaluation of health-related quality of life  
Health-related quality of life (HRQoL) was determined at study entry and at 12 and 24 
months with 2 patient-reported outcomes, the Psoriasis Disability Index (PDI)59 and the 
Psoriasis Life Stress Inventory (PLSI).60 The PDI is a self-administered, psoriasis-specific 
quality of life questionnaire, which has been validated and used in many studies. It grades 
functional disability due to psoriasis in the preceding 4 weeks before its completion. The PDI 
consist of 15 questions that can further be subgrouped to 5 issues: daily activities, 
work/school, personal relationships, leisure, and treatments. With a 4-point scale, rating from 
"not at all" to "very much", the grades are summed to yield a total score, from 0 to 45. 
 The PLSI evaluates patients’ stress related to having to cope with psoriasis on an every 
day bases. The PLSI is also composed of 15 questions, which are rated on a 4-point scale 
from "not at all" to "very much" experienced stress in the previous 4 weeks. The score is 
calculated by summing the grades for each question and can range from 0 to 45. Both the 
PDI and PLSI have been used in English for evaluation of psoriasis. Icelandic versions of the 
questionnaires were used, previously translated and validated by the Nordic Quality of Life 
study.266 
3.7.2 End of study questionnaire 
At the end of the RCTs 24-month study period, all patients answered a study-specific 
questionnaire composed of 20 multiple-choice and 3 short-answer questions. The main 
objective of this questionnaire was to rate the overall experience of having tonsillectomy as a 
treatment for psoriasis. The answers were rated on a scale ranging from “not at all” to “very 
much”. Included in the questionnaire were issues concerning the difficulty of the procedure, 
experience of complications, recovery time and if the patient felt that the operation was 
worthwhile. Patients were also asked if their clinical symptoms had improved by the surgery 
and if their use of psoriasis treatments had changed. Furthermore, the questionnaire 
contained questions about the quality of life and frequency of sore throat and/or streptococcal 
throat infections and subsequent exacerbation of psoriasis after removal of their tonsils.  
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3.7.3 Retrospective study questionnaire 
A study-specific anonymous questionnaire containing 15 short-answer and multiple-choice 
questions was designed. The main objective of this questionnaire was to evaluate the ratio of 
patients with psoriasis exacerbations associated with sore throats to assess the usefulness of 
tonsillectomy as a treatment option.  
The questionnaire was divided into 5 main topics: (1) General demographics; (2) 
Psoriasis phenotypes, age at onset and onset associated with a sore throat or streptococcal 
throat infection; (3) History of sore throats and previous streptococcal throat infections, 
diagnosed by a throat culture, rapid antigen detection test (strep test) or a physician. Further, 
whether psoriasis exacerbations were experienced within 3 weeks of a sore 
throat/streptococcal throat infection; (4) Other known psoriasis aggravating factors, 
including general malaise, stressful life events, cold climate, alcohol and drugs; (5) History 
of tonsillectomy after psoriasis onset, the age at the time of the surgery and the 
tonsillectomy’s impact on psoriasis.   
3.8 Preparation of tonsil tissue 
After surgical removal from the pharynx, the tonsils were immersed in cold sterile saline and 
transported to the department of Immunology. There the tonsils were prepared for utilisation 
(Figure 5). This part of the research was done in collaboration with Sigrún Laufey 
Sigurðardóttir who conducted her PhD project at the same time.198,244,267 
3.8.1 Bacterial culture and typing 
Bacterial throat swabs were taken from all included patients at study entry. After tonsil 
excision, swabs were taken from the surface epithelia and tonsil crypts. Typing of the 
bacteria was performed by culture on sheep blood agar. Subspecies of Streptococcus were 
identified with a Streptex kit (Thermo Fisher Scientific, Remel, Lenexa, USA). 
3.8.2 Segregation of tonsil cells 
Tonsils were minced into small pieces, passed through a tea strainer and washed with Hank’s 
balanced salt solution (HBSS, Gibco, Invitrogen Ltd, Paisley, UK). Tonsil mononuclear cells 
(TMCs) were isolated using a Ficoll density gradient centrifugation (Sigma-Aldrich, St. 
Louis, MO, USA) by collection at the interphase fraction,268 and washed with HBSS. TMCs 
were then set up for cell culture by resuspending them in Roswell Park Memorial Institute 
media 1640 (RPMI, Gibco) at a density of 1.0 x 106 cells/ml, with 10% heat-inactivated fetal 
calf serum (Gibco), 100 µg/mL streptomycin (Sigma-Aldrich) and 100 U/mL penicillin 
(Sigma-Aldrich). 
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3.9 Isolation of blood and skin cells 
Venous blood samples were taken at months 2, 12 and 24. Peripheral blood mononuclear 
cells (PBMCs) were collected the same way as the TMCs or at the interphase fraction formed 
by Ficoll density gradient centrifugation. The cells were resuspended in supplemented 
RPMI-1640 medium for cell culturing (Figure 5).  
 Four mm skin biopsies were taken from lesional psoriasis skin and stored in saline until 
transported to the department of Immunology. Statamatrix-TM matrices (Cell Sciences, 
Canton, USA) were prepared as previously described.269 In short, subcutaneous fat was 
removed from the skin biopsies and the tissue minced to 2 mm pieces before being placed on 
the surface of the matrix.  The matrix with skin explants was then placed into one well of a 
24-well cell culture plate (Nunc, Thermo Fisher Scientific, Roskilde, Denmark). The culture 
was maintained with 2 ml/well Iscove’s Modified Dulbecco’s Medium (Gibco) with 10% 
heat-inactivated fetal calf serum, 100 µg/mL streptomycin, 100 U/mL penicillin (Sigma-
Aldrich) and 3.5 µl/L 2-mercaptoethanol. Culture medium was replaced 3 times per week 
and treated with IL-2 (100 U/ml) and IL-15 (20 ng/ml). T cells were expected to spill from 
the matrices into the wells from day 7 to day 21.  However, T cells yielded were too low and 
thus this analysis was aborted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Processing of tonsil tissue, blood samples and skin biopsies  
Tonsils	   Blood	   Skin	  
HLA	  typing	  Bacterial	  swab	  surface/crypts	  
Frozen	  in	  -­‐70°	  
Frozen	  in	  -­‐70°	  
T	  cells	  isolated	  
on	  statamatrix	  
Mononuclear	  
cell	  isolation	  
Serum	  
cytokines	  
PBMC	  
isolation	  
Peptide	  pool	  
stimulation	  
FACS	  
staining	  Peptide	  pool	  stimulation	  
FACS	  
staining	  
Peptide	  pool	  
stimulation	  
FACS	  
staining	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3.10 Peptide stimulation 
3.10.1 Homologous streptococcal and keratin peptides 
Arranged preparations of homologous peptides derived from human keratin 17 (K17) and 
streptococcal M protein 6 (M6) were used to stimulate T cells. These had previously been 
prepared as described by Johnston et al.224 In summary, the amino acid sequence of K17 was 
split into a complete set of 9 overlapping residue peptides, and compared with the sequence 
of the M6 protein using the FASTA algorithm. The FASTA algorithm is a software package 
used to identify similar protein and nucleic acid sequences.270 Sequence homologous 
peptides were confined to the conserved C-terminal of the M6 protein whereas the 
homologous K17 peptides were located in the coil-forming part of the keratin. The K17 
peptides that shared 4-6 amino acids with the M6 peptides, were then selected according to 
predicted binding to HLA-Cw*0602. These homologous K17 and M6 peptides were then 
blended into 16 peptide pools, each containing 8 peptides. Thus, in total 64 short peptides 
were used (Table 5).  
3.10.2  Determination of M/K peptide-reactive T cells 
After isolation of PBMCs and TMCs, cells were cultured in complete RPMI in cell culture 
tubes (Nunc) at a density of 1x106 cells/ml. The cells were stimulated with the 16-peptide 
pools (2 µg/ml total peptide each) for 16 hours, with the addition of anti-CD28 and anti-
CD49d monoclonal antibodies (1µg/ml each, Serotec Scandinavia, Oslo, Norway) as co-
stimulation. After the first 2 hours of stimulation, brefeldin A (10µg/ml, Sigma-Aldrich) was 
added to the cell cultures to inhibit cytokine secretion and thus promote an intracellular 
Table 5. Composition of peptide pools  
The table shows the size and location of the homologous keratin17 and M6 peptides. 
 1 2 3 4 5 6 7 8 
9 31K17-12 130-K17-9 206-K17-9 236K17-12 372-K17-9 261-M6-9 262M6-12 355-M6-9 
10 101-K17-12 134K17-12 212K17-12 238-K17-9 379K17-12 282-M6-9 285M6-12 368M6-16 
11 125-K17-9 135-K17-9 217-K17-9 239K17-12 379-K17-9 299M6-12 146M49 382M6-12 
12 127-K17-9 139-K17-9 220-K17-9 309-K17-9 396-K17-9 299-M6-9 338M6-20 384-M6-9 
13 128-K17-9 162-K17-12 220K17-12 334-K17-12 404-K17-9 306-M6-9 338M6-12 464M6-12 
14 128-K17-10 165-K17-12 145K10 338-K17-12 407-K17-9 319M6-12 344M6-12 468M6-16 
15 146K17 168-K17-9 145K17 351K17-12 415-K17-12 324-M6-9 354M6-12 GAGEa 
16 146K9 179-K17-9 231-K17-9 366-K17-12 255-M6-12 327-M6-9 345-M6-9 BMRF-1b 
Blue boxes: human keratin peptides, yellow boxes: streptococcal peptides, grey boxes: control peptides. 
aPeptide used as a negative control for Cw6 binding.271 bPeptide from Epstein-Barr Virus Protein BMRF-1 as a 
positive control.272 Each peptide is situated in 2 different pools. 
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cytokine build up. The cultures were then further incubated for 14 hours at a 5° slant at 37°C 
in a humidified 5% CO2 atmosphere. Anti-CD3 antibodies (1µg/ml, Serotec Scandinavia) 
and streptokinase (200U/ml, Hoechst Marion Roussel AB, Stockholm, Sweden) were used as 
positive controls for T cell activation. As >90% of the T cells that respond to the 
homologous peptides express the skin-homing molecule CLA,224 anti-CLA as well as anti-
CD4 and anti-CD8 were used to characterize cells of interest. The cells were stained on ice in 
the dark for 20 minutes, washed twice with phosphate-buffered saline (PBS) before being 
fixed with 500µl cold (4°C) 2% paraformaldehyde for 10 min and further washed with PBS. 
Finally the cells were treated with permeabilizing buffer (0.5% BSA, 0.1% saponin, 0.1% 
sodium azide, Sigma-Aldrich) for 10 min at room temperature, followed by a wash and 
resuspension with the same buffer. The cells were then stained with anti-IL-17A or anti-IFN-
γ in the dark for 20 min at 4°C, washed with permeabilizing buffer (1.5 ml) and centrifuged 
at 500xg for 5 min. Lastly, the cells were resuspended in 250µl of a fixing buffer composed 
of permeabilizing buffer and 1% paraformaldehyde. Fluorescence activated cell-sorting 
(FACS) analysis was carried out on a FACScalibur flow cytometer (BD Biosciences), gated 
on light scatter, CD4, CD8 and CLA expression, capturing a minimum of 200,000 events 
guided by appropriate isotype control antibodies. Data were analysed with CellQuest (BD) 
software. 
Table 6. Antibodies for cell surface receptors and intracellular cytokines 
Antibody Conjugate Clone Provider 
CD3 APC UCHT-1 Biolegenda 
CD4 PE Clone 3.9 Biolegend 
CD4 Percp-cy5.5 RPA-T4 Biolegend 
CD8 Percp-cy5.5 RPA-T8 Biolegend 
CLA FITC HECA-452 Biolegend 
CD45RO PE UCHL1 Biolegend 
CD45RA PE HI100 Biolegend 
CCR4 PE 205410 R&D Systemsc 
CCR6 APC 53103 R&D Systems 
CCR7 APC 150503 R&D Systems 
CCR8 APC 191704 R&D Systems 
CCR10 APC 314305 R&D Systems 
CXCR3 PE 173 Biolegend 
CXCR6 PE 56811 R&D Systems 
IL-10 PE JES3-7D9 Biolegend 
IL-17A AF 647 eBio64CAP17 eBioscienced 
IL-22 PE 142928 R&D Systems 
IFN-γ PE 4S.B3 Biolegend 
aBiolegend, San Diego, CA, USA, bBecton Dickinson, Franklin Lakes, NJ, USA, cR&D Systems, Minneapolis, 
MN, USA, deBioscience, San Diego, CA, USA  
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3.11 Cytokine measurements 
Enzyme linked immunosorbent assay (ELISA, R&D Systems, Minneapolis, MN) measured 
serum cytokines before and after tonsillectomy with 50µl of serum or standard, measured in 
duplicates. The optical density was identified at 450 nm and cytokine concentrations 
calculated from the standard curve.  
3.12  HLA-Cw*0602 typing 
All participating patients were genotyped for HLA-Cw*0602 after being followed up for 24-
months. The DNA was prepared from PBMCs and the HLA-Cw*0602 status determined by 
allele specific PCR amplification by genotyping 7 SNPs in exons 2 and 3 of the HLA-C 
gene, as previously described.85  
3.13  Expression of the data and statistics 
Data analyses were performed using R software, version 2.10 (The R foundation, Austria) 
and P values of less than or equal to 0.05 were considered significant. Patient demographics 
were summarised descriptively and data were tested for normality using the Kolmogorov-
Smimov test. In general, categorical variables were compared with Chi-Square or Fisher’s 
exact test as appropriate and continuous variables with unpaired Student’s t-test. Data were 
analysed on an intention-to-treat basis and missing values replaced with the last observed 
value (last observation carried forward). Correlation data were determined with Spearman's 
rank correlation test.  
Intracellular flow cytometric responses were determined as followed: if more than 
0.05% of the CLA+CD8+ or CD4+ T cells expressed IFN-γ or IL-17 compared with the 
unstimulated T cell culture or fluorescence minus 1 control the response was interpreted 
positive. After stimulation with the 16-peptide pools, the frequency of T cells that responded 
to each pool was interpreted as a percentage of CLA+ cells in each of the T cell 
subpopulations, normalized using square root normalization, and finally expressed as an 
average for each patient.  
Analysis of variance (ANOVA) test for repeated measurements was used to compare 
peptide responses, PASI, PDI and PLSI scores between the groups and different time points. 
The square root of the peptide responses, PDI and PLSI scores was used to better 
approximate normality in the ANOVA model. For the retrospective case study, multivariable 
analyses were performed with a logistic regression and a model of sore throat aggravation 
was pursued. Variables with a p < 0.1 were entered into the logistic regression model and 
associations in the multivariate logistic models were presented as odds ratios (OR) with 95% 
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confidence interval (CI). Linear regression was used to evaluate the effects of HLA-Cw*0602 
carriage on improvement after tonsillectomy (change in PASI, PDI and PLSI over 24 
months). Of the 3 different models that were tested, dominant (phenotype effected by 1 or 2 
HLA-Cw*0602 alleles), recessive (both HLA-Cw*0602 alleles required to effect phenotype) 
and additive (phenotype changes sequentially with each HLA-Cw*0602 allele), the recessive 
model was used. The linear model assumptions were checked by visual analysis of residual 
plot.  
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4 Results 
Recruitment for the randomized controlled trial took place from November 2007 to 
November 2008. Of the 54 screened patients, were 25 excluded. Sixteen did not meet the 
inclusion criteria and 3 eligible patients declined participation after being screened. Six 
patients were excluded for reasons of chronic diseases, pregnancy and ongoing systemic 
treatment for psoriasis (Figure 6). The remaining 29 patients fulfilled all the inclusion 
criteria and were enrolled in the study. All enrolled patients had plaque psoriasis and a 
history of psoriasis exacerbation during or after a sore throat. No significant differences 
were between groups, and although the TX group had slightly higher baseline PASI, PDI 
and PLSI scores compared with the controls, these differences were not statistically 
significant (Table 7).  
 
Figure 6. Study flow diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
54 screened for eligibility 
14 completed the 24-month follow-up	
Allocated to tonsillectomy 
(n = 15) 
 
Discontinued (n = 2): 
Lymphoma after 12 months 
Tonsillectomy after 18 months  
Allocated to control group 
(n = 14) 
 
12 completed the 24-month follow-up	
	
29 randomized 
Discontinued (n = 1):  
Received methotrexate for psoriatic 
arthritis after 12 months 
 
Excluded (n = 25) 
Did not meet inclusion criteria (n = 16) 
Declined participation (n = 3) 
Excluded for other reasons (n = 6) 
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 Of the 29 included patients, 14 patients in the TX group and 12 controls completed the 
24-month follow-up period. One patient in the TX group discontinued the study after 12 
months for reasons of psoriatic arthritis where his rheumatologist initiated methotrexate 
treatment. Two controls were discontinued, 1 because of a lymphoma diagnosis after 12 
months of follow-up and the other violated the protocol and had tonsillectomy after 18 
months of follow-up.  
Table 7. Baseline demographic information of the patients in the RCT 
 
 
TX group 
(n = 15) 
Control group 
(n = 14) 
Men, n (%) 3 (20) 6 (43) 
Age, mean yr ± SD 35.3 ± 9.9 35.9 ± 9.8 
BMI (kg/m2) mean ± SD  25.2 ± 5.3 25.4 ± 3.6 
Smokers, n (%) 4 (27) 6 (43) 
Age at psoriasis onset, mean yr ± SD 15 ± 7.9 15 ± 7.1 
Sore throat induced psoriasis onset, n (%) 3 (20) 2 (14) 
Duration of psoriasis, mean yr ± SD 19.9 ± 9.5 20.5 ± 11.7 
Psoriasis family history, n (%) 12 (80) 12 (86) 
Psoriatic arthritis, n (%) 4 (27) 1 (7) 
PASI score, mean ± SD 11.0 ± 5.7 9.3 ± 3.7 
PDI score, mean ± SD 10.4 ± 7.1 9.3 ± 7.3 
PLSI score, mean ± SD 12.0 ± 6.1 10.0 ± 7.0 
Treatments, n (%)   
Topical agents 8 (53) 8 (57) 
Phototherapy 5 (33) 4 (29) 
Systemic therapy 1 (7) 0 
TX, tonsillectomy; SD, standard deviation; BMI, body mass index; PDI, Psoriasis Disability Index; PLSI, 
Psoriasis Life Stress Inventory; PASI, Psoriasis Area and Severity Index. 
4.1 Tonsillectomy improves plaque psoriasis  
The TX group showed clinical improvement with a significant reduction in the mean PASI 
score, both with time and compared with the control group (Figure 7A, p < 0.001). Up to 
60% of the TX group reached a PASI 50 response (50% reduction in PASI score) (Figure 
7B), and the PASI reduction ranged from 30-90% for 13 of 15 tonsillectomized patients 
(Figure 7C). The improvement was observed already at the first follow-up visit 2 months 
after the surgery and was generally maintained throughout the study period (Figure 7A and 
7C). The controls showed no corresponding improvements (Figure 7D). Two 
tonsillectomized patients did not clinically improve (patient 4 and 6, Figure 7C).  
4.2 Tonsillectomy reduces M/K peptide-reactive T cells 
In order to investigate the effect of tonsillectomy on M/K peptide-reactive T cells (T cells 
that respond to both streptococcal M proteins and skin keratins), PBMCs isolated from 
tonsils and blood were stimulated with homologous M proteins and keratin peptides  
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Figure 7. Clinical improvement throughout the 24-month study period  
(A). The tonsillectomized patients had a significantly lower mean PASI score compared with the controls (p < 
0.001). (B). Percentage of patients in the tonsillectomy (TX) group that reached 50% improvement (PASI 50), 
75% improvement (PASI 75), and 90% improvement (PASI 90) at each time point measured. (C). Individual 
percentage PASI changes for the TX group during the 24-month study period. PASI score at study entry is set 
as 0. Patients 4 and 6 (arrows) did neither clinically improve nor show significant changes in M/K peptide-
reactive skin-homing T cells in blood. (D). The controls showed no corresponding clinical improvement. 
 (Table 5) and then stained for CLA, CD8, CD4 and intracellular expressed IL-17 (T17 
cells) and IFN-γ (T1 cells). For each patient the responses to all 16 peptide pools were 
determined at study entry and at 2, 12 and 24 months after square root normalization and 
expressed as an average percentage of CLA+ T cells in each T cell subpopulation. 
Tonsillectomy was generally associated with a marked reduction in the frequency of skin-
homing T cells responding to the 16-peptide pools by producing cytokines highly relevant 
to the pathogenesis of psoriasis (Figure 3A, paper I). Similar results were not observed for 
the control group (Figure 3B, paper I).  
4.2.1 The frequency of M/K peptide-reactive T cells in tonsils and the blood correlate 
The frequency of M/K peptide-reactive skin-homing T cells in tonsils and blood at the time 
of tonsillectomy showed a strong positive correlation. This applied to IL-17 producing Tc17 
cells (Figure 8A, r = 0.644, p = 0.015), IFN-γ producing Tc1 (Figure 8B, r = 0.788, p < 
0.001) and Th1 (r = 0.679, p = 0.001, data not shown) cells. However, significant 
correlation was not observed for Th17 (r = 0.315, p = 0.273, data not shown). 
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D) PASI change – Controls 
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Figure 8. Correlation of M/K peptide-reactive T cells in tonsils and blood 
A significant correlation was observed between the frequency of M/K peptide-reactive skin-homing CD8+ T 
cells in blood and tonsils at the time of tonsillectomy. (A). M/K peptide-reactive CLA+CD8+ T cells producing 
IL-17 (r = 0.644, p = 0.015) (B). M/K peptide-reactive CLA+CD8+ T cells producing IFN-γ (r = 0.788, p > 
0.001). 
4.2.2 M/K peptide-reactive T cells decrease after tonsillectomy  
The frequency of M/K peptide-reactive skin-homing T cells that produce IL-17 in the blood 
decreased significantly after tonsillectomy compared with the controls. This applied both to 
CD8+ Tc17 cells (Figure 9A, p = 0.009) and CD4+ Th17 cells (p = 0.003). Similar 
frequency reduction was observed for M/K peptide-reactive skin-homing IFN-γ–producing 
CD8+ Tc1 cells (Figure 5A, paper I, p = 0.003). No significant reduction in the frequency of 
M/K peptide-reactive skin-homing CD4+ Th1 cells was seen (p = 0.137). The frequency of 
T cells responding to anti-CD3 antibodies or streptokinase antigen did not decrease after 
tonsillectomy, indicating the specificity of the response. Interestingly, the 2 patients who did 
not clinically improve after tonsillectomy (patient 4 and 6, Figure 7C) did not show 
significant changes in the frequency of M/K peptide-reactive skin-homing T cells, further 
supporting the association between clinical improvement and reduction in the frequency of 
M/K peptide-reactive cells. 
4.2.3 A positive correlation exists between PASI and the frequency of M/K peptide-reactive T 
cells 
A significant positive correlation was observed between the degree of clinical improvement 
and reduction in the frequency of circulating M/K peptide-reactive skin-homing IL-17 
producing T cells, both Tc17 (Figure 9B, r = 0.565, p < 0.001) and Th17 (r = 0.452, p = 
0.003, data not shown). A significant positive correlation was also seen between clinical 
improvement and reduction in the frequency of M/K peptide-reactive skin-homing Tc1 cells 
A) γ B) 
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(Figure 5B, paper I, r = 0.594, p < 0.001). No correlation was observed for Th1 cells (r = 
0.236, p = 0.137) or controls (Figure 5C and 9C, paper I).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Frequency of circulating M/K peptide-reactive CD8+IL-17+ T cells 
(A). Tonsillectomized patients showed a significant reduction in the frequency of circulating M/K peptide-
reactive skin-homing CD8+ T cells that produce IL-17 compared with the controls (p = 0.009). (B). A strong 
correlation between percentage reduction of PASI (clinical improvement) and percentage decrease of 
circulating M/K peptide-reactive CLA+CD8+IL-17+ T cells (r = 0.5650, p < 0.001) was seen throughout the 
24-month study period. (C). No correlation was observed for the controls (r = 0.274, p = 0.130). (B) and (C). 
T cell frequency and PASI score at study entry were set as 0 for each participant. The vertical axis displays the 
percentage changes in PASI and horizontal axis percentage changes in the frequency of M/K peptide-reactive 
CD8+ T cells (3 data points/patient). 
4.3 Tonsillectomy improves health-related quality of life 
The Psoriasis Disability Index (PDI) was used to evaluate changes in HRQoL after 
tonsillectomy, and was applied at study entry and after 12 and 24 months. Tonsillectomized 
patients reported a significant improvement in HRQoL both with time (p = 0.026) and 
compared with the control group (Figure 10, p = 0.037, 95% confidence interval (CI), 1.43 
to 3.58) with an average 50% improvement of quality of life after tonsillectomy. 
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Furthermore, a significant positive correlation between clinical improvement (PASI score) 
and HRQoL (PDI score) was seen (Figure 3A, paper II, r = 0.297, p = 0.008). The HRQoL 
domains most markedly influenced were work and/or school activity, relationships and the 
use of psoriasis treatment (Table II, paper II). No corresponding improvement was observed 
in the control group. 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Changes in health-related quality of life 
The mean Psoriasis Disability Index (PDI) score decreased significantly in the tonsillectomy group both with 
time (p = 0.026) and compared with the control group (p = 0.037). No corresponding changes were seen for 
the controls. *Denotes statistical significance. 
The Psoriasis Life Stress Inventory (PLSI) was also completed at study entry and at 12 
and 24 months. Tonsillectomized patients observed significantly less stress associated with 
psoriasis both with time (p < 0.001) and compared with the controls (Figure 11, p < 0.002, 
95% CI, 1.39 to 3.10). The PLSI score improved on average by 59% for the TX group. The 
control group did not report corresponding changes. Furthermore, a positive correlation was 
observed between clinical improvement and stress due to psoriasis (PLSI) (Figure 3B, paper 
II, r = 0.310, p = 0.005).  
 
Figure 11. Changes in psoriasis-related stress 
The Psoriasis Life Stress Inventory (PLSI) score decreased significantly in the TX group, both with time and 
compared with the control group (p < 0.001 and p = 0.002 respectively). No corresponding changes were 
reported by the controls. *Denotes statistical significance. 
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4.4 Tonsillectomized patients require less treatment 
No reported differences in psoriasis treatments were seen between the TX and control group 
prior to tonsillectomy. The first 8 weeks after randomization patients were required to be off 
all psoriasis treatments. Thereafter, treatment requirements were monitored closely 
throughout the 24-month study period. The TX group required significantly less topical 
treatment after tonsillectomy compared with the control group (27% vs 86%, p = 0.003). No 
difference in phototherapy was seen between the groups. Despite a marked clinical 
improvement, one patient in the TX group was started on methotrexate by his rheumatologist 
due to psoriatic arthritis, 12 months after tonsillectomy (Table II, paper I).  
4.5 Tonsillectomy safety assessment 
The otolaryngologist who performed the tonsillectomies followed patients after the surgery. 
No major post-operative complications were reported. One patient required a visit to the 
hospital the day after tonsillectomy because of minor post-tonsillectomy bleeding. Tonsil 
tissue remnants could not be detected in tonsillectomized patients, evaluated at the end of 
the 24-month follow-up.  
4.6 End of study questionnaire 
At the end of the RCT, after the patient code was broken, the tonsillectomized patients 
completed a short study-specific questionnaire that was aimed at summing up their 
experience. Majority (80%) reported that the procedure was quite difficult and that the 
recovery time after the surgery was longer than they had anticipated in the beginning. There 
were no major post-operative complications reported, only one minor bleeding the day after 
the tonsillectomy. Nevertheless, 13 out of 15 (87%) tonsillectomized patients deemed the 
whole experience worthwhile and 12 out of 15 (80%) concluded that they had observed a 
marked improvement of their psoriasis lesions after tonsillectomy. One patient was unsure 
about the clinical improvement and 2 patients reported no or minimal changes in psoriasis 
symptoms. This is in concordance with the objective evaluations of the study, where 13 out 
of 15 (87%) tonsillectomized patients improved significantly compared to the controls. 
Twelve (80%) of the tonsillectomized patients reported a noticeable reduction in the 
requirement of psoriasis treatments, mostly moisturizers and topical treatments. 
Furthermore, one of the 4 patients, who had concomitant psoriatic arthritis, reported an 
improvement of arthritis after the tonsillectomy. 
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4.7 HLA-Cw*0602 carriage is a predictor of tonsillectomy outcomes  
Thirteen patients with plaque psoriasis that met all inclusion criteria were added to the 
original RCT tonsillectomy group, 8 new patients and 5 controls from the RCT that 
underwent tonsillectomy after the initial 24-month follow-up (demographics, Table I, paper 
III). These patients were followed up for 24-months with regular assessments of PASI, PDI 
and PLSI scores. Hence, a total of 28 tonsillectomized patients were included in the cohort 
presented in paper III. All patients were genotyped for HLA-Cw*0602. Four patients (14%) 
were homozygous carriers of HLA-Cw*0602, 17 (61%) were heterozygous and 7 (25%) 
were HLA-Cw*0602-negative (Table II, paper III). Twenty-five patients completed the 24-
month study period. One HLA-Cw*0602-negative patient discontinued after 18 months and 
2 heterozygous patients after 12 and 18 months.  
 Homozygous carriers of HLA-Cw*0602 improved significantly more after 
tonsillectomy, with a mean 82% improvement in PASI, compared with a mean 42 and 31% 
PASI improvement of the heterozygous and HLA-Cw*0602-negative patients respectively 
(p < 0.001) (Figure 12 and Table III, paper III). Thus, all homozygous patients reached 
PASI 75 at month 6 and almost PASI 90 by month 12 after the tonsillectomy. In accordance 
with the marked clinical improvement, the homozygous HLA-Cw*0602 patients also 
reported a significantly better HRQoL after the surgery, with a mean 87% reduction in PDI 
scores compared with 38% and 41% for the heterozygous and HLA-Cw*0602-negative 
patients, respectively (p < 0.001). A significant difference was also seen in psoriasis-related 
stress, with the homozygous patients reporting a mean 82% decrease in PLSI scores 
compared with 60% for the heterozygous patients and 54% for the HLA-Cw*0602-negative 
patients (p < 0.001). The homozygous HLA-Cw*0602 patients had a closer association to 
streptococcal throat infections and they significantly more often reported that their psoriasis 
onset was triggered by a throat infection compared with the heterozygous and HLA-
Cw*0602-negative patients (100% vs. 29% and 29% respectively, p = 0.007). Moreover the 
homozygous patients reported a significantly higher frequency of streptococcal throat 
infections per lifetime than the heterozygous and HLA-Cw*0602-negative carriers (3.5 vs 
1.4 and 1.1 times, respectively, p = 0.038) (Table II, paper III). Tonsil throat swabs, taken 
from the tonsil crypts after surgical removal, showed that 3 out of 4 homozygous patients 
carried group A, C, G streptococci or Streptococcus anginosus compared with 11 out of 17 
and 3 out of 7 of the heterozygous and HLA-Cw*0602-negative patients respectively. 
Cigarette smoking was significantly more common in the homozygous patient group 
compared with the heterozygous and negative patients (100% vs. 29% and 43%, p = 0.013). 
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Figure 12. Tonsillectomy efficacy outcomes and HLA-Cw*0602 status  
Homozygous HLA-Cw*0602 patients showed a significant mean percentage reduction of (A) Psoriasis Area 
Severity Index (PASI), (B) Psoriasis Disability Index (PDI) and (C) Psoriasis Life Stress Inventory (PLSI) 
after tonsillectomy at all time points measured, compared with heterozygous and HLA-Cw*0602-negative 
patients. *Statistical significance. 
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4.8 Streptococcal throat infections cause exacerbation of plaque psoriasis 
A study-specific questionnaire was designed to estimate of the proportion of patients with 
plaque psoriasis who have disease exacerbations after sore throat and/or streptococcal throat 
infection and might therefore benefit from tonsillectomy. A total of 275 patients with 
psoriasis were recruited, 127 males and 148 females (demographics Table I, paper IV).  
 Of the 207 patients with plaque psoriasis (75% of participants), 42% reported 
exacerbation associated with a sore throat. Furthermore, of the 96 patients with plaque 
psoriasis and a history of confirmed streptococcal throat infection, 72% reported 
streptococcal-associated psoriasis exacerbation (Table II, paper IV). Patients, who reported 
aggravation during streptococcal throat infections, were more likely to report psoriasis 
exacerbation associated with sore throat (92% vs 8%, p < 0.001). Moreover, patients with 
early-onset psoriasis reported sore throat-associated psoriasis exacerbation more frequently 
than late-onset patients with psoriasis (51% vs. 30%, p = 0.046). Women reported an 
association between sore throat and aggravation of psoriasis more frequently than men (61% 
vs. 32%, p < 0.001), and this difference remained significant after adjustment for age, 
psoriasis subtypes (see Table I, paper IV), and other aggravating factors (OR = 2.5, 95%CI, 
1.37 - 4.58, p = 0.003).  
Other environmental factors reported to cause psoriasis exacerbation such as general 
malaise, stress, cold climate and alcohol intake were significantly more often reported by the 
patients who had psoriasis exacerbation associated with sore throat (Table III, paper IV). 
After adjustment for gender, age, and psoriasis subtypes, this difference was still significant 
for general malaise (OR = 3.0, 95%CI, 1.58 - 5.74, p < 0·001) and cold climate (OR = 9.2, 
95%CI, 3.83 - 22.3, p < 0·001).  
Twenty percent (56 out of 275) of included patients had been tonsillectomized after the 
onset their psoriasis. Of the 37 tonsillectomized patients with plaque psoriasis, 49% reported 
a marked improvement after the tonsillectomy. Moreover, 3 out of 4 of patients with guttate 
psoriasis and 6 out of 11 patients with both guttate and plaque psoriasis reported 
improvement after tonsillectomy (Table IV, paper IV). Furthermore, all patients in this sub-
cohort who reported improvement after tonsillectomy had early onset psoriasis and they also 
more often reported sore throat-associated psoriasis exacerbation compared with patients 
who did not improve after the tonsillectomy (p = 0.015).  
 
 
 
   
63 
 
5 Discussion 
Psoriasis is a complex multifactorial autoimmune disease that has a profound effect on 
patients’ quality of life.5 The disease is caused by a combination of multiple genetic 
polymorphisms78-82 and environmental factors,110,118 manifesting as a range of disease 
phenotypes, which differ in course, severity, and response to treatment.13,273  
Streptococcal throat infections are associated with both the initiation and exacerbation of 
psoriasis,23,196,197 and tonsillectomy has been reported to induce long-term remissions.242,244 T 
cells that respond to amino acid sequences shared by streptococcal M proteins and skin 
keratins (M/K peptide-reactive T cells) have been detected in the blood of patients with 
psoriasis.224 These T cells are CD8+ and recognize the M/K peptides most likely in the 
context of MHC class I molecules, such as HLA-Cw6, which is the product of the strongest 
psoriasis susceptibility allele.85 Furthermore, T cells clones with the same T cell receptor Vβ 
gene rearrangements have been isolated from the skin and the palatine tonsils of the same 
patients with psoriasis,231 suggesting that these cells are responding to one or a few dominant 
closely-related antigen determinants. Based on these and other findings, the investigations 
described in this thesis were devised to test the hypothesis that immune responses against 
streptococcal throat infections may induce streptococcal antigen-specific T cells in the tonsils 
in patients with psoriasis and promote their migration into the skin. In the skin they are able 
to recognize homologous keratin antigens resulting in eruption of guttate or exacerbation of 
plaque psoriasis. If true, removal of the tonsils might be expected to be associated with 
reduced frequency of these cells in the periphery and subsequent clinical improvement of 
psoriasis. The overall aim of this thesis was to test this hypothesis and assess the clinical, 
psychosocial and immunological effects of tonsillectomy on patients with chronic plaque 
psoriasis.  
The results show that patients with plaque psoriasis and a history of sore throat-
associated psoriasis exacerbation significantly improve after tonsillectomy, and that 
tonsillectomy leads to significant decrease in the frequency of circulating M/K peptide-
reactive T cells compared with matched controls. Clinical improvement after tonsillectomy 
was accompanied by significantly improved health-related quality of life. Furthermore, 
patients with plaque psoriasis that were homozygous HLA-Cw*0602 carriers had 
significantly greater benefit from tonsillectomy than heterozygous and non-carriers and had 
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stronger association with streptococcal throat infections. Finally, the findings indicate that 
42% of Icelandic patients with plaque psoriasis experience disease exacerbation associated 
with sore throat and 72% report worsening of psoriasis associated with confirmed 
streptococcal throat infections. 
5.1 Tonsillectomy is beneficial for selected patients with plaque psoriasis 
Although previous studies have reported the beneficial effect of tonsillectomy (reviewed 
in242-244), this is to our knowledge, the first prospective randomized controlled study on the 
effect of tonsillectomy on psoriasis. Thirteen out of 15 tonsillectomized patients clinically 
improved, with PASI reductions ranging from 30-90% and up to 60% of patients reached a 
PASI 50 response. The improvement was observed already 2 months after surgery and was 
generally maintained throughout the 24-month follow-up period. Moreover, 
tonsillectomized patients required significantly less topical treatment than controls, 
indicating that tonsillectomy may be used as an adjunct to existing treatment, to reduce the 
use of time consuming therapy or allow the use of less potent drugs to control the disease. 
Patients in the RCT recently completed a 5-year follow-up after tonsillectomy indicating 
long-lasting beneficial effects of tonsillectomy.  
The ultimate aim of psoriasis treatment is achieving clear skin. A PASI 75 response is 
still considered the standard of response assessment, used in most clinical trials of 
psoriasis,274 although PASI 90 and even PASI 100 response rates are becoming important 
secondary endpoints. To that end, a 60% PASI 50 response of tonsillectomized patients 
does not seem impressive. However, patients on methotrexate have also been shown to have 
about 60% PASI 50 response after 16 weeks of treatment,275,276 and methotrexate is usually 
the first choice systemic agent for patients with moderate to severe psoriasis.  
Patients in the RCT did not show any clear association between the degree of 
improvement and carriage of the HLA-Cw*0602 allele. HLA-Cw*0602 is the major psoriasis 
susceptibility allele,85 and we predicted that HLA-Cw*0602-positive patients would show 
more improvement than non-carriers, since carriage of HLA-Cw*0602 has been linked to a 
higher frequency of streptococcal throat carriage/infections96,101 and streptococcal-
associated psoriasis exacerbations.27,101 After including 8 additional patients with plaque 
psoriasis and a history of sore-throat associated psoriasis exacerbation and 5 controls from 
the RCT to the tonsillectomy group, we found that patients who were homozygous for HLA-
Cw*0602 showed significantly more improvement compared with heterozygous HLA-
Cw*0602 patients and non-carriers. Strikingly, all 4 homozygous patients reached PASI 75 
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by months 6 and PASI 90 by month 12. These results are similar to those seen with recently 
introduced biologics.277 Why should patients carrying two copies of the HLA-Cw*0602 
allele respond better to tonsillectomy than heterozygotes? Possibly, they show a stronger 
response to streptococcal proteins since homozygotes have twice as many HLA-Cw*0602 
molecules on the surface of their cells than heterozygotes. It has been reported that 
homozygous HLA-Cw*0602 individuals are 2.5 fold more likely to get psoriasis and have an 
earlier disease onset compared with heterozygotes.92 While over 60% of patients with 
psoriasis are HLA-Cw*0602-positive, the frequency in the general population is only 10-
15%.85,88 However, 7-26% of patients with plaque psoriasis have been shown to be 
homozygous HLA-Cw*0602 carriers.92,100 Patients with psoriasis might also be carrying 
other risk alleles such as ERAP1, or LCE genes that possibly magnify the effects of HLA-
Cw*0602 carriage.90,109 Increased risk for psoriasis has been seen in HLA-Cw*0602-positive 
smokers compared to HLA-Cw*0602-positive non-smokers,278 suggesting an additive effect 
of smoking in triggering psoriasis in some genetically predisposed individuals. Interestingly, 
smoking was significantly more common in the homozygous group compared to the 
heterozygous and non-carriers, with all 4 homozygous patients being smokers. Smoking is a 
known risk factor for psoriasis,279 that increases oxidative damage, promotes an 
inflammatory state, and may even modify gene expression of psoriasis-associated genes, 
including the HLA genes.280 
These observations are interesting because accumulating evidence shows that different 
psoriasis genotypes can be useful in predicting treatment reponses.281 Thus, patients 
carrying HLA-Cw*0602 respond better to the interleukin-12/23 inhibitor ustekinumab102,103 
and etanercept has also been shown to be more effective in early-onset psoriasis (typically 
associated with HLA-Cw*0602 carriage) compared with late-onset psoriasis.104 The clinical 
findings of this thesis suggest that HLA-Cw*0602 homozygosity may be a relatively strong 
predictor of favourable outcomes after tonsillectomy of patients with plaque psoriasis and a 
history of streptococcal-associated psoriasis exacerbation.  
5.2 CD8+ T cells might be the ultimate effector cells in psoriasis 
The palatine tonsils are in many ways unique; They are the only secondary lymphoid tissue 
that is encapsulated by a multilayer squamous epithelium.172 Furthermore, they are ideally 
situated for antigen sampling of the large amount of material that is inhaled or ingested 
every day. We found that tonsillectomy was associated with a significant reduction in the 
frequency of M/K peptide-reactive skin-homing T cells, i.e, those CLA+ T cells that 
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respond to homologous peptides present in both streptococcal M proteins and keratins 
upregulated in psoriatic skin, by producing cytokines highly relevant to the pathogenesis of 
psoriasis. Thus, the frequency of M/K peptide-reactive skin-homing Tc17 and Tc1 cells not 
only decreased significantly after tonsillectomy compared with the controls, but the cell 
reduction correlated strongly with clinical improvement. Moreover, the frequency of M/K 
peptide-reactive skin-homing Tc17 and Tc1 was strongly correlated in the tonsils and blood. 
These findings suggest that effector CD8+ T cells originating in the tonsils may be involved 
in psoriasis pathogenesis, at least in a subset of patients. Although both T17 and T1 cells are 
thought to be important in psoriasis pathogenesis,156 increasing evidence supports IL-17 
producing T cells as the main effector pathogenic cells.282 T17 cytokines are crucial for 
sustaining the chronic inflammation in psoriasis and blockade of IL-23 or IL-17 has been 
shown to completely clear psoriasis.283-285 Furthermore, recent studies have confirmed an 
important role of CD8+ T cells in psoriasis, possibly making Tc17 cells key effector cells in 
psoriasis pathogenesis.143,155,286,287 This is in line with the findings of this thesis since the 
M/K peptide-reactive CD4+ T cells did not shown as much consistency as the CD8+ IL-17- 
and IFN-γ-producing T cells. CD8+ T cells produce a similar profile of proinflammatory 
cytokines as CD4+ T cells,288 and are abundant in the psoriatic epidermis close to 
keratinocytes, inducing characteristic histological changes such as parakeratosis and 
acanthosis.143,289 Moreover, using a human-mouse xenograft model it has been shown that 
blocking α1β1-intregrin, which is critical for the entry of T cells into the transplanted human 
epidermis,155 or neutralization of CD8+ T cells, prevents the development of psoriasis.287 
CD8+ T cells have also been shown to migrate early in the marginal zone of evolving 
psoriatic plaque.290 Furthermore and importantly, CD8+ T cells recognize peptide antigens 
presented in the context of MHC class I molecules, such as HLA-Cw6,167 that is the protein 
product of the strongest psoriasis susceptibility allele.85 However, it is important to note, 
that the immunological part of the RCT was designed to detect maximal numbers of T cells 
that responded to determinants that streptococcal M proteins share with human type 1 
keratins. Thus, the study does not distinguish between T cells that might respond 
exclusively to either keratin or M protein determinants. Moreover, it is not possible to 
evaluate if the responding T cells are specific for dominant autoepitopes or determinants 
that reflect epitope spreading.  
Psoriasis is an autoimmune disease, likely mediated by clonally expanded T 
cells,141,143,291,292 and T cells clones with the same TCR Vβ gene rearrangements in both 
tonsils and psoriasis skin have been reported, suggesting a common origin.231 Despite great 
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advances in characterization of the molecular mechanisms operating in psoriasis, the 
putative autoantigen(s), responsible for activating and sustaining the immune reaction seen 
in psoriasis, is still unknown. A spectrum of possible autoantigens have been suggested, 
many of which are keratinocyte-derived.142,233,293 Our findings do not exclude that other 
antigens may be involved in the pathogenesis such as maspin, ezrin, PRDX2, HSP27233 or 
melanocyte-derived peptides, also presented in the context of HLA-Cw*0602.167 Indeed, 
there maybe several autoantigens involved in psoriasis. However, cross-reaction between 
streptococcal M proteins and human keratins has repeatedly been suggested,195,222-
224,229,294,295 and increased frequency of circulating M/K peptide-reactive skin-homing CD8+ 
T cells has been observed in patients with psoriasis, compared with non-psoriatic 
controls.224 Furthermore, streptococci can induce the production of key psoriasis cytokines 
(IL-17, IL-22 and IFN-γ) in circulating CLA+ memory T cells cultured together with both 
lesional and nonlesional epidermal cell from psoriasis patients.199 Nevertheless, we do not 
exclude the possibility that other streptococcal antigens, including peptidoglycans237 might 
play a role in the immunopathogenesis of psoriasis.  
Of the 15 patients in the RCT, 2 patients did not show clinical improvement after 
tonsillectomy. Interestingly, these 2 patients did not exhibit any change in the frequency of 
circulating M/K peptide-reactive T cells either. Furthermore, one of these admitted during 
the final study visit that he never observed any association between his psoriasis 
exacerbations and sore throat and/or streptococcal throat infections. The second patient was 
also uncertain about this association. These observations support the notion that only 
patients with a history of skin disease exacerbation associated with sore throat may benefit 
from tonsillectomy. 
Collectively the results indicate that streptococcal throat infections in the tonsils might 
induce a T cell-mediated autoimmune response against skin proteins, preferentially 
presented by HLA-Cw6, in some patients with chronic plaque psoriasis. The initial priming 
phase might involve streptococcal superantigens, which stimulate the upregulation of skin-
homing molecules on T cells. This streptococcal-induced immune response could then 
extend to the skin by molecular mimicry.  
5.3 Tonsillectomy improves patient reported outcomes 
The second aim of the thesis was to assess the psychosocial effects tonsillectomy has on 
plaque psoriasis by using patient reported outcomes. The tonsillectomy had a significant 
positive impact on the quality of life of patients with chronic plaque psoriasis compared with 
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the matched control group. Thus, HRQoL improved by 50% and psoriasis-related stress was 
almost 60% lower after the surgery. As expected, the improvements in quality of life and 
stress associated with psoriasis correlated positively with clinical improvement. The quality 
of life and stress indices are patient reported measures or the “real-world” impact of 
treatment and extend the clinical findings. Furthermore, the end-of-study questionnaire, 
which was applied to all tonsillectomized patients at the end of the 24-month follow-up, gave 
important feedback and evaluation of the whole experience of treating plaque psoriasis with 
tonsillectomy. Tonsillectomy involves risks inherent in both anaesthesia and surgery. Studies 
on tonsillectomy have shown that majority of patients have an uncomplicated post-operative 
course, although there is a minor risk of laryngospasm, bronchospasm, infections and post-
operative bleeding.241 Furthermore, recovery time for adults tends to be longer than for 
children. As such, 80% of the patients in the study concluded that the surgery had been quite 
difficult and that the recovery time was longer than they had anticipated. However, despite 
these risks and a prolonged recovery time, 13 out of 15 (87%) patients in the RCT reported 
that the procedure was worth all the effort. Moreover, 80% of the tonsillectomized patients 
noted a general decreased need for psoriasis treatments after the surgery, which is in accord 
with the finding that tonsillectomized patients with plaque psoriasis used fewer symptomatic 
treatments than controls.  
5.4 Streptococci cause exacerbation of chronic plaque psoriasis 
The third aim of the thesis was to assess the frequency of patients reporting psoriasis 
exacerbation associated with symptomatic sore throat, as to better estimate the potential of 
tonsillectomy as a treatment option. The retrospective questionnaire reported that 42% of 
the participating Icelandic patients associate exacerbation of plaque psoriasis with sore 
throats. Moreover, 72% reported an aggravation of plaque psoriasis associated with a 
confirmed streptococcal pharyngitis. This strong association could in part be explained 
recall bias, but is nevertheless noteworthy and higher than previously reported.196 
Furthermore, our cohort only included Icelandic patients with psoriasis and Iceland’s 
geographical isolation through the centuries might have resulted in the emergence of 
patients that are more influenced by streptococcal throat infections and other psoriasis 
trigger factors. However, we are not aware of an increased carriage of HLA-Cw*0602 
among Icelandic patients with psoriasis or increased frequency of streptococcal throat 
infections in Iceland, compared with other countries.  
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Patients with early onset psoriasis significantly more often reported sore throat-
associated psoriasis aggravation, which is in line with previous studies.16,105 Furthermore, 
patients that reported sore throat-associated aggravation of psoriasis significantly more often 
reported psoriasis exacerbation due to various other environmental factors. These findings 
are consistent with emerging data that plaque psoriasis is indeed a synonym for different 
phenotypes such as early and late onset psoriasis16 and stable and dynamic psoriasis.143 Our 
results show that patients prone to psoriasis exacerbations linked with sore throat and/or 
streptococcal throat infections have a dynamic plaque phenotype, which is characterized by 
a fluctuating disease course and increased sensitivity to numerous environmental triggers. 
Furthermore, patients with dynamic psoriasis are more often carriers of HLA-Cw*0602.27 
One might consider this plaque phenotype somewhat similar to guttate psoriasis,96 or a 
phenotype that lies between typical chronic plaque and guttate psoriasis, sharing some 
characteristics from both. 
Interestingly, females reported significantly more frequent sore throat-associated 
psoriasis exacerbation than men. The reason for this is currently unclear and although 
female sex hormones might be involved, there are no reports available. Women tend to have 
an earlier psoriasis onset than men,27,100,296,297 and they have been reported to be more 
frequently carriers of HLA-Cw*0602,100,298,299 although there is no logical explanation to 
why women should be HLA-Cw*0602-positive more often than men. One study has 
observed that women are more frequently affected with recurrent tonsillitis than men.300 
The tonsils are a major site for streptococcal carriage and infections. In the cohort from 
paper IV, the combined asymptomatic carrier frequency of Lancefield groups A, C, G 
streptococci and Streptococcus anginosus was 67% (14 out of 21) in the HLA-Cw*0602 
patient groups and 43% (3 out of 7) in the HLA-Cw*0602-negative group. This is in line 
with previous studies showing increased prevalence of positive streptococcal throat swabs 
in HLA-Cw*0602-positive patients compared to HLA-Cw*0602-negative patients,101 and 
suggests that HLA-Cw*0602 carriage may impact the bacterial colonization of the tonsils. 
Although a streptococcal carrier frequency of 43-67% is very high, especially compared to 
the frequency among the general population,175,301 it should be noted that included patients 
were selected on the basis of their history of sore throat-associated psoriasis exacerbation. 
Streptococci are known to invade epithelial cells and macrophages efficiently,180-182,184 
making antibiotics unable to eradicate group A streptococci in up to 30% of patients with 
pharyngotonsillitis.302 Although commonly used for treatment of streptococci, penicillin 
does not reach high intracellular concentration,303 probably because the intracellular niche is 
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protected from treatment. Moreover, even treatment with antibiotics that are active 
intracellularly is likely to have a temporary benefit since up to 20% of the general 
populations are carriers of throat streptococci.197 Our results do not exclude the possibility 
that the microbiota of the skin has a role in psoriasis pathogenesis. However, streptococci 
have not been reported to be significantly more common in psoriatic skin compared to 
controls.304 
The homozygous patients also reported significantly more streptococcal throat infections 
per lifetime, and more often that their psoriasis onset was triggered by a sore throat, 
compared to the heterozygous and HLA-Cw*0602-negative patients. Proteins from β-
haemolytic streptococci have been shown to induce the expression of the skin-homing 
molecule CLA on T cells,209,210 thus providing an immunological link between the tonsils 
and the skin. CLA+ T cells are more frequent in the tonsils and blood of patients with 
psoriasis compared with healthy individuals.305 The immunological development of the 
tonsils of genetically predisposed individuals may become dysregulated because of chronic 
streptococcal throat infections. The dysregulation might even cause a further vulnerability to 
streptococcal infections. This is supported by the notation that psoriasis tonsils are 
histologically different from hypertrophic tonsils,198 and patients with psoriasis do not have 
increased susceptibility to other throat infections.198 Furthermore, HLA-Cw*0602-positive 
healthy individuals do not have increased risk for streptococcal pharyngitis,306 which points 
to the possibility of involvement of other psoriasis susceptibility alleles. Thus, neither HLA-
Cw*0602, nor streptococcal infections per se are necessary for the development of psoriasis. 
The mechanism whereby HLA-Cw*0602 predisposes to psoriasis has yet to be explained. 
Our data, and those of others167,199,224,228,231 are consistent with the hypothesis that 
autoantigens presented in the binding pockets of HLA-Cw*0602 on epidermal cells are 
recognized by CD8+ T lymphocytes infiltrating lesional epidermis.142  
5.5 Hypothetical scenarios 
It has been suggested that several mechanisms might induce pathogenic T cells that drive 
psoriasis skin inflammation, since psoriasis is both genetically and clinically heterogeneous. 
Two of the best-defined psoriasis pathomechanisms hitherto proposed are the molecular-
mimicry based pathogenesis that generates potentially auto-reactive T cells in the tonsils 
and a mechanism that produces pathogenic T cells by expansion of T cells within the skin or 
local skin lymph nodes. Possibly both of these pathomechanisms are operating in patients in 
different ratios. Thus, it is likely that the bulk of pathogenic T cells in patients with guttate 
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psoriasis and some patients with plaque psoriasis are produced in the tonsils while in other 
patients, effector T cells are produced mainly in other secondary lymphoid tissues. This 
might explain why guttate patients often go into spontaneous remission or clear completely 
after tonsillectomy while plaque psoriasis is more chronic and seldom heals completely after 
tonsillectomy. Plaque psoriasis usually evolves during a much longer time compared to the 
acute onset of guttate psoriasis and often it is difficult for plaque patients to pinpoint the 
exact time they started noticing their lesions and thus if psoriasis debut was associated with 
a sore throat. Furthermore, many streptococcal species colonize the throat without giving 
symptoms. We propose therefore that when genetically predisposed individuals get acute, 
subacute or asymptomatic streptococcal infection in the throat, a certain scenario can be 
initiated.  
First, streptococci infect or colonise the tonsils causing a bacterial-driven immune 
reaction (Figure 13A). This includes invasion of tonsil cells both epithelial cells, 
macrophages and APCs. Streptococcal antigens, such as M proteins, are presented in the 
context of MHC to naïve T cells recirculating through the tonsils, resulting in clonal 
expansion of streptococcal-specific effector T cells, both CD4+ and CD8+ T cells. 
Activation of CD8+ T cells might involve both a direct activation by a streptococcal 
infected dendritic cell or cross-presentation of extracellular streptococcal antigens through 
MHC class I. Streptococcal superantigens may aid by mass activation of T cells and 
inducing skin-homing properties on T cells.209,210 The activated T cells take part in fighting 
the ongoing bacterial infection along with humoral immune responses. After resolution, 
most of the clones die through apoptosis but some become memory T cells, ready to 
respond upon a second antigen encounter. Some streptococcal antigens may also enter the 
bloodstream where they become internalized by monocytes that present them as APCs in 
other secondary lymphoid tissues such as skin draining lymph nodes. Some of the 
streptococcal-reactive memory T cells, which include (M protein) peptide-reactive T cells 
stay in the tonsils as tissue-resident memory T cells, others, recirculate going from lymph 
node to lymph node, and those memory T cells that express CLA also home to skin.  
In the skin, the CD8+ T cells migrate to the epidermis where they cross-recognise 
keratin peptides, some of which are homologous to streptococcal M peptides, presented by 
APCs or in HLA-Cw6 molecules on keratinocytes.  The CD8+ T cells might also become 
activated in local draining lymph nodes by APCs that have migrated from lesional 
epidermis. CD4+ T cells become activated in local draining lymph nodes, but to what 
antigen they are responding is yet to be shown.  It has been suggested that CD4+ T cells 
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Figure 13. Activation of M/K peptide-active T cells in tonsils and skin 
(A) An infection or colonization of the tonsils by streptococci causes activation of effector CD4+ (blue) and 
CD8+ (red) T cells. Streptococcal superantigens induce the expression of skin-homing cutaneous lymphocyte-
associated antigen (CLA) on effector T cells. (B) Some streptococcal components, M-proteins, enter the 
bloodstream and are taken up by monocytes that migrate as APCs into skin. Circulating CLA+ effector CD4+ 
T cells migrate into the dermis and CLA+ effector CD8+ T cells migrate mostly into the epidermis where they 
might promote the characteristic keratinocyte proliferation of psoriasis by cross-recognizing keratin peptides 
that share sequences with streptococcal M peptides. APCs at the dermal–epidermal junction can present PG to 
CD4+ T cells via HLA class II molecules and keratin determinants to CD8+ T cells via HLA class I. 
Reproduced with permission.142 Copyright Elsevier Inc. 
respond to peptidoglycans presented by APCs.237 Recognition of self-peptides causes a pro-
inflammatory stimulus that breaks immunologic tolerance, causing activation of pDCs, 
mDCs, neutrophils, T cells and more cells relevant in the pathogenesis of psoriasis. This 
causes characteristic proliferation of keratinocytes and the release of key cytokines and 
chemokines. In the end, a vicious chronic psoriasis inflammatory loop, sustained by the IL-
23/IL-17 axis is established.  It is therefore possible that the CD8+ T cells are key players in 
the initiation of the plaque formation but require a complex interplay between various cell 
types such as the CD4+ T cells, within the skin for maintenance of the chronic 
Conversely, most CD8+ T cells migrate into the lesional
epidermis [5] whe e APCs would p ese t predominantly K
peptides, some of which will share sequences with strep-
tococcal M-protein (Figure 3, step 6). It is therefore pos-
tulated that most of the oligoclonal T cells observed in
l sional epide is [22] are specific for such cross-reactive
determinants that are presented by HLA class I molecules
on the surface of keratinocytes, and on DCs located in the
epidermis an at the dermis–epidermis junction (Figure 3,
step 8). A similar interaction might take place, to some
extent, in draining lymph nodes between both naı¨ve and
effector CD8+ T cells and DCs that have migrated to lymph
nodes from lesional epidermis. At the same time, PG inside
APCs in psoriatic lesions (Figure 3, steps 7 and 8), th
tonsils and lymph nodes draining lesional skin might have
an adjuvant effect via intracellular innate immune recep-
tors, and this effect might be different or exaggerated in
psoriasis patients [12]. Furthermore, it has been reported
recently that CD8+ T cells express TLR2 (a receptor f r
PG), ligation of which lowers their TCR activation
threshold [55] (Figure 3, step 8). Thus, the key to the
strong association between psoriasis and streptococcal
throat infections might be the concurrence in the pathogen
of (a) components with adjuvant activity, (b) amino acid
sequences that mimic human keratin, and (c) the release of
streptococcal uperantigens that have been r ported to
promote the expression of the skin-homing CLA epitope
[21].
Recirculation of pathogenic T cells in psoriasis
A recent proposal has suggested that psoriasis lesions
might be initiated and maintained by T cells that reside
in the skin without the need for recruitment from the
circulating T cell pool [56]. This hypothesis is based mainly
on the observation that transplants of uninvolved (i.e. non-
psoriatic) skin from psoriasis patients onto SCID mice,
which are also deficient in type I and type II interferon
receptors (and therefore also with greatly impaired NK cell
function, AGR129mice) became lesional after 4 to 5 weeks,
and a marked proliferation of the human T cells in the
graft, especially the epidermal CD8+ T cells, was observed
during this latent period [57]. This is a challenging prop-
ositio but thus f r it has not been reported how long t e
psoriatic lesions last in this animal model. It is well
documented that DCs have a very short half-life at inflam-
matory sites and, furthermore, that a substantial pro-
portion of effector T cells also become apoptotic during
an ong ing immunological response [reviewed in Ref. 58],
Figure 3. Recruitment of T cells, macrophages, and/or antigen-presenting cells (APCs) into psoriatic lesions. Step 1: Some streptococcal components, including PG (red)
and M-protein (black), enter the bloodstream and are taken up by monocytes/macrophages that migrate as APCs into developing psoriatic lesions. Step 2: There is an
increased frequency i the blood of psoriasis patients of both CD4+ and CD8+ T cells, which re pond to antige determinants that are common to both streptococcal M-
protein and type 1 Ks. Step 3: Re-circulating CLA+ effector CD4+ T cells migrate mainly into the lesional dermis. Step 4: CLA+ effector CD8+ T cells migrate mostly through the
dermis and into the epidermis. Entry of CD8+ T cells into the epidermis is required for the characteristic keratinocyte proliferation of psoriasis. Step 5: Streptococcal
components, including PG, are presented mainly in the dermis and hence mostly to CD4+ T cells. Step 6: K peptides that cross-react with streptococcal M-protein
determinants are presented predominantly in the epidermis and therefore to CD8+ T cells. Step 7: APCs at the dermal–epidermal junction can present PG to CD4+ T cells via
HLA class II molecules. Step 8: The same junctional APCs present keratin determinants to CD8+ T cells via HLA class I. PG might also lower the activation threshold of CD8+ T
cells expressing TLR2 [55].
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which are required for the development of psoriatic lesions
[5]. As shown in Figure 2 and elaborated in Box 1, we
propose that APCs in the tonsils and draining lymph nodes
present various streptococcal determinants to T cells. At
the same time, CLA expression on the resultant effector T
cells might be enhanced by streptococcal superantigen [21]
(Figure 2, steps 1 and 3)) which facilitates their egress into
the skin. As most CD4+ T cells in psoriatic lesions localize
to the dermis, they associate with APCs that might be
presenting streptococcal components, including PG [51],
and some might therefore expand clonally in response to
antigen determinants on PG (Figure 3, steps 5 and 7).
Figure 2. Psoriasis and three concurrent features of streptococcal throat infections. Step 1: Infection or colonization of tonsils by superantigen-producing microbes such as
Streptococcus spp. increases expression of skin-homing cutaneous lymphocyte-associated antigen (CLA) by tonsillar T cells. Steps 2 and 3: Streptococcal throat infections
or their persistence promotes maturation of both effector CD4+ (blue) and CD8+ (red) T cells that recognize streptococcal components, including PG (red) and M-protein
determinants (black). CD8+ T cells (but not CD4+ T cells) also express Toll-like receptor 2 on their surface (TLR2) (purple), which can bind PG. Macrophages and antigen-
presenting cells (APC) with internalized streptococcal components. Internalized PG might also provide adjuvant activity by binding to intracellular innate immune receptors
within APCs.
Box 1. Proposed etiological and pathogenic sequence in psoriasis
1) Genetically determined abnormal innate immune response asso-
ciated with deviated T cell responses (e.g. IFN-g or IL-17 bias?)
against microbes containing PG (proposed in Ref. [12] and here)
2) Increased frequency of streptococcal throat infections in psoriasis
patients [18]
3) Infection and colonization of tonsils by superantigen-producing
microbes increases expression of the skin-homing cutaneous
lymphocyte antigen (CLA) by tonsil T cells [21] (Figure 2, step 1)
4) Streptococcal throat infections or their persistence promote
maturation of effector T cells that recognize streptococcal
components including PG and M-protein determinants [12] (and
proposed here, Figure 2, steps 2 and 3).
5) Association between streptococcal throat infections and psoriasis
is strong du to concurrence of superantigen produ tion, PG that
bind to innate immune recept rs (e.g. TLR2) and M-protein that
mimics type 1 keratins in the epidermis (proposed here, Figure 2
steps 1–3).
6) Some streptococcal comp ents, in luding PG and M-protein,
enter the bloodstream where they are taken up by monocytes/
macrophages (proposed in Ref. 12 and here, Figure 3, step 1) NB
Macrophages are not found in efferent lymph nor have hey been
observed to migrate from (lymphoid) tissues into the circulation.
7) Increased frequency in the blood of psoriasis patients of both
CD4+ and CD8+ T cells that r spond to antigen det rminants that
are common to streptococcal M-protein and type 1 keratins
[43,44,47–49] (Figure 3, step 2).
8) Re-circulating CLA+ effector CD4+ T cells migrate mainly into
lesional dermis but CLA+ effector CD8+ T cells migrate mostly
through the dermis and into the epidermis [5,6] (Figure 3, steps 3
and 4).
9) Entry of CD8+ T cells is required for the characteristic keratinocyte
proliferation in psoriasis [5] (Figure 3 step 4).
10) Streptococcal components, including PG, are presented mainly in
the dermis and hence primarily to CD4+ T cells (Figure 3 step 5). K
peptides that share determinants with streptococcal M-protein
are predominantly presented in the epidermis and therefore
mainly to CD8+ T cells (proposed here, Figure 3, step 6).
11) Antigen presenting cells at the d rmal–epidermal junction
present PG d terminants to CD4+ T via HLA class II (Figure 3,
step 7), and present keratin determinants to CD8+ T cells via HLA
class I molecules (Figure 3, step 8). At the same time PG inside
antigen-presenting cells might mediate an adjuva t effect for
both CD4+ and CD8+ T cells via intracellular innate immune
receptors (proposed here, Figure 3, steps 7 and 8).
12) Recruit ent of naı¨ve T cells to the tonsils and draining lymph nodes
is probably required for maintaining persistent psoriatic plaques.
There is a close correlation between the frequency of CLA+ T cells in
the blood of psoriasis patients and their disease severity [59].
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inflammation. Hypothetically, an effective way to break the cycle would be to shut down 
the production of effector T cells in the tonsils and kill self-reactive T cells already in the 
skin.  This might be achieved with tonsillectomy, perhaps followed by UVB phototherapy. 
5.6 Strengths and limitations of the study 
This thesis adds important knowledge to the psoriasis literature on the association of 
streptococcal throat infections with plaque psoriasis and the effect of tonsillectomy. One of 
the major strengths of this study is its design as a prospective randomized controlled trial 
with observer-blinded assessments. Furthermore, there were no significant demographic 
differences between the tonsillectomy group and the controls, which further strengthen the 
study. Nevertheless, it is essential to critically evaluate the overall study design and 
acknowledge its various weaknesses.  
The study’s small cohort may limit the study. Iceland is a small country and has 
proportionally fewer patients with psoriasis to choose from, and thus not easy to recruit 
patients who are willing to undergo surgery and be followed-up with interviews, biopsies 
and blood samples for 24 months. The study cohort is furthermore limited to Icelandic 
patients with psoriasis. Possibly, Icelanders are more influenced by psoriasis environmental 
trigger factors such as streptococcal throat infections, although we are not aware of any such 
increased influence.  
Observer bias was addressed, by having the same person performing all the interviews 
and assessments. Furthermore this person was observer-blinded in regards to tonsils status, 
which further reduced bias. However, patients were not blinded to tonsillectomy treatment 
and this might have influenced patient reported outcomes, HRQoL and psoriasis-related 
stress questionnaires.  
Retrospective data were used in the retrospective questionnaire (paper IV) and some of 
the data collected for papers I and III. This may have caused recall bias because of inaccurate 
recall of past events and inflated the findings. Checking against medical records could have 
been undertaken, to minimize this form of bias, although many streptococcal throat 
infections are diagnosed with an instant strep-test or by physicians, most often at the primary 
healthcare level. Additionally, physicians working at hospitals in Iceland cannot easily 
access primary health care records, and it would have been time-consuming to contact these 
facilities for better information.  
Response bias (selection bias) could have affected the results in paper IV. It could be 
argued that patients who agreed to answer the questionnaire differ with regards to disease 
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characteristics from those who declined participation and hence, produce biased results. 
Furthermore, that study might reflect patients with a more severe form of psoriasis, since 
dermatologists were treating the patients recruited.  
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6 Conclusions 
The key aim of this thesis was to investigate the effect tonsillectomy has on plaque psoriasis 
and to define further the association between throat infections and the onset or exacerbation 
of psoriasis. The data herein demonstrate significant clinical, psychosocial and 
immunological improvement after tonsillectomy of patients with plaque psoriasis and 
history of sore throat-associated psoriasis exacerbation, compared with controls. In 
particular, it was demonstrated that sore throat and streptococcal throat infection causes 
exacerbation of psoriasis in more patients with plaque psoriasis than previously reported. 
Furthermore, removing the tonsils from patients with plaque psoriasis causes clinical 
improvement, which correlates closely with a decreased frequency of circulating T cells that 
recognize auto-epitopes that are over-expressed in psoriatic skin lesions. This was especially 
apparent for patients carrying both HLA-Cw*0602 alleles. These findings are in 
concordance with the hypothesis that the palatine tonsils may play a crucial role in the 
pathogenesis of psoriasis by producing pathogenic T cells, which migrate to the skin, react 
to autoantigens and thereby take part in creating the vicious cycle of chronic inflammation 
representative of psoriasis. 
Possible future avenues of research would include a larger, randomized controlled 
tonsillectomy trial to confirm the findings of the current study, where emphasis should be 
placed on a much larger group of homozygous HLA-Cw*0602 patients. In particular, it 
would be interesting to explore if M/K peptide-reactive skin-homing T cells in homozygous 
patients decrease significantly more compared to the non-carriers. Furthermore, a larger 
cohort opens up possibilities for further stratification of patients that could benefit from 
tonsillectomy. This might be done with respect to disease history, severity, gender and 
genotype. The next steps would also include determination of peptide-reactive skin-homing 
T cells in the skin. In this respect, tonsil tissue, blood and skin samples could be collected 
and compared for skin-homing markers and TCR rearrangements, determined using DNA 
and RNA sequencing.  
The heterogeneity of psoriasis emphasises the importance of tailoring individual 
therapies for patients (personalized medicine). Stratification of psoriasis phenotypes is 
central in personalized psoriasis treatments and in the near future we will likely be able to 
assess patients from both a clinical and genetic perspective and create genomic and 
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transcriptomic patient profiles.307 In conclusion, the observations in this thesis add important 
information that can aid in the stratification of patients with psoriasis and they elucidate 
further the pathogenic relationship between streptococcal throat infections and autoimmune 
sequelae in psoriasis.  
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Improvement of Psoriasis after Tonsillectomy Is Associated
with a Decrease in the Frequency of Circulating T Cells That
Recognize Streptococcal Determinants and Homologous Skin
Determinants
Ragna Hlin Thorleifsdottir,*,†,‡ Sigrun Laufey Sigurdardottir,*,‡ Bardur Sigurgeirsson,†
Jon Hjaltalin Olafsson,†,‡ Martin Ingi Sigurdsson,‡,x Hannes Petersen,‡,{
Sigurlaug Arnadottir,*,‡ Johann Eli Gudjonsson,‖ Andrew Johnston,‖ and
Helgi Valdimarsson*,‡
Exacerbation of chronic psoriasis can be associated with streptococcal throat infections, and T cells that respond to peptide sequen-
ces common to streptococcal M proteins and skin keratins have been detected in patients’ blood. To our knowledge, we have
conducted the first blinded, prospective study to assess the impact of tonsillectomy on psoriasis. Twenty-nine patients with chronic
psoriasis and history of exacerbation after sore throat were randomly assigned to tonsillectomy (n = 15) or control (n = 14) groups
and monitored for 2 y clinically and by enumeration of circulating skin homing T cells that respond to short homologous M
protein or keratin peptides. Thirteen patients (86%) showed sustained improvement after tonsillectomy ranging from 30 to 90%
reduction in disease severity. Furthermore, there was a close correlation between the degree of clinical improvement in individual
patients and reduction in the frequency of peptide-reactive skin-homing T cells in their circulation. No corresponding clinical or
immunologic changes were observed among the controls. These findings indicate that tonsillectomy may have a beneficial effect on
chronic psoriasis because the palatine tonsils generate effector T cells that recognize keratin determinants in the skin. The
Journal of Immunology, 2012, 188: 000–000.
P soriasis is a common inflammatory skin disease that can beassociated with arthritis and tends to have a fluctuatingcourse. Several distinct but overlapping clinical variants
have been identified, but chronic plaque-type lesions are most
common. Psoriatic plaques are characterized by a marked kera-
tinocyte hyperproliferation, altered differentiation, and keratin ex-
pression, and they are associated with dermal and epidermal in-
filtration of leukocytes. It is now generally accepted that these
changes are triggered and maintained by oligoclonal T lympho-
cytes, indicating that the psoriatic process is driven by conventional
Ags (1). The pathological epidermal hyperplasia coincides with
epidermal influx of a1b1 integrin-positive CD8
+ T cells and can be
prevented by specific blocking of this integrin (2). Recent studies
indicate that, in addition to Th1 cells, Th17 cells also have an
important role in psoriasis (3), as well as IL-17–producing CD8+
T cells (4), and that the keratinocyte hyperproliferation might be
driven by the Th17 cytokine IL-22, either directly or indirectly (5,
6). IFN-g is also a powerful inducer of the chemokine CCL20,
a ligand for CCR6, which is expressed by T cells that can produce
IL-17. In this way IFN-g may play a major role in enhancing the
IL-17 response (4). Psoriasis has a strong genetic component, with
a 40–70% concordance in identical twins (7, 8). Several suscep-
tibility alleles have now been identified and confirmed (9), and
HLA-Cw*0602 has recently been implicated as the strongest
susceptibility allele in psoriasis (10). On the basis of this and
various other pathological features of psoriasis, we have argued
that CD8+ T cells are likely to be the ultimate effector cells that
recognize autoepitopes presented in the context of HLA-Cw6 or
other HLA class I molecules on the surface of APCs and kerati-
nocytes (11). The pathogenic activity of these CD8+ T cells is,
however, likely to require a local interaction with CD4+ T cells,
involving cross-presenting dendritic cells (11).
A strong association between streptococcal throat infection and
the acute guttate variant of psoriasis (an early onset form) has been
demonstrated in many studies. Furthermore, it has been demon-
strated in a prospective study that chronic plaque psoriasis may also
exacerbate after such infections and, furthermore, the psoriasis
patients had an ∼10-fold higher frequency of streptococcal throat
infections than age-matched household controls (12). Moreover,
worsening was exclusively associated with throat infection by the
three groups of b-hemolytic streptococci (A, C, and G) that ex-
press M protein on their surface (12), a major virulence factor
composed of two polypeptide chains with a helical coiled-coil
configuration. Interestingly, mAbs raised against group A strep-
tococci cross-reacted with keratin defined as the a helical coiled-
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coil autoantigen in human skin (13, 14). Although psoriasis is
mediated by T cells and not by Abs, these findings potentially
linked keratin to psoriasis.
An extensive homology between streptococcal M protein and
keratin was first reported ∼20 y ago (15). Of ∼4200 mammalian
proteins that were compared, human type 1 keratins that are up-
regulated in psoriasis (16) showed the strongest homology with
the streptococcal M protein. On the basis of this and other find-
ings, it was proposed in 1995 that psoriasis can be initiated by
streptococcal superantigens and maintained by T cells that rec-
ognize streptococcal M protein determinants in the palatine tonsils
and homologous keratin determinants in the skin (17). Subse-
quently, a markedly increased frequency of T cells that recognize
such determinants was detected in the blood of patients with
chronic psoriasis compared with allergic dermatitis patients and
HLA-Cw*0602–positive healthy controls (18, 19). Notably, the
great majority (.90%) of the circulating T cells that responded to
the homologous K and M peptides expressed the skin-homing
entity cutaneous lymphocyte-associated Ag (CLA) (19).
There are several reports of partial or complete remission of
psoriasis following tonsillectomy (20, 21), including three patients
who were shown to have identical T cell clones in their palatine
tonsils and skin lesions (20). However, to our knowledge, no con-
trolled prospective trial has been reported. As most psoriasis pa-
tients have a fluctuating disease activity and spontaneous remissions
are not uncommon, matched patient controls are essential to de-
termine whether tonsillectomy has any beneficial effect.
To our knowledge, we have conducted the first blinded, pro-
spective study to assess the clinical and immunologic impact of
tonsillectomy on chronic psoriasis. We argued that if T cells,
primed against streptococcal M protein determinants in the pala-
tine tonsils, play a pathogenic role in psoriasis, then the numbers
of these cells should decrease in the circulation after tonsillectomy
and this should be associated with reduced disease activity.
Materials and Methods
Study population and clinical follow-up
Twenty-nine patients with chronic plaque psoriasis were recruited and ran-
domly allocated into tonsillectomy (TX) and control groups. The study was
approved by the Icelandic National Bioethics Committee (VSNb2006090015/
03-15). Written informed consent was obtained from each patient. Patients
were eligible for the study if they were$18 y age, had been diagnosed by a
dermatologist with chronic plaque psoriasis, and had a history of psoriasis
exacerbation during or shortly after throat infections. Patients with heart
and lung diseases were excluded. The patients were off treatment, in-
cluding antibiotics, for at least 4 wk before they entered the study and for
2 mo thereafter. Subsequently, the participants were allowed to have
treatment according to what they and their dermatologists thought indi-
cated. Their disease course was followed for at least 2 y and their disease
severity assessed by the Psoriasis Area and Severity Index (PASI) (22),
which is the standard method for evaluating changes in the extent and
activity of this disease. The clinical evaluation was observer-blinded with
regard to tonsillectomy. The participants were evaluated clinically at study
entry and after 2, 6, 12, 18, and 24 mo and blood samples were obtained at
study entry and after 2, 12, and 24 mo. The patients’ need for anti-psoriasis
treatment during the follow-up was also monitored. The patients were all
examined for tonsillar remnants at the end of the study.
Homologous peptide Ags
The amino acid sequence of keratin 17 was split into a complete set of
overlapping residue peptides that were then used as a library to compare
with the sequence of the M6 protein using the FASTA algorithm (23). The
homologous M peptides were restricted to the conserved C-terminal half of
the protein whereas the homologous keratin peptides were present in two
coil-forming regions of keratin 17. Each homologous M peptide shared
four to six amino acids with the corresponding K peptide, and they were
further selected on the basis of predicted binding to HLA-Cw*0602 as
previously described (19). Thus, 64 short, mostly 9- to 12-aa overlapping
peptides derived from human cytokeratin 17 or streptococcal M6 protein
(homologous K/M peptides) were selected on the basis of sequence ho-
mology and predicted binding to HLA-Cw*0602 as previously described
(19). The peptides were blended into 16 peptide pools, each containing 8
peptides. Supplemental Table I shows the size and location of the over-
lapping homologous K/M peptides, and supplemental Table II shows their
sequences and lists some relevant references.
Enumeration of peptide-reactive T cells
The frequency of T cells that respond to amino acid sequences common to
keratin and M protein was determined as previously described (19). Briefly,
PBMCs or tonsillar mononuclear cells were isolated from heparinized
venous blood of psoriatic individuals or tonsillar tissue (24) by Ficoll
(Sigma-Aldrich, St. Louis, MO) density gradient sedimentation. Single-
cell suspensions of tonsillar mononuclear cells were prepared as described
(24). The PBMCs or tonsillar mononuclear cells were cultured at a density
of 1 3 106 cells/ml in complete RPMI 1640 in cell culture tubes (Nunc,
Thermo Fisher Scientific, Roskilde, Denmark) and stimulated for 16 h with
the 16 peptide pools (see Supplemental Table I) at a final concentration of
2 mg/ml, in the presence of the costimulatory Abs to CD28 and CD49d (1
mg/ml each; Serotec Scandinavia, Oslo, Norway). After the first 2 h the
secretion inhibitor brefeldin A was added (10 mg/ml; Sigma-Aldrich) and
the cultures incubated for a further 14 h at a 5˚ slant at 37˚C in a humid-
ified 5% CO2 atmosphere. Anti-CD3 (1 mg/ml; Serotec Scandinavia) and
streptokinase (200 U/ml; Hoechst Marion Roussel, Stockholm, Sweden)
were used as positive controls. The great majority (.90%) of the T cells
responding to the homologous K and M peptides express the skin-homing
entity CLA (19). After the incubation, the mononuclear cells were there-
fore stained with anti–CLA-FITC (BioLegend, San Diego, CA) and anti-
CD4 or CD8-PerCP mAbs (BioLegend) on ice, in the dark for 20 min.
After two washes in PBS, the cells were fixed in 500 ml cold (4˚C) 2%
paraformaldehyde for 10 min at room temperature and after a further wash
they were treated with permeabilizing buffer (0.5% BSA, 0.1% saponin,
0.1% sodium azide; Sigma-Aldrich) for 10 min at room temperature,
followed by a wash and resuspension in the same buffer. The cells were
then stained with anti–IFN-g-PE (BioLegend) and anti–IL-17A-AF647 for
20 min at 4˚C in the dark, washed in 1.5 ml permeabilizing buffer,
centrifuged for 5 min at 500 3 g, and resuspended in 250 ml per-
meabilizing buffer supplemented with 1% paraformaldehyde. Lympho-
cytes were analyzed using a FACSCalibur flow cytometer (BD Biosciences)
gating on light scatter and CD4, CD8, and CLA expression, capturing
a minimum of 200,000 events guided by appropriate isotype control Abs.
The source and characteristics of the various Ab conjugates used for the
flow cytometric analyses are shown in Supplemental Table III.
HLA-Cw*0602 typing
Genotyping of blood mononuclear cells for HLA-Cw*0602 alleles was
performed as previously described (10).
Serum IL-8 ELISA
Serum IL-8 was used as a serological inflammatory marker and measured at
study entry and after 24 mo by Quantikine ELISA (R&D Systems, Min-
neapolis, MN) as directed by the manufacturer.
Table I. Baseline demographic information and disease characteristics
of the patients
TX Group
(n = 15)
Control Group
(n = 14)
Males/females 3/12 6/8
Age, y (6SD) 35.3 6 9.9 35.9 6 9.8
Body mass index 6 SD 25.2 6 5.3 25.4 6 3.6
Duration of psoriasis, y (6SD) 19.9 6 9.5 20.5 6 11.7
Age at onset, y (range) 15 (4–35) 15 (2–28)
Family history (n) 12 12
Psoriatic arthritis (n) 4 1
Psoriatic nails (n) 10 9
HLA-Cw*060-positive 11 13
PASI score 6 SD 11.0 6 5.7 9.3 6 3.7
Prior treatments (n)
Topical 8 8
UVB 5 4
Systemic 1 0
Values are means unless specified otherwise.
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Expression of the data and statistics
Flow cytometric responses were rated positive when .0.05% of the CLA+
CD4 or CD8+ T cell populations expressed IFN-g or IL-17 brighter than
the corresponding unstimulated culture or fluorescence minus one control.
The frequency of T cells that responded to each of the 16 peptide pools
was determined as a percentage of CLA+ cells in each of the T cell sub-
populations and then expressed as an average for each patient after square
root normalization.
Data were tested for normality using the Kolmogorov–Smimov test. PASI
scores and peptide responses were compared between the groups and dif-
ferent time points using an ANOVA test for repeated measurements. For
peptide response measurements, the square root of the peptide responses was
used to better approximate normality. Correlation between peptides responses
was performed using R, version 2.10 (The R Foundation, Vienna, Austria).
Results
Clinical findings
Twenty-nine patients with chronic plaque psoriasis were recruited
and randomly allocated into TX and control patient groups. De-
mographic information about the participants at study entry and
their disease characteristics are presented in Table I.
As depicted in Fig. 1A the mean PASI score decreased signif-
icantly in the TX group, both with time after tonsillectomy and
compared with the controls (p , 0.001). Thus, 13 of 15 tonsil-
lectomized patients showed an improvement ranging from 30 to
90% reduction of the PASI score (Fig. 1C), and up to 60% (9 of
15) reached 50% reduction in skin lesions at some stage during the
study (Fig. 1B). The improvement was in most cases observed
within 2 mo and was generally maintained throughout the 2-y
follow-up (Fig. 1C). No consistent corresponding clinical changes
were observed among the control patients (Fig. 1D). Furthermore,
12 (86%) of the controls used topical treatment at some time point
during the study compared with only 4 (27%) in the TX group
(Table II). However, three patients in each group had been given
phototherapy and one patient in the TX group was started on
methotrexate after 12 mo because of arthritis. There was no clear
association between the degree of improvement and carriage of
the HLA-Cw*0602 allele, but more patients need to be studied in
this context.
The effect of tonsillectomy on serum concentration of IL-8
To objectively assess changes in inflammatory activity, serum
levels of IL-8 were measured at study entry and after 24 mo, and, as
shown in Fig. 2, a slight but significant decrease was observed in
the tonsillectomized patients but not in the control patients despite
their more frequent topical treatment (Table II).
FIGURE 1. Clinical changes during the 2-y follow-up. (A) A significant decrease in the mean PASI score was observed in the tonsillectomized patients
both with time and when compared with the controls (p , 0.001). (B) Percentage of tonsillectomized patients that reached 50% improvement (PASI50),
75% improvement (PASI75), and 90% improvement (PASI90) at each time point. (C) Percent changes in the PASI scores of individual participants
throughout the 2-y of study, with the scores at study entry for each patient being set as 0. Thirteen of 15 participants in the TX group improved clinically
(range, 30–90%) after tonsillectomy. Patients 4 and 6 (arrows) did not show significant changes in blood frequencies of peptide-reactive skin-homing
T cells. No corresponding clinical improvement was observed in the controls (D).
Table II. Psoriasis treatments during the 2-y follow-up
Treatment 6–24 mo TX Group (n = 15) Control Group (n = 14)
Topical, n (%)a 4 (27) 12 (86)
Phototherapy, n (%) 3 (20) 3 (21)
Systemic, n (%) 1 (7)
aCorticosteroid creams and vitamin D analog creams.
The Journal of Immunology 3
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The effect of tonsillectomy on the frequency of the circulating
peptide-reactive T cells
The frequency of T cells responding to each of 16 pools of ho-
mologous M protein and keratin peptides (see Supplemental Table
I) was determined at study entry and after 2, 12, and 24 mo by flow
cytometry as a percentage of skin homing (CLA+) cells in each
T cell subpopulation. Fig. 3A shows the marked general decline
usually observed in the frequency of circulating CD8+ T cells
responding to each of the 16 peptide pools in one representative
patient before and 2 mo after tonsillectomy. Similar declines were
observed in the tonsillectomized patients after 12 and 24 mo,
whereas no consistent corresponding changes were detected in the
control patients (Fig. 3B). The average responses of each patient
to all 16 peptide pools were then calculated at each time point
after square root normalization (Figs. 4, 5, Supplemental Fig. 1).
As shown in Fig. 4, there was a very strong positive correlation
between the frequency of peptide-reactive skin homing CD8+
T cells in tonsils and blood at the time of the tonsillectomy. This
applied to both IFN-g– and IL-17–producing CD8+ T cells (r =
0.788, p , 0.001 and r = 0.644, p = 0.015, respectively). A sig-
nificant correlation was also observed between the frequency of
IFN-g–producing skin-homing CD4+ T cells in tonsils and blood
(r = 0.679, p = 0.001), but a corresponding correlation was not
observed for IL-17–producing skin-homing CD4+ T cells (r =
0.315, p = 0.273) (data not shown). After tonsillectomy, the fre-
quency of circulating peptide-reactive IFN-g–producing skin
homing CD8+ T cells decreased significantly compared with the
controls (p = 0.003) (Fig. 5A). Furthermore, there was a highly
significant correlation between the extent of clinical improvement
(decreases in PASI scores) of individual patients and the degree of
decline in the frequency of peptide-reactive skin homing IFN-g+
CD8+ T cells in their blood (r = 0.594, p , 0.001). As depicted
in Supplemental Fig. 1, similar associations were observed for
peptide-reactive skin-homing IL-17–producing CD8+ T cells in
the tonsillectomized patients (r = 0.560, p , 0.001). A weaker
association was found for skin-homing IL-17+CD4+ T cells
(p = 0.003), but the association was not significant for IFN-g+
CD4+ T cells (p = 0.137). No associations between changes in
PASI scores and frequency of circulating peptide-reactive CD8+ or
CD4+ T cells were found in the control patients (Fig. 5C, Sup-
plemental Fig. 1C). No decreases were observed after tonsillec-
tomy in the frequencies of circulating T cells that responded to
anti-CD3 Ab stimulation or to the control Ag streptokinase (data
not shown).
Discussion
It has previously been reported that psoriasis patients have in their
circulation T cells that recognize determinants that streptococcal M
protein share with some human keratins (18, 19) and the great
majority of these T cells are CLA+ (19). We now report that
patients with chronic psoriasis and a history of disease exacer-
bation in association with sore throat generally improve after
tonsillectomy, and concurrently the numbers of circulating T cells
that recognize these shared determinants show a marked decline.
These findings indicate that effector T cells originating from the
palatine tonsils may be involved in the pathogenesis of psoriasis.
First, there is a very close correlation between the frequency of
such T cells in the tonsils and peripheral blood (Fig. 4), suggesting
that the tonsillar T cells are recirculating. Second, the extent of the
decline in the numbers of these T cells in the circulation correlates
fairly closely with the degree of clinical improvement of indi-
vidual patients (Fig. 5B).
Note that this study was designed to detect maximal numbers of
T cells that are specific for determinants that streptococcal M
proteins share with human type 1 keratins. Thus, the study does not
distinguish between T cells that recognize primary, dominant
FIGURE 2. Serum concentrations of IL-8. Serum
levels of IL-8 were measured at study entry and after
24 mo, and (A) a slight but significant decrease was
observed in the tonsillectomized patients (p = 0.034)
but not in the control patients (B) (p = 0.275) despite
more topical treatment (Table II) (Wilcoxon matched
pairs signed rank test).
FIGURE 3. Tonsillectomy was associated with a striking reduction in
the frequency (percentage) of circulating T cells that recognized the 16
homologous peptide pools. Frequency (percentage) of circulating CLA+
CD8+ T cells producing IFN-g after stimulation with the homologous
keratin and M protein peptide pools at study entry and after 2 mo: (A)
representative tonsillectomized psoriasis patient; (B) representative control
psoriasis patient. The responses of each patient to all 16 peptide pools were
then calculated for each time point and expressed, after square root nor-
malization, as an average for each patient (see Fig. 5, Supplemental Fig. 1).
4 EVIDENCE FOR MOLECULAR MIMICRY IN PSORIASIS
   
101 
 
 
autoepitopes and determinants that reflect epitope spreading or
T cells that may respond exclusively to either keratin or M protein
determinants.
Furthermore, our observations do not exclude the possibility that
other Ags may be involved in the pathogenesis of psoriasis, in-
cluding other streptococcal (25) or peptidoglycan components
(26). Note in this context that we selected M protein and keratin
peptides that were predicted to bind relatively strongly with HLA-
Cw*0602, which is carried by ,50% of patients with chronic
psoriasis (27), although this may vary between populations (28,
29). Second, we selected for this study patients who reported
aggravation of their disease in association with sore throat,
which only applies to ∼40% of patients with chronic psoriasis in
Iceland (R.H. Thorleifsdottir, J.H. Eysteinsdottir, J.H. Olafsson,
B. Sigurgeirsson, M.I. Sigurdsson, and H. Valdimarsson, manu-
script in preparation). It remains to be investigated whether
patients who have not noticed worsening in association with sore
throat also improve after tonsillectomy. Furthermore, two of the
patients in our study did not improve after tonsillectomy (see
arrows in Fig. 1C), although no tonsillar remnants could be
detected in these patients after the operation. Thus, indications for
tonsillectomy of patients with chronic psoriasis remain to be pre-
FIGURE 4. There was a signifi-
cant correlation between the fre-
quency of peptide-reactive skin-
homing CD8+ T cells in the blood
and tonsils at the time of the tonsil-
lectomy. (A) IFN-g–producing pep-
tide-specific CD8+ T cells (r = 0.788,
p , 0.001). (B) IL-17–producing
peptide-specific CD8+ T cells (r =
0.644, p = 0.015). Data expressed as
a square root normalized average of
peptide-reactive skin-homing T cells
(Spearman rank correlation test).
FIGURE 5. Changes in the blood
frequencies of IFN-g–producing
peptide-specific CD8+ T cells in the
tonsillectomized and control patients.
(A) Box plot shows a significant
decrease in the average frequency
of peptide-reactive IFN-g–producing
skin-homing (CLA+) CD8+ T cells in
the tonsillectomized compared with
the controls (p = 0.003, ANOVA). (B)
Close correlation throughout the 2-y
study period (three data points per
patient) between clinical improve-
ment (percentage reduction of PASI)
and percentage reduction in the blood
frequency of skin-homing IFN-g pro-
ducing peptide-reactive CD8+ T cells
(r = 0.594, p , 0.001). No such
correlation was observed in the con-
trols (r = 20.023, p = 0.896). The T
cell frequency data are expressed as
a square root normalized average of
peptide-reactive skin-homing T cells.
PASI and T cell frequency at study
entry were set as 0 for each partici-
pant. In (B) and (C), the vertical axis
shows percentage changes in the PASI
scores and the horizontal axis per-
centage changes in the frequency of
peptide-reactive CLA+CD8+ T cells
during the study period (Spearman
rank correlation test).
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cisely defined. It is therefore not possible at this stage to estimate
how large a proportion of patients with chronic psoriasis might
benefit from tonsillectomy, and information is also lacking about
how long such improvement may last beyond the 2-y follow-up in
the present study. Note that the tonsillectomized patients not only
benefited in terms of reduction of skin lesions but also required less
symptomatic treatment than the control patients, and longer term
follow-up studies should therefore also focus on that issue.
Recent studies have indicated that CD8+ T cells may play
a more direct role than CD4+ T cells in the pathogenesis of pso-
riasis (2, 4, 11). Thus, the great majority of T cells in lesional
epidermis are CD8+ and, furthermore, psoriasis lesions do not
develop when CD8+ T cells are prevented to migrate from dermis
into epidermis (2). Our data support this, as there is a stronger
correlation between clinical improvement and reduction in the
frequency of cross-reactive CD8+ than CD4+ T cells.
Our findings may help to identify some of the autoepitopes that
are recognized by T cells in psoriatic lesions. It has been reported
by many groups that these lesions are infiltrated by oligoclonal
T cells (1), and although most of these clones are transient (1) and
probably reflect autoepitope spreading (30), others are dominant
and persist or even reappear in lesional skin after treatment-
induced remission (31, 32).
Only symptomatic treatments are currently available for psori-
asis, and symptoms usually relapse when treatment is discontinued.
It is still not clear if and to what extent Ag-specific immuno-
therapeutic measures, which are curative in some animal models of
autoimmunity, are directly applicable to human autoimmune dis-
eases. This is probably partly because epitope spreading makes it
difficult to identify primary and dominant autoepitopes in humans
(30, 33). However, identification of circulating T cells that respond
to homologous M protein and keratin determinants in patients
with treatment-induced remission (32) may help to identify pri-
mary autoepitopes that might be targeted for highly specific im-
munotherapy for psoriasis.
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SUPPLEMENTARY FIGURE 1. Changes in the blood frequencies of IL-17 producing 
peptide-reactive CD8+ T cells the tonsillectomized and control patients. Panel a) shows by 
a box plot the average frequency of peptide-reactive IL-17 producing skin homing CD8+ 
T cells in the tonsillectomized and control patients (p = 0.009, ANOVA). Panel b) shows a 
close correlation between clinical improvement (percent reduction of PASI) and percent 
reduction in the blood frequency of skin homing IL-17 producing peptide-reactive CD8+ 
T cells (r = 0.594, p < 0.001). No such correlation was observed in the controls (panel c, r 
= 0.274, p = 0.130). Data expressed as a square root normalized average peptide-reactive 
skin homing T cells. PASI and T cell frequency at study entry was set as zero for each 
participant. Spearman's rank correlation test. 
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Supplemental Table I. Composition of peptide pools1 
 
1 2 3 4 5 6 7 8 
9 31-K17-12 
130-K17-
9 
206-K17-
9 
236K17-
12 
372-K17-
9 261-M6-9
262-M6-
12 355-M6-9
10 101-K17-12 
134K17-
12 
212K17-
12 
238-K17-
9 
379-K17-
12 282-M6-9
285-M6-
12 
368-M6-
16 
11 125-K17-9 
135-K17-
9 
217-K17-
9 
239K17-
12 
379-K17-
9 
299-M6-
12 146M49 
382-M6-
12 
12 127-K17-9 
139-K17-
9 
220-K17-
9 
309-K17-
9 
396-K17-
9 299-M6-9 M146 384-M6-9
13 128-K17-9 
162-K17-
12 
220-K17-
12 
334-K17-
12 
404-K17-
9 306-M6-9
338M6-
12 
464-M6-
12 
14 128-K17-10 
165-K17-
12 145K10 
338-K17-
12 
407-K17-
9 
 319-M6-
12 
344-M6-
12 M159 
15 146K17 168-K17-9 145K17 
351-K17-
12 
415-K17-
12 324-M6-9
354-M6-
12 GAGE 
16 146K9 179-K17-9 
231-K17-
9 
366-K17-
12 
255-M6-
12 327-M6-9 345-M6-9 BMRF-1 
 
 
 
                                                 
1 White boxes are human keratin peptides, light gray boxes are streptococcal peptides and dark grey 
boxes are controls. 
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1 White boxes are human keratin peptides, light gray boxes are streptococcal peptides and dark grey 
boxes are controls. 
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Supplemental Table II. Peptide sequences derived from keratin and M6 protein. 
Peptide name 1  Sequence 2 Peptide name  Sequence 
31-K17-12 ISSVLAGASCPA 464-M6-12 ALTVMATAGVAA3 
101-K17-12 GGGFAGGDGLLV4     
125-K17-9 RLASYLDKV 306-M6-9 NLTAELDKV 
127-K17-9 ASYLDKVRA     
128-K17-10 SYLDKVRALE     
146K17 SYLDKVRALEEANADLEVKI5 M146 AKKQVEKALEEANSKLAALE5,6
146K9 SYLDKVQALEEANNDLENKI5 146M49 AKKKVEADLAEANSKLQALE5 
128-K17-9 SYLDKVRAL     
130-K17-9 LDKVRALEE 344-M6-12 KALEEANSKLAA 
134-K17-12 RALEEANADLEV 354-M6-12 AALEKLNKELEE 
135-K17-9 ALEEANADL 345-M6-9 ALEEANSKL 
309-K17-9 KTEELNKEV 355-M6-9 ALEKLNKEL 
139-K17-9 ANADLEVKI     
162-K17-12 YSPYFKTIEDLR4     
165-K17-12 YFKTIEDLRNKI4     
168-K17-9 TIEDLRNKI     
179-K17-9 ATIENAHAL     
206-K17-9 ARTGLRQTV 324-M6-9 SRQGLRRDL 
217-K17-9 DVNGLRRVL 282-M6-9 SRKGLRRDL 
372-K17-9 QIQGLIGSV     
212-K17-12 QTVEADVNGLRR 319-M6-12 QISDASRQGLRR 
220-K17-12 GLRRVLDELTLA 285-M6-12 GLRRDLDASREA 
220-K17-9 GLRRVLDEL 327-M6-9 GLRRDLDAS 
145K17 LRRVLDELTLARTDLEMQIE5     
145K10 LRRVLDELTLTKADLEMQIE5 382-M6-12 EAEAKALKEQLA 
231-K17-9 ARTDLEMQI 261-M6-9 DIGALKQEL 
236-K17-12 EMQIEGLKEELA 384-M6-9 EAKALKEQL 
238-K17-9 QIEGLKEEL 262-M6-12 IGALKQELAKKD 
239-K17-12 IEGLKEELAYLR 368-M6-16 KLTEKEKAELQAKLEA 
334-K17-12 LRRVLQGLEIIL7 M149 KLTEKEKAELQAKLEAEAKA5,6 
338-K17-12 LQGLEIILQSQL7 255-M6-12 EQKSKQDIGALK4 
351-K17-12 MKASLENSLEET 338-M6-12 AKKQVEKALEEA6 
366-K17-12 YCMQLSQIQGLI4,7     
379-K17-12 SVEEQLAQLRCE 299-M6-12 QVEKDLANLTAE 
379-K17-9 SVEEQLAQL 299-M6-9 QVEKDLANL 
396-K17-9 QEYQILLDV     
404-K17-9 VKTRLEQEI   
407-K17-9 RLEQEIATY GAGE YRPRPRRY8 
415-K17-12 YRRLLEGEDAHL4 BMRF1 YRSGIIAVV9 
 1 Peptide name indicates the start position in the protein sequence, protein name and sequence length.  
2 Sequences used in Johnston A. et al. Clin Exp Immunol 2004; 138:83-93, except where indicated. 
3 Examples of sequence homologies shared by K and M peptides in bold face. 
4 Sequence or partial sequence used in Dionne S.O. et al. Immunogenetics 2004; 56:391-8.  
5 Sequence used in Gudmundsdottir A.S. et al. Clin Exp Immunol 1999; 117:580-6. 
6 Sequence used in Sigmundsdottir H. et al. Scand J Immunol 1997; 45:688-97. 
7 Sequence used in Shen Z. et al. J Dermatol Sci 2005; 38:25-39. 
8 A peptide used as a negative control for Cw6 binding (van den Eynde B.  et al. J. Exp. Med. 1995 182 
689-698). 
9 A peptide from Epstein-Barr Virus Protein BMRF1 as a positive control (Steven N.M. et al., J. Exp. 
Med. 1997 185 1605-1617). 
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 Supplemental Table III.  Antibodies used for flow cytometric analysis. 
Target Conjugate Source Clone Isotype
CD4 PerCP-Cy5.5 BD Biosci SK3 G1
CD8 PerCP-Cy5.5 BD Biosci SK1 G1
IgG1 control PerCP-Cy5.5 BD Biosci X40  
CLA FITC BioLegend HECA-452 Rat IgM
Rat IgM control FITC BioLegend  
IFN-γ PE BioLegend 4S.B3 G1
IL-17A A647 eBioscience eBio64CAP17 G1
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3VRULDVLV LV D FKURQLF LQÀDPPDWRU\ VNLQ GLVHDVHZLWK
SURIRXQGHIIHFWVRQSDWLHQWV¶ KHDOWKUHODWHGTXDOLW\RI
OLIH+54R/7ZHQW\QLQHSDWLHQWVZLWKSODTXHSVRULD
VLVDQGDKLVWRU\RI VWUHSWRFRFFDODVVRFLDWHGSVRULDVLV
H[DFHUEDWLRQVZHUH UDQGRPO\ DVVLJQHG WR WRQVLOOHFWR
P\n RUFRQWUROn JURXSVDQGIROORZHGIRU
PRQWKV3DWLHQWVZHUHHYDOXDWHGZLWKWKH3VRULDVLV
'LVDELOLW\ ,QGH[ 3VRULDVLV /LIH 6WUHVV ,QYHQWRU\ DQG
3VRULDVLV$UHDDQG6HYHULW\,QGH[+54R/DQGSVRULD
VLVUHODWHGVWUHVVLPSURYHGVLJQL¿FDQWO\LQWKHWRQVLOOHF
WRP\JURXSFRPSDUHGZLWKWKHFRQWUROJURXSp 
DQGp UHVSHFWLYHO\ZLWKDPHDQLPSURYH
PHQWLQ+54R/DQGDPHDQLPSURYHPHQWLQSVR
ULDVLVLQGXFHG VWUHVV &OLQLFDO LPSURYHPHQW FRUUHODWHG
VLJQL¿FDQWO\ZLWKLPSURYHG+54R/U p 
DQG SVRULDVLVUHODWHG VWUHVV U  p  2I
WKHWRQVLOOHFWRPL]HGSDWLHQWVFRQFOXGHGWKDWWKH
SURFHGXUHZDVZRUWKZKLOH7RQVLOOHFWRP\PD\LPSURYH
TXDOLW\RIOLIHIRUVHOHFWHGSDWLHQWVZLWKSODTXHSVRULDVLV
Key words: chronic plaque psoriasis; streptococcal throat in-
fection; tonsillectomy; health-related quality of life; Psoriasis 
Disability Index; Psoriasis Life Stress Inventory. 
Accepted Nov 2, 2016; Epub ahead of print xx
Acta Derm Venereol 2017; 97: XX–XX.
Corr: Ragna Hlin Thorleifsdottir, Department of Medical Sciences, Derma-
tology, Uppsala University, Akademiska University Hospital, SE-751 85 
Uppsala, Sweden. E-mail: ragnahlin@gmail.com
Psoriasis is a complex multifactorial disease caused by a combination of genetic and environmental factors 
(1), affecting approximately 2–3% of the world’s popu-
ODWLRQ3VRULDVLVKDVDVLJQL¿FDQWQHJDWLYHLPSDFWRQ
many areas of health-related quality of life (HRQoL), 
including physical, occupational, social, psychological, 
and sexual wellbeing (3–5). Patients with psoriasis have 
reduced HRQoL, similar to that caused by major chronic 
illnesses such as cancer, myocardial infarction and dia-
betes mellitus (6). Many patients have low self-esteem 
and feel embarrassed, helpless, and stigmatized due to the 
visible nature of psoriasis (7, 8), which FDXVHVVLJQL¿FDQW
daily stress for patients (9). Clinical assessments, such as 
the Psoriasis Area and Severity Index (PASI) (10), do not 
DGHTXDWHO\UHÀHFWWKHJHQHUDOLPSDFWWKDWWKHGLVHDVHKDV
on the lives of patients with psoriasis, but instead give a 
static score of clinical disease severity (11). 
Many environmental factors have been implicated in 
SVRULDVLVLQSDUWLFXODUWKURDWLQIHFWLRQZLWKȕKDHPRO\WLF
streptococci has been associated with both the initiation 
and exacerbation of psoriasis (12–15). T cells primed 
by streptococcal antigens in the tonsils may react with 
homologous antigens in the skin (16–18), and there 
are several reports of partial or complete remission of 
psoriasis after tonsillectomy (reviewed by (19–21)). We 
reported previously on a randomized controlled trial exa-
PLQLQJWKHFOLQLFDOHI¿FDF\DQGLPPXQRORJLFDOLPSDFWRI
tonsillectomy on plaque psoriasis. The results indicated 
WKDWWRQVLOOHFWRP\FDQOHDGWRDVLJQL¿FDQWFOLQLFDOLPSUR-
YHPHQWLQSODTXHSVRULDVLVZLWKDVLJQL¿FDQWUHGXFWLRQ
in the frequency of skin-homing T cells that recognize 
homologous streptococcal M-protein and skin keratins 
:HUHSRUWKHUH¿QGLQJVUHODWHGWRSDWLHQW+54R/
and psoriasis-induced stress and their association with 
clinical improvement after tonsillectomy. 
METHODS
Patients
Patient eligibility criteria have been detailed previously (22). 
%ULHÀ\HOLJLEOHSDWLHQWVZHUH\HDUVRIDJHKDGPRGHUDWH
to-severe chronic plaque psoriasis diagnosed by a dermatologist; 
had a history of sore throat-associated psoriasis exacerbation; and 
ZHUHZLOOLQJWRXQGHUJRWRQVLOOHFWRP\([FOXVLRQFULWHULDZHUH
underlying medical conditions, such as heart and lung diseases 
and bleeding disorders; alcohol or drug abuse; pregnancy; and 
previous tonsillectomy. Before study initiation patients were re-
quired to discontinue all psoriasis treatment except moisturizers 
within the previous 4 weeks.
Fifty-four patients were screened for the study, the majority of 
whom were referred by a dermatologist (44%) or responded to an 
advertisement (46%). A few patients had heard about the study by 
other means (6%) or were referred by an otolaryngologist (4%). 
Written informed consent was obtained from each patient before 
initiation of study participation. A total of 29 patients met the 
inclusion criteria.
Study design
This was a single-centre, 24-month, parallel, assessor-blind, 
randomized controlled trial. Data were collected within the de-
Patient-reported Outcomes and Clinical Response in Patients with 
Moderate-to-severe Plaque Psoriasis Treated with Tonsillectomy: 
A Randomized Controlled Trial
Ragna Hlin THORLEIFSDOTTIR1,2, Sigrun Laufey SIGURDARDOTTIR3, Bardur SIGURGEIRSSON1, Jon Hjaltalin OLAFSSON1, 
Martin Ingi SIGURDSSON4, Hannes PETERSEN5, Johann Eli GUDJONSSON6, Andrew JOHNSTON6 and Helgi VALDIMARSSON3
1Faculty of Medicine, Section of Dermatology, University of Iceland, Reykjavik, Iceland, 2Department of Medical Sciences, Dermatology, 
Uppsala University, Uppsala, Sweden, 3Department of Immunology, 4Department of Anesthesiology and Critical Care, 5Department of 
Otolaryngology-Head and Neck Surgery, Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland, and 6Department of 
Dermatology, University of Michigan Medical School, Ann Arbor, MI, USA
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R. H. Thorleifsdottir et al.2
www.medicaljournals.se/acta
partments of Dermatology and Otolaryngology-Head and Neck 
Surgery in Landspitali, The National University Hospital of Ice-
land, Reykjavik, Iceland, from November 2007 to January 2011. 
The study was conducted in accordance with the 1964 Declaration 
of Helsinki and its later amendments and approved by the National 
Bioethics Committee of Iceland (VSNb2006090015/03-15) and 
the Data Protection Authority of Iceland. 
A sealed allocation sequence with a numerical code was created 
by the study supervisor before recruitment began, with a simple 
UDQGRPL]DWLRQLQDUDWLR7KHSDWLHQWVZKRPHWWKHLQFOXVLRQ
criteria were allocated into tonsillectomy and control groups (Fig. 
1). The allocation was concealed until the end of the study in order 
to reduce study bias. Recruitment and follow-up of all patients was 
performed by the same investigator throughout the study, who was 
unaware of the allocation system and thus the tonsil status of the 
patients. Detailed data were collected on patients’ demographics 
and psoriasis features. Patient-reported outcomes were measured 
at baseline and at months 12 and 24.
Study end-points
3ULPDU\HQGSRLQWVZHUHGH¿QHGDVFOLQLFDOO\VLJQL¿FDQWFKDQJHV
in HRQoL, assessed by the Psoriasis Disability Index (PDI) and 
Psoriasis Life Stress Inventory (PLSI) at 12 and 24 months. These 
parameters, along with secondary end-points, were compared with 
baseline scores and between the 2 groups. Secondary end-points 
included the correlations between the change in clinical disease 
severity (Psoriasis Area and Severity Index, PASI score) and 
HRQoL scores (PDI and PLSI) as well as evaluation of a study-
VSHFL¿FTXHVWLRQQDLUHDSSOLHGDWWKHHQGRIWKHVWXG\
Questionnaires
+54R/ZDV DVVHVVHGZLWK D SVRULDVLVVSHFL¿F TXHVWLRQQDLUH
the Psoriasis Disability Index (PDI) (23). The PDI is a validated 
self-administered questionnaire covering aspects of functional 
disability owing to psoriasis in the preceding 4 weeks. The PDI 
DGGUHVVHVLVVXHVWKDWFDQJURXSWRGRPDLQVGDLO\DFWLYLWLHV
work/school, personal relationships, leisure, and treatment. The 
PDI score is rated on a 4-point scale, with grades from “not at 
all” to “very much” and the total score, ranging from 0 to 45, is 
calculated by summing the scores given to each question. The 
total score can therefore range from none to maximal impairment 
of quality of life. 
Psoriasis-related stress was assessed with the Psoriasis Life 
Stress Inventory (PLSI) (24). The PLSI is a 15-item questionnaire 
that estimates psychosocial stress due to psoriasis. For each ques-
tion the patients must rate the level of stress experienced over the 
previous 4 weeks on a 4-point scale, ranging from “not at all” to 
“very much.” The PLSI score, ranging from 0 to 45, is calculated 
by summing the scores for each question. Both the PDI and PLSI 
have been used in the English version for evaluation of psoriasis. 
The questions were translated into Icelandic using the translation-
back-translation procedure and validated by the Nordic Quality 
of Life study (25). The patients completed both questionnaire at 
study entry and at 12 and 24 months.
After the 24-month study period, participants answered a 
VWXG\VSHFL¿FTXHVWLRQQDLUHZLWK WKH DLPRI UDWLQJ WKH RYHUDOO
experience of having tonsillectomy as a treatment for psoriasis. 
The questionnaire was composed of 20 multiple-choice questions, 
rated on a scale ranging from “not at all” to “very much” and 3 
VKRUWDQVZHUTXHVWLRQV7KHTXHVWLRQVDGGUHVVHGGLI¿FXOWLHVDV-
sociated with the tonsillectomy, recovery time, complications, 
and whether the operation had been worthwhile. Also, questions 
about self-perceived improvement in psoriasis, psoriasis nails and/
or psoriatic arthritis and regarding HRQoL and psoriasis stress. 
Moreover, participants were asked about the use of psoriasis 
treatments, such as moisturizers, topical treatments or systemic 
therapy, and if they had experienced sore throat or streptococcal 
throat infections with subsequent exacerbation of psoriasis after 
removal of their tonsils. 
Clinical evaluation
&OLQLFDO IROORZXS KDV EHHQ GHWDLOHG SUHYLRXVO\ %ULHÀ\
clinical severity was assessed by PASI score (10) at study entry 
and at 2, 6, 12, 18 and 24 months. The use of psoriasis treatment 
agents during the follow-up period was monitored closely. 
Statistical analysis
Patient demographics were summarized descriptively and data 
were tested for normality using the Kolmogorov-Smirnov test. 
PDI and PLSI scores at months 12 and 24 were compared between 
the groups and with baseline scores using analysis of variance 
(ANOVA) test for repeated measurements. Data for months 12 
and 24 were analysed with the intent-to-treat method, where any 
missing data were replaced using the last observation carried for-
ward (LOCF) method. Square root transformation of the results 
7DEOH,'HPRJUDSKLFGDWDIRUWKHSDUWLFLSDWLQJSDWLHQWV
ZLWKSVRULDVLV
Tonsillectomy group 
(n = 15)
Control group 
(n = 14)
Men, n (%) 3 (20) 6 (43)
Age, years, mean ± SD 35.3 ± 9.9 35.9 ± 9.8
BMI (kg/m2) mean ± SD 25.2 ± 5.3 25.4 ± 3.6
Smokers, n (%) 4 (27) 6 (43)
Age at psoriasis onset, years, mean ± SD 15 ± 7.9 15 ± 7.1
Sore throat psoriasis onset, n (%) 3 (20) 2 (14)
Duration of psoriasis, years, mean ± SD 19.9 ± 9.5 20.5 ± 11.7
Psoriasis family history, n (%) 12 (80) 12 (86)
Psoriatic arthritis, n (%) 4 (27) 1 (7)
PASI score, mean ± SD 11.0 ± 5.7 9.3 ± 3.7
PDI score, mean ± SD 10.4 ± 7.1 9.3 ± 7.3
PLSI score, mean ± SD 12.0 ± 6.1 10.0 ± 7.0
Previous treatments, n (%)
Topical agents 8 (53) 8 (57)
Phototherapy 5 (33) 4 (29)
Systemic therapy 1 (7) 0
SD: standard deviation; BMI: body mass index, PASI: Psoriasis Area and Severity 
Index, PDI: Psoriasis Disability Index, PLSI: Psoriasis Life Stress Inventory.
)LJ  &216257 &RQVROLGDWHG 6WDQGDUGV RI 5HSRUWLQJ 7ULDOV
ÀRZGLDJUDP
54 screened for eligibility
Excluded (n = 25)
  Did not meet inclusion criteria (n = 16)
  Declined participation (n = 3)
  Excluded for other reasons (n = 6)
29 randomized
Allocated to tonsillectomy (n = 15)
Discontinued (n = 1):
  Received methotrexate for psoriatic
  arthritis after 12 months
14 completed the 24-month follow-up
Allocated to control group (n = 14)
Discontinued (n = 2):
  Lymphoma after 12 months
  Tonsillectomy after 18 months
12 completed the 24-month follow-up
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3Tonsillectomy and quality of life in patients with psoriasis
Acta Derm Venereol 97, 2017
was used to better approximate normality in the ANOVA model. 
6WDWLVWLFDOVLJQL¿FDQFHZDVGH¿QHGE\p < 0.05. Spearman’s rank 
correlation analysis was performed to evaluate the relationships 
between clinical improvement and improvement in HRQoL (PDI 
and PLSI scores) from baseline to month 24. Data analyses were 
performed using R software, version 2.10 (The R foundation, 
Austria).
RESULTS
Of the 54 patients with psoriasis who were screened, 
38 met all the inclusion criteria. Six eligible patients 
were excluded due to chronic disease, ongoing systemic 
psoriasis treatment and pregnancy, and 3 declined to par-
ticipate after screening. Thus, a total of 29 patients with 
plaque psoriasis and a history of psoriasis exacerbation 
during or after a sore throat were enrolled in the study 
(Fig. 1). Fourteen patients in the tonsillectomy group 
and 12 in the control group completed the 24-month 
follow-up, which took place from November 2008 to 
January 2011. One patient in the tonsillectomy group was 
started on methotrexate to treat his psoriatic arthritis after 
12 months of participation. Two patients in the control 
group did not complete the study, one was diagnosed 
with lymphoma after 12 months, and the other violated 
the protocol by having tonsillectomy after 18 months of 
follow-up. There were no clinically meaningful differen-
ces between the groups and, although the tonsillectomy 
group had slightly higher baseline PASI, PDI and PLSI 
scores compared with the control group, these differences 
ZHUHQRWVWDWLVWLFDOO\VLJQL¿FDQW7DEOH,
There was a significant improvement in HRQoL 
after tonsillectomy (Fig. 2A). The mean PDI score de-
FUHDVHGVLJQL¿FDQWO\LQWKHWRQVLOOHFWRPL]HGJURXSERWK
with time (p = 0.026) and compared with the controls 
(p  FRQ¿GHQFH LQWHUYDO &, ±
The patients’ quality of life improved in mean by 50%. 
In accordance with a report (26), we divided the PDI 
data into 5 domains, to identify the areas that were most 
LQÀXHQFHGE\WKHWRQVLOOHFWRP\7DEOH,,7KHUHZHUH
VLJQL¿FDQWFKDQJHVLQ+54R/DVVRFLDWHGZLWKZRUNDQG
or school after 12 and 24 months (p = 0.02 and p = 0.022, 
respectively) compared with the control group. The 
change in HRQoL associated with relationships was 
VLJQL¿FDQW DIWHU PRQWKV p = 0.04) and the change 
LQ+54R/ OLQNHG WR WKH WUHDWPHQWVZDV VLJQL¿FDQW DW
24 months (p = 0.04). No corresponding improvement 
in PDI scores (p = 0.803, 95% CI 3.38–4.23) or PDI 
domains was observed in the control group. 
The tonsillectomized patients reported that their stress 
associated with having psoriasis decreased considerably 
after the tonsillectomy (Fig. 2B). Their PLSI score de-
FUHDVHGVLJQL¿FDQWO\ERWKZLWKWLPHp < 0.001) and com-
pared with the controls (p = 0.002, 95% CI 1.39–3.10), 
and improved, in mean by 59%. The control group did 
QRWH[KLELWDQ\VLJQL¿FDQWLPSURYHPHQWLQSV\FKRVRFLDO
stress related to coping with psoriasis (p = 0.654, 95% 
CI 2.67–3.56).
A significant positive correlation was observed 
between clinical improvement and increased HRQoL 
(r = 0.297, p = 0.008) (Fig. 3A). Likewise, there was a 
)LJ  &KDQJHV LQ KHDOWKUHODWHG TXDOLW\ RI OLIH
+54R/ DQG SVRULDVLVLQGXFHG VWUHVV RI WKH 
SDUWLFLSDWLQJSVRULDVLVSDWLHQWVGXULQJWKHPRQWK
IROORZXS Panel A: Tonsillectomized patients reported 
DQ LPSURYHPHQW LQ+54R/ZLWKD VLJQL¿FDQWGHFUHDVH
in the mean Psoriasis Disability Index (PDI) score, both 
with time (p=0.026) and compared with the controls 
(p   FRQ¿GHQFH LQWHUYDO &, ±
No corresponding changes were observed for the control 
group. Panel B: Tonsillectomized patients reported less 
daily stress associated with their psoriasis, which was 
UHÀHFWHGLQVLJQL¿FDQWO\GHFUHDVHG3VRULDVLV/LIH6WUHVV
Inventory (PLSI) score, both with time (p < 0.001) and 
compared with the controls (p = 0.002, 95% CI 1.39–3.10). 
The control group observed no corresponding changes. 
7;WRQVLOOHFWRP\JURXS6WDWLVWLFDOVLJQL¿FDQFH
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7DEOH,,0HDQFKDQJHVLQGRPDLQVRIWKH3VRULDVLV'LVDELOLW\,QGH[3',EHIRUHDQGDIWHUWRQVLOOHFWRP\RIWKH
SDUWLFLSDWLQJSDWLHQWVZLWKSVRULDVLV
 
PDI change at 12 months PDI change at 24 months
Tonsillectomy 
Mean ± SD
Controls  
Mean ± SD p-value
Tonsillectomy 
Mean ± SD
Controls  
Mean ± SD p-value
Daily activity 1.53 ± 3.18 0.29 ± 1.20 ns 1.79 ± 2.91 0.18 ± 2.89 ns
Work/school 1.00 ± 1.56 –0.07 ± 0.47 0.02 0.86 ± 1.66 –0.64 ± 1.29 0.02
Relationships 1.13 ± 1.96 0.07 ± 0.27 0.04 0.71 ± 1.98 –0.27 ± 1.10 ns
Leisure 1.07 ± 1.91 0.00 ± 0.88 ns 1.07 ± 2.13 0.27 ± 1.19 ns
Treatment 0.60 ± 1.06 0.07 ± 0.92 ns 1.00 ± 1.11 0.09 ± 0.94 0.04
QVQRQVLJQL¿FDQW6'VWDQGDUGGHYLDWLRQ
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VLJQL¿FDQW SRVLWLYH FRUUHODWLRQ EHWZHHQ LPSURYHPHQW
in PASI score and improved psoriasis-related stress 
(r = 0.310, p = 0.005) (Fig. 3B).
At the end of the study, all the patients who had tonsil-
OHFWRP\DQVZHUHGDVKRUWVWXG\VSHFL¿FTXHVWLRQQDLUH
Twelve (80%) patients felt that the surgery had been quite 
GLI¿FXOWDQGWKDWWKHUHFRYHU\WRRNPRUHWLPHWKDQWKH\
had expected. No major post-operative complications 
were reported, but one patient had minor bleeding the 
day after the procedure. Nevertheless, 13 (87%) of the 
patients thought that the surgery was worthwhile and 
12 (80%) concluded that their psoriasis had improved 
markedly after the surgery. Two patients did not think 
that there was any clinical difference regarding psoriasis 
symptoms and one was unsure. When asked about the 
use of moisturizers, topical treatments and other psoriasis 
treatments during the 2 years after the tonsillectomy 12 
(80%) patients reported less or fewer psoriasis treat-
ments after the surgery. One out of 4 patients who had 
concomitant psoriasis arthritis reported an improvement 
in arthritis after the tonsillectomy.
DISCUSSION 
We and others (22, 27, 28) have previously reported that 
WRQVLOOHFWRP\FDQKDYHPDUNHGFOLQLFDOEHQH¿WVIRUVHOHF-
WHGSDWLHQWVZLWKSVRULDVLV:HQRZH[WHQGWKHVH¿QGLQJV
to demonstrate that the improvement in clinical activity 
of psoriasis achieved through tonsillectomy, despite 
EHLQJDQRYHUDOOGLI¿FXOWSURFHGXUHWRJRWKURXJKOHDGV
WRDVLJQL¿FDQWSRVLWLYHLPSDFWRQWKHDFWLYLWLHVRIGDLO\
life and psychosocial wellbeing of patients. Thus, the 
HRQoL improved by 50% and tonsillectomized patients 
reported almost 60% lower psoriasis-related stress after 
the surgery. Furthermore, we found that the increased 
HRQoL and improved psoriasis-related stress correlated 
positively with the observed clinical improvement, as 
assessed by PASI scores. 
Patients with psoriasis have a 10-fold higher frequency 
of symptomatic streptococcal throat infections than 
matched household controls (14), and the asymptomatic 
carrier rate for group A, C and G Streptococci has been 
reported to be as high as 44% in patients with plaque 
psoriasis and a known history of psoriasis exacerbation 
associated with sore throat (29). Furthermore, up to 70% 
of Icelandic patients with plaque psoriasis report an 
exacerbation of psoriasis symptoms during streptococcal 
throat infections (30). Thus, the genetic background of 
patients with psoriasis appears to be permissive for both 
streptococcal carriage and symptomatic streptococcal 
throat infections, and the latter has long been associated 
ZLWKÀDUHVRIJXWWDWHSVRULDVLVDVZHOODVZRU-
sening of chronic plaque psoriasis (13, 14). It would be of 
interest to measure antistreptolysin O (ASO) titres (32) 
in patients who have tonsillectomy and correlate titres 
with both clinical improvement and increased HRQoL. 
:HKDYHUHFHQWO\UHSRUWHGWKDWSDWLHQWVZKREHQH¿WPRVW
from tonsillectomy, both clinically and in terms of quality 
RIOLIHVLJQL¿FDQWO\PRUHRIWHQKDYHSVRULDVLVRQVHWDVVR-
ciated with a throat infection. Furthermore, these patients 
reported an increased frequency of streptococcal throat 
infections per lifetime and were carriers of both copies 
of HLA-Cw*0602 (33). The mechanism whereby HLA-
Cw*0602 predisposes to psoriasis is currently unknown. 
Our data, and those of others (17, 34–37), are consistent 
with the hypothesis that autoantigens presented in the 
binding pockets of HLA-Cw*0602 on epidermal cells are 
UHFRJQL]HGE\&'7O\PSKRF\WHVLQ¿OWUDWLQJOHVLRQDO
epidermis (18). 
Although not yet validated, our end-of-study ques-
tionnaire gave an insight to the experience of having 
tonsillectomy to treat plaque psoriasis. Despite the risk of 
having the surgery, risk of post-operative complications 
and prolonged recovery time, 87% of the patients thought 
that the procedure was worthwhile, and 80% reported 
a marked improvement, which is concordant with the 
)LJ&RUUHODWLRQEHWZHHQFOLQLFDOLPSURYHPHQWLPSURYHGKHDOWKUHODWHGTXDOLW\RIOLIH+54R/DQGSVRULDVLVUHODWHGVWUHVVRIWKH
WRQVLOOHFWRPL]HGSDWLHQWVZLWKSVRULDVLVGXULQJWKHPRQWKIROORZXS3DQHO$$VLJQL¿FDQWSRVLWLYHFRUUHODWLRQZDVQRWHGEHWZHHQWKHFKDQJH
in clinical status (PASI score) and change in health-related quality of life (PDI score) (r = 0.297, p 3DQHO%/LNHZLVHWKHUHZDVDVLJQL¿FDQW
positive correlation between the change in clinical status and the change in psoriasis-related stress (PLSI score) (r = 0.310, p = 0.005). Spearman’s rank 
correlation test. PASI: Psoriasis Area and Severity Index, PDI: Psoriasis Disability Index, PLSI: Psoriasis Life Stress Inventory.
r = 0.297, p = 0.008 
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recorded reduction in PASI scores, ranging from 30% to 
90%, in 87% of patients (22). Furthermore, 80% of the 
patients reported that their need for psoriasis treatment 
in the form of moisturizers, topical treatments, ultravio-
let light treatment or other treatments was noticeably 
less after the tonsillectomy. This is in accordance with 
RXUSUHYLRXV¿QGLQJWKDWSDWLHQWVZLWKSODTXHSVRULDVLV
needed less symptomatic treatment after tonsillectomy 
compared with controls (22). 
One out of the 4 patients with concomitant plaque 
psoriasis and psoriatic arthritis (PsA) reported at the 
end of the study that his arthritis had improved after the 
tonsillectomy. Interestingly, this patient was homozygous 
for HLA-Cw*0602, which is strongly associated with cu-
taneous psoriasis (38, 39), early onset psoriasis (40–42), 
and psoriasis exacerbations after streptococcal throat 
infection (43, 44). There are very few studies that have 
explored a possible link between PsA, the tonsils and 
streptococcal throat infections. DNA encoding the 16S 
ribosomal RNA gene of group A streptococci has been 
found in WKHEORRGDQGV\QRYLDOÀXLGRISDWLHQWVZLWK3V$
(45), and synovial T cells from patients with PsA have 
been reported to respond to streptococcal superantigens, 
but not to conventional streptococcal antigens (46).
There is currently no cure for psoriasis, and available 
treatments only offer symptomatic relief, as psoriasis 
typically relapses when treatments are discontinued. 
Our results suggest that selected patients with plaque 
psoriasis and a history of sore throat-associated exacerba-
WLRQFRXOGEHQH¿WIURPWRQVLOOHFWRP\ERWKZLWKUHVSHFW
to clinical measures of disease severity (PASI) as well 
as improved quality of life and reduced disease-related 
stress. Although our patient cohort was followed for 
only 2 years, we have observed that the improvement 
remains at least 5 years post-tonsillectomy (unpublished 
data). We therefore conclude that tonsillectomy may be 
DVLJQL¿FDQWDGGLWLRQWRWKHFXUUHQWSVRULDVLVWUHDWPHQW
for a selected patient group, and offer a long-lasting 
improvement. However, more robust trials and long-
term follow-up of tonsillectomized patients with plaque 
psoriasis are needed. 
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ORIGINAL ARTICLES
HLA-Cw6 homozygosity in plaque
psoriasis is associated with streptococcal
throat infections and pronounced
improvement after tonsillectomy:
A prospective case series
Ragna H. Thorleifsdottir, MD,a,b,e Sigrun L. Sigurdardottir, PhD,b Bardur Sigurgeirsson, MD, PhD,a
Jon H. Olafsson, MD, PhD,a Hannes Petersen, MD, PhD,c Martin I. Sigurdsson, MD, PhD,d
Johann E. Gudjonsson, MD, PhD,f Andrew Johnston, PhD,f and Helgi Valdimarsson, MD, FRCPb
Reykjavik, Iceland; Uppsala, Sweden; and Ann Arbor, Michigan
Background: Carriage of the HLA-Cw*0602 allele is associated with a particular set of clinical features and
treatment responses in psoriasis. Tonsillectomy can improve psoriasis.
Objectives:We sought to evaluate whether HLA-Cw*0602 predicts a favorable outcome after tonsillectomy
of patients with psoriasis.
Methods: This prospective case series followed up 28 tonsillectomized patients with plaque psoriasis for
24 months. The Psoriasis Area and Severity Index, Psoriasis Disability Index, and Psoriasis Life Stress
Inventory were used for assessment. Tonsils were swabbed for bacteria and patients genotyped for HLA-
Cw*0602.
Results: After tonsillectomy, HLA-Cw*0602 homozygotes showed significantly more improvement,
compared with heterozygous and HLA-Cw*0602enegative patients. Thus, Psoriasis Area and Severity
Index score was reduced by 82% in the homozygous patients compared with 42% and 31%, respectively
(P\ .001), Psoriasis Disability Index score improved by 87% compared with 38% and 41%, respectively
(P \ .001), and Psoriasis Life Stress Inventory score was 82% reduced compared with 60% and 54%,
respectively (P\.001). The homozygotes more often had psoriasis onset associated with a throat infection
(P = .007) and an increased frequency of streptococcal throat infections per lifetime (P = .038).
Limitations: Few patients were included and some data were retrospective.
Conclusions: Homozygous HLA-Cw*0602 carriage in plaque psoriasis may predict a favorable outcome
after tonsillectomy. ( J Am Acad Dermatol 2016;75:889-96.)
Key words: chronic plaque psoriasis; HLA-Cw*0602; Psoriasis Disability Index; Psoriasis Life Stress
Inventory; sore throat; streptococcal throat infection; tonsillectomy.
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Psoriasis is a common T-lymphocyte-mediated
skin disease caused by a combination of genetic and
environmental factors1 with over 60 genetic suscep-
tibility loci now reported to be associated with
psoriasis.2,3 HLA-Cw*0602 is the major psoriasis
susceptibility allele4 and over 60% of patients with
psoriasis carry 1 or 2 copies of HLA-Cw*0602,
whereas the frequency in
the general population is
only 10% to 15%.4 Although
various environmental fac-
tors have been reported to
influence psoriasis, throat in-
fections with b-hemolytic
streptococci have most
convincingly been associ-
ated with both initiation and
exacerbation of psoriasis.5-7
It was proposed that T cells,
primed by streptococcal an-
tigens in the palatine tonsils,
may migrate to the skin
where they may react to an-
tigens that share sequence
homology with streptococcal
proteins.8-10 A number of studies have shown partial
or complete remission of psoriasis after tonsillec-
tomy,11-13 and we have recently conducted a pro-
spective, randomized, and controlled study
indicating that tonsillectomy can lead to a marked
clinical improvement of chronic plaque psoriasis.14
Carriage of the HLA-Cw*0602 allele has been
associated with a particular set of clinical features
in psoriasis.15 HLA-Cw*0602epositive patients usu-
ally have a younger onset age,16,17 more severe
psoriasis course,18 guttate or eruptive plaque psori-
asis phenotypes,15,19 more frequent streptococcal
throat carriage or infections,18,20 and streptococcal-
associated psoriasis exacerbation.18 We therefore
wanted to evaluate whether patients with psoriasis
carrying the HLA-Cw*0602 allele, with a history of
sore throateinduced onset or exacerbation of psori-
asis, respondedmore favorably to tonsillectomy than
HLA-Cw*0602enegative patients.
METHODS
Study design
This was a prospective case series study with a 24-
month follow-up period. The researchwas approved
by the National Bioethics Committee of Iceland
(VSNb2006090015/03-15) and the Data Protection
Authority of Iceland, and conducted in accordance
with the 1964 Declaration of Helsinki and its later
amendments. Data were collected within the
Departments of Otolaryngology-Head and Neck
Surgery, Dermatology, and Immunology at
Landspitali-National University Hospital of Iceland,
Reykjavik, Iceland, from November 2007 to January
2011.
Subjects and follow-up
In all, 28 patients with chronic plaque psoriasis
were included in the study
and signed informed consent
was obtained from each
participant before initiation.
Fifteen patients participated
in our previous study,14 and
an additional 13 patients
who fulfilled the inclusions
criteria were recruited.
Inclusion criteria included:
(1) age at least 18 years; (2)
dermatologist-diagnosed
moderate to severe plaque
psoriasis; (3) history of pso-
riasis exacerbation in associ-
ation with sore throats and/
or streptococcal throat infec-
tions, as recalled by the pa-
tients; (4) no other health issues that could pose a
risk for patients undergoing tonsillectomy and anes-
thesia, including heart and lung diseases, alcohol
and substance abuse, and bleeding disorders; and
(5) consent to have tonsillectomy.
Demographic data and psoriasis features were
collected at study entry. Included patients were
followed up for 24 months, starting 2 months after
tonsillectomy. Psoriasis severity was assessed by the
Psoriasis Area and Severity Index (PASI)21 at study
entry and at 2, 6, 12, 18, and 24 months. The
participants were evaluated by the same observer
throughout the study period and the clinical evalu-
ation was carried out before patients were typed for
HLA-Cw*0602 carriage.
The Psoriasis Disability Index (PDI)22 was used to
assess health-related quality of life. The PDI is a
validated psoriasis-specific questionnaire that in-
cludes 15 questions concerning functional disability
as a result of psoriasis in the preceding month. The
score is rated on a 4-point scale and the total score,
which can range from 0 to 45, is calculated by
summing the scores to each question. For assessment
of stress related to having to cope with psoriasis on a
daily bases the Psoriasis Life Stress Inventory (PLSI)23
was used. The PLSI is a 15-item scale that rates the
level of stress experienced over the previous month.
The PLSI score is calculated from a 4-point scale,
ranging from 0 to 45, by summation. The higher the
PDI and PLSI scores, the greater impairment in
CAPSULE SUMMARY
d Tonsillectomy can improve psoriasis, yet
the patient group likely to benefit the
most is poorly defined.
d We show that homozygous HLA-
Cw*0602 carriage is associated with a
particularly favorable outcome after
tonsillectomy in patients with
streptococcal-associated psoriasis
exacerbation.
d Profiling patients with psoriasis can
identify those who could benefit most
from tonsillectomy.
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Abbreviations used:
PASI: Psoriasis Area and Severity Index
PDI: Psoriasis Disability Index
PLSI: Psoriasis Life Stress Inventory
quality of life. Both these questionnaires were
completed by the patients at study entry and at 12
and 24 months and both were previously translated
into Icelandic using the translation-back-translation
procedure and validated by the Nordic Quality of
Life study.24
HLA-Cw*0602 genotyping
All participating patients were genotyped for
HLA-Cw*0602 after the 24-month clinical follow-up
period. DNA was prepared from peripheral blood
mononuclear cells and HLA-Cw*0602 was deter-
mined by polymerase chain reaction amplification
by genotyping 7 single nucleotide polymorphisms in
exons 2 and 3 of the HLA-C gene, as previously
described.4
Bacterial culture and typing
After removal of the tonsils, bacterial throat swabs
were taken, both from the tonsil surface as from deep
within the tonsil crypts. Typing of the bacteria was
performed by culture on sheep blood agar.
Subspecies of Streptococcus were identified with a
Streptex kit (Thermo Fisher Scientific/Remel,
Lenexa, KS).
Statistical analysis
Data were tested for normality using the
Kolmogorov-Smirnov test. Categorical variables
were compared with Fisher exact test and statistical
significance was defined by P less than or equal to
.05 on 2-tailed tests. The effects of HLA-Cw*0602
genotype and improvement after tonsillectomy
(determined by change in PASI, PDI, and PLSI scores
over 24 months) were modelled using linear regres-
sion and analyzed on an intention-to-treat basis with
missing values being replaced with the last non-
missing assessment (last observation carried for-
ward). Three different models were tested,
dominant (either 1 or 2 HLA-Cw*0602 alleles effects
phenotype), recessive (2 HLA-Cw*0602 alleles
required to effect phenotype), and additive (pheno-
type changes sequentially with each HLA-Cw*0602
allele), where the recessive model was used for
calculations. The linear model assumptions were
checked by visual analysis of residual plot. Data
analyses were performed using software (R, Version
2.10, R Foundation, Vienna, Austria).
RESULTS
The study cohort consisted of 28 patients (6 men
and 22 women) with chronic plaque psoriasis and a
history of psoriasis exacerbation associatedwith sore
throat and/or streptococcal throat infection (Table I).
All patients reported an early onset of psoriasis (type I
psoriasis)16 and the onset was attributed to strepto-
coccal pharyngitis in 11 (39%) patients. There were
no differences between the groups at baseline,
although the homozygous HLA-Cw*0602 carriers
had slightly higher baseline PASI, PDI, and PLSI
scores compared with the heterozygous and HLA-
Cw*0602enegative groups. Four (14%) patients were
HLA-Cw*0602 homozygotes, 17 (61%) were hetero-
zygotes, and 7 (25%)were HLA-Cw*0602 negative. In
all, 25 patients finished the 24-month follow-up. Two
patients in the heterozygous group discontinued the
study after 12 and 18 months of follow-up and 1
patient in the HLA-Cw*0602enegative group discon-
tinued after 18 months.
HLA-Cw*0602 homozygosity is associated with
streptococcal throat infections
The HLA-Cw*0602 homozygous patients signifi-
cantly more often reported that their psoriasis onset
was triggered by a throat infection, compared with
HLA-Cw*0602 heterozygotes and noncarriers (100% vs
29%, P = .007) (Table II). In concordance with this,
cultures from tonsil swabs, which were taken after
removal of the tonsils, revealed that 75% of the
homozygous patients were carriers of group A, C, or
G streptococci or Sanginosus at the timeof the surgery,
compared with 65% of the heterozygous patients
and 43% of the HLA-Cw*0602enegative patients.
Furthermore, HLA-Cw*0602 homozygotes reported a
significantly higher frequency of streptococcal throat
infections per lifetime than the heterozygotes and
noncarriers (3.5 vs 1.4 and 1.1 times, respectively,
P = .038). The homozygous patients were all smokers,
and they all had a family history of psoriasis (Table II).
There were no significant differences between homo-
zygous, heterozygous, and HLA-Cw*0602enegative
patients concerning age at psoriasis onset, body mass
index, psoriasis nail changes, arthritis involvement, or
stress- or alcohol-associated psoriasis exacerbation
(data not shown).
HLA-Cw*0602 homozygosity is associated with
pronounced improvement after tonsillectomy
There was an association between the degree of
clinical improvement after tonsillectomy and car-
riage of HLA-Cw*0602 (Fig 1). Thus, patients who
were homozygous HLA-Cw*0602 carriers showed
significantly more clinical improvement than the
J AM ACAD DERMATOL
VOLUME 75, NUMBER 5
Thorleifsdottir et al 891
   
120 
 
 
 
 
 
 
heterozygous and the HLA-Cw*0602enegative pa-
tients at all time points (Table III). The homozygous
patients had a mean 82% PASI reduction during the
24-month follow-up, compared with 42% for the
heterozygous group and 31% for the HLA-
Cw*0602enegative group (P \ .001 for overall
change by linear regression). All 4 homozygotes
achieved at least 75% improvement in PASI score by
month 6 and almost 90% improvement in PASI score
by month 12. The clinical improvement was accom-
panied by markedly improved health-related quality
of life (PDI) and psoriasis-related stress (PLSI).
Again, the homozygous patients fared best, reporting
mean PDI and PLSI score reductions of 87% and 82%,
compared with 38% and 60% for the heterozygous
patients and 41% and 54% for the HLA-
Cw*0602enegative patients (P \ .001 for overall
change by linear regression).
The use of psoriasis treatments was monitored
throughout the 24-month follow-up period (Table
IV). There was a significant decrease in the use of
psoriasis treatments after tonsillectomy. Before ton-
sillectomy, 75% (n = 21) of patients used some form
of treatment for psoriasis (topicals, phototherapy, or
systemic therapy), but after tonsillectomy only 32%
(n = 9) of patients required treatment (P = .003).
DISCUSSION
HLA-Cw*0602 is the major psoriasis susceptibility
allele, located in the psoriasis susceptibility locus 1.4
Given that HLA-Cw*0602 carriage has been associ-
ated with a higher frequency of streptococcal throat
carriage/infections18,20 and streptococcal-associated
psoriasis exacerbation,18 we typed our study cohort
for HLA-Cw*0602 and found an association between
the magnitude of improvement after tonsillectomy
and HLA-Cw*0602 carriage status. Patients who were
homozygotes showed significantly more improve-
ment than the HLA-Cw*0602 heterozygous and non-
carriers. Thus, all HLA-Cw*0602 homozygotes
reached at least 75% improvement in PASI score by
month 6 and approached 90% improvement in PASI
score bymonth 12. Their health-related quality of life
also improved markedly (almost 90% reduction in
PDI score) after the surgery and they experienced
82% less stress related to having psoriasis. These
improvements are comparable with results seen by
recently introduced biologics.25
Table II. HLA-C genotypes and disease characteristics of the 28 participating patients with psoriasis
Disease characteristics
HLA-Cw*0602
P value*Homozygous Heterozygous Negative
n (%) 4 (14) 17 (61) 7 (25)
Sore throateinduced psoriasis onset,y n (%) 4 (100) 5 (29) 2 (29) .007z
Sore throat/y,y mean 6 SD 5.3 6 3.5 3.9 6 2.9 6.9 6 3.6 .768
Strep throat/lifetime,x mean 6 SD 3.5 6 2.1 1.4 6 1.5 1.1 6 0.6 .038z
Streptococcal carriage,k n (%) 3 (75) 11 (65) 3 (43) .527
Cigarette smoking, n (%) 4 (100) 5 (29) 3 (43) .013z
Psoriasis family history, n (%) 4 (100) 14 (82) 5 (71) .314
*HLA-Cw*0602 homozygous patients compared with heterozygous and HLA-Cw*0602enegative patients.
yAs recalled by the patients.
zStatistically significant.
xStreptococcal throat infections diagnosed by a physician, throat culture, or strep test (rapid antigen detection test).
kCultured at the time of tonsillectomy.
Table I. Demographic and clinical characteristics of the 28 participating patients with psoriasis
Demographics
HLA-Cw*0602
Homozygous, n = 4 Heterozygous, n = 17 Negative, n = 7
Men, n (%) 0 5 (29) 1 (14)
Age, y, mean 6 SD 32.5 6 5.9 33.2 6 11.8 35.1 6 6.0
Body mass index, kg/m2 mean 6 SD 24.0 6 1.5 25.6 6 4.9 23.6 6 3.4
Age at psoriasis onset, y, mean 6 SD 14.3 6 6.9 13.9 6 6.5 16.0 6 7.3
Psoriasis duration, y, mean 6 SD 18.3 6 10.1 19.3 6 9.3 19.1 6 8.6
Psoriatic arthritis, n (%) 1 (25) 4 (24) 1 (14)
Initial PASI score, mean 6 SD 13.5 6 1.7 12.3 6 4.9 9.9 6 3.2
Initial PDI score, mean 6 SD 13.3 6 2.8 12.4 6 7.2 10.4 6 6.4
Initial PLSI score, mean 6 SD 14.0 6 1.9 12.0 6 5.1 12.3 6 5.5
PASI, Psoriasis Area and Severity Index; PDI, Psoriasis Disability Index; PLSI, Psoriasis Life Stress Inventory.
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A
B
C
Fig 1. Tonsillectomy efficacy outcomes through month 24. A, Mean percentage reduction
of Psoriasis Area Severity Index (PASI) score; point lines denote 75% and 90% reduction from
baseline. B, Mean percentage improvement in Psoriasis Disability Index (PDI) score. C, Mean
percentage improvement in Psoriasis Life Stress Inventory score. *Statistical significance, where
HLA-Cw*0602homozygouspatients are comparedwithheterozygousandHLA-Cw*0602enegative
patients.
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The carriage of HLA-Cw*0602 has been associated
with a particular set of clinical features in patients with
psoriasis,15 suchas guttateor eruptiveplaquepsoriasis
phenotypes,15,19 and more frequent streptococcal
throat carriage or infections.18,20 Furthermore, an
increasing body of evidence has emerged suggesting
that different psoriasis genotypes might predict
different treatment responses.26 Thus, 2 recent studies
showed that carriageofHLA-Cw*0602predicts a better
response to the interleukin-12/23 inhibitor ustekinu-
mab27,28 and etanercept was also shown to be more
effective in early-onset psoriasis compared with late-
onset psoriasis.29
The mechanism whereby HLA-Cw*0602 predis-
poses to psoriasis remains to be elucidated. However,
our data and those of others9,30-33 are consistent with
the hypothesis that CD81 T lymphocytes infiltrating
lesional epidermis recognize autoantigens presented in
the context of HLA-Cw6 expressed on the surface of
epidermal cells.10 ThusHLA-Cw*0602mayplay a direct
role in the pathogenesis of psoriasis.34 Our data and
those of an earlier study20 indicate that HLA-Cw*0602
carriage may impact the bacterial colonization of the
tonsils. The tonsils are a major site for streptococcal
carriage, and streptococcal throat infections are associ-
ated with onset and exacerbation of psoriasis.6,7,10,11
Throat swabs taken from both the surface and from
deep within tonsil crypts revealed a high level of
streptococcal throat carriage in our patients.
Combined carrier frequency of Lancefield groups A,
C, or G Streptococcus or S anginosuswas almost 70% in
homozygous and heterozygous HLA-Cw*0602 patients
compared with 43% of noncarriers. S anginosus can
cause pharyngitis, is sometimes b-hemolytic, and
carries a typeable Lancefield group antigen, A, C, G,
or F.35 The genetic background of patients with psori-
asis is thus associated with both asymptomatic and
symptomatic streptococcal throat infections compared
with age- and sex-matched control subjects,7,36 and
streptococcal tonsillitis has long been associated with
flares of guttate psoriasis5,37,38 and exacerbation of
plaque psoriasis.6,7,39 It should be noted that the
participants included in the current study all had a
history of psoriasis exacerbation in association with
sore throat, which applies to approximately 40% of
patients with plaque psoriasis in Iceland.40
Smoking is an important environmental risk factor
for many chronic diseases, including several auto-
immune diseases such as rheumatoid arthritis and
systemic lupus erythematosus.41,42 Although there is
a strong link between palmoplantar pustulosis and
smoking, with up to 80% of patients being smokers
or ex-smokers,43 smoking is also a risk factor for the
development of psoriasis.44 Interestingly, smoking
Table III. Tonsillectomy outcomes in relation to HLA-Cw*0602 carriage during the 24-month follow-up
Parameter
HLA-Cw*0602
P value*Homozygous, n = 4 Heterozygous, n = 17 Negative, n = 7
Mean PASI score improvement, % 82 42 31 \.001
Month 2 72 42 23 \.001
Month 6 79 43 41 \.001
Month 12 88 44 29 \.001
Month 18 86 43 42 \.001
Month 24 88 43 20 \.001
Mean PDI score improvement, % 87 38 41 \.001
Month 12 83 38 56 .004
Month 24 91 67 26 .005
Mean PLSI score improvement, % 82 60 54 \.001
Month 12 79 54 59 .03
Month 24 85 68 48 .04
PASI, Psoriasis Area and Severity Index; PDI, Psoriasis Disability Index; PLSI, Psoriasis Life Stress Inventory.
*HLA-Cw*0602 homozygous patients compared with heterozygous and HLA-Cw*0602enegative patients.
Table IV. Use of psoriasis treatments before and
after tonsillectomy of the 28 participating patients
Treatment, n (%)
HLA-Cw*0602
Homozygous,
n = 4
Heterozygous,
n = 17
Negative,
n = 7
Before tonsillectomy
Topical therapy* 0 7 (41) 4 (57)
Phototherapyy 2 (50) 5 (29) 2 (29)
Systemic therapy 1z (25) 0 0
After tonsillectomy
Topical therapy* 0 3 (18) 2 (29)
Phototherapyy 0 3 (18) 0
Systemic therapy 1z (25) 0 0
*Corticosteroid creams, vitamin-D analog creams, or combination
of both.
yWith or without topical psoriasis treatment.
zThis patient was treated with methotrexate before tonsillectomy.
His rheumatologist initiated methotrexate treatment again for
psoriatic arthritis after 12 mo of study follow-up.
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was significantly more common in our homozygous
HLA-Cw*0602 patients compared with the heterozy-
gous and HLA-Cw*0602enegative patients
(P = .013). Smoking increases oxidative damage
and promotes heightened inflammatory state and
may modify expression of several psoriasis-
associated genes, including the HLA genes.45
Homozygous HLA-Cw*0602 individuals have about
a 2.5-fold increased risk for psoriasis compared with
HLA-Cw*0602 heterozygotes46 and a recent study
reported that HLA-Cw*0602epositive smokers have
a further increased risk of developing psoriasis
compared with nonsmoking HLA-Cw*0602 carriers,
suggesting that smoking might trigger psoriasis in
some genetically predisposed individuals.47
In this study, the need for psoriasis treatment
decreased significantly after tonsillectomy. Although
all groups required less treatment after the proce-
dure, this was not significant for the homozygous
HLA-Cw*0602 group. However, because the homo-
zygous group only included 4 patients, it is difficult
to draw concrete conclusions. The only patient who
received systemic treatment before tonsillectomy
was homozygous for HLA-Cw*0602. He improved
considerably after the tonsillectomy but systemic
therapy was restarted after 12 months of follow-up
because of psoriatic arthritis symptoms. The other 3
homozygotes did not require any psoriasis treatment
during the 24-month follow-up. Thus, available data
do not indicate that improvement of psoriasis after
tonsillectomy can be attributed to additional psoria-
sis treatment. Furthermore, we have previously
shown that tonsillectomized patients with plaque
psoriasis use less treatment and improve significantly
more compared with matched control subjects.14
Taken together, our findings indicate that HLA-
Cw*0602 homozygosity can be regarded as a predic-
tor of favorable outcomes after tonsillectomy of
patients with plaque psoriasis and a history of
streptococcal-associated psoriasis exacerbation.
Profiling patients who have psoriasis with respect
to disease history and genotype can help identify
patients with psoriasis who could benefit the most
from tonsillectomy. Although our patients were only
followed up for 24 months, we observed that
improvement after tonsillectomy remains largely
unchanged for at least 5 years (unpublished data).
However, in view of the relatively few patients
genotyped for HLA-Cw*0602, our findings need to
be expanded with more HLA-C-typed patients.
The authors would like to thank the patients who
participated in the study for their contribution. The authors
furthermore thank the staff at Landspitali-NationalUniversity
Hospital of Iceland Dermatology Outpatient Center;
Otolaryngology-Head and Neck Surgery; and Immunology
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Streptococcal throat infections are known to trigger or 
exacerbate psoriasis, and several studies support the 
EHQH¿W RI WRQVLOOHFWRP\ 7R HYDOXDWH WKH SRWHQWLDO RI
WRQVLOOHFWRP\ DV D WUHDWPHQW ZH XVHG D UHWURVSHFWLYH
VWXG\VSHFL¿FTXHVWLRQQDLUH WRDVVHVV WKHSURSRUWLRQRI
SVRULDVLV SDWLHQWV ZLWK VRUH WKURDWDVVRFLDWHG SVRULDVLV
H[DFHUEDWLRQV 2XU VXUYH\ VDPSOHG  SVRULDVLV SD
WLHQWV2ISDWLHQWVZLWKSODTXHSVRULDVLVUHSRUWHG
VRUH WKURDWDVVRFLDWHG SVRULDVLV H[DFHUEDWLRQV DQG RI
SDWLHQWV ZLWK FRQ¿UPHG VWUHSWRFRFFDO LQIHFWLRQV 
UHSRUWHGDJJUDYDWLRQ1RWDEO\ZRPHQDQGSDWLHQWVZLWK
HDUO\RQVHWSVRULDVLVZHUHPRUHOLNHO\WRUHSRUWSVRULD
sis exacerbation after a sore throat (p p 
UHVSHFWLYHO\2WKHUSVRULDVLV DJJUDYDWLRQ IDFWRUVZHUH
PRUH FRPPRQ LQ SDWLHQWV ZLWK VRUH WKURDWDVVRFLDWHG
exacerbations (p  2I WRQVLOOHFWRPL]HG SDWLHQWV
UHSRUWHG VXEVHTXHQW LPSURYHPHQWDQGKDGPRUH
IUHTXHQWVRUHWKURDWDVVRFLDWHGDJJUDYDWLRQRISVRULDVLV
WKDQ SDWLHQWVZKRGLG QRW LPSURYH DIWHU WRQVLOOHFWRP\
(p  7KHVH ¿QGLQJV VXJJHVW D FORVHU DVVRFLDWLRQ
between sore throats, streptococcal throat infections and 
SODTXH SVRULDVLV WKDQ UHSRUWHG SUHYLRXVO\ Key words: 
chronic plaque psoriasis; sore throat; streptococcal throat 
infections; tonsillectomy.
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Psoriasis is a multifactorial disease caused by a combina-
tion of genetic and environmental factors. The disease 
has a strong genetic basis; more than 60 susceptibility 
ORFLKDYHEHHQLGHQWL¿HGLQFOXGLQJ+/$&ZFDU-
riage of which is associated with an approximate 10-fold 
LQFUHDVHGULVNRIGHYHORSLQJSVRULDVLV1XPHURXVHQ-
vironmental agents have been reported to trigger and/or 
exacerbate psoriasis, including psychological stressors, 
physical trauma, cold climate, cigarette smoking, alco-
KRO LQWDNHDQGFHUWDLQGUXJV±6LPLODUO\YDULRXV
microorganisms have been implicated, including fungi 
Malassezia, Candida albicansDQGYLUXVHVSDSLOORPD-
YLUXVHVUHWURYLUXVHV+RZHYHUWKURDWLQIHFWLRQVZLWK
ȕKDHPRO\WLFVWUHSWRFRFFL have most convincingly been 
linked with the initiation and exacerbation of psoriasis.
The association between guttate psoriasis and strep-
tococcal infections has been recognized for 100 years 
±+RZHYHURQO\DIHZUHWURVSHFWLYH
DQGRQHSURVSHFWLYHVWXG\KDYHOLQNHGH[DFHUED-
tion of plaque psoriasis with streptococcal throat infec-
tions. Moreover, such infections are approximately 10 
times more frequent in patients with plaque psoriasis 
compared with age- and sex-matched household con-
WUROV,WKDVEHHQUHSRUWHGWKDWWRQVLOVIURPSDWLH
nts with psoriasis are more frequently infected with 
ȕKDHPRO\WLFVWUHSWRFRFFLHVSHFLDOO\JURXS&VWUHSWR-
cocci, than are recurrently infected tonsils from patients 
ZLWKRXWSVRULDVLV1HYHUWKHOHVVWKHLPPXQRORJLFDO
basis for the association of psoriasis and streptococcal 
throat infections is still under investigation.
3DOPRSODQWDU SXVWXORVLV 333 LV D SDLQIXO FKURQLF
LQÀDPPDWRU\ FRQGLWLRQ UHVWULFWHG WR WKH SDOPV DQG
or soles, which was previously regarded as a variant of 
pustular psoriasis, but is now categorized with acropustu-
ODUGLVHDVHV8SWRRISDWLHQWVZLWK333KDYH
FRQFRPLWDQW SODTXH SVRULDVLV  DQG DOWKRXJK333
and plaque psoriasis have different sites of predilection 
DQGSDWKRPHFKDQLVPV  WKH\PD\ VKDUH FRPPRQ
triggering mechanisms. Streptococcal throat infections 
have been linked to PPP and studies have indicated that 
333PD\LPSURYHDIWHUWRQVLOOHFWRP\±
We have recently reported that patients with plaque 
psoriasis and a history of sore throat-associated pso-
ULDVLV H[DFHUEDWLRQ LPSURYH DIWHU WRQVLOOHFWRP\ 
The main aim of the current study was to estimate 
the proportion of patients with plaque psoriasis who 
experienced disease aggravation after sore throats or 
streptococcal throat infections, and therefore might be 
PRUHOLNHO\WREHQH¿WIURPWRQVLOOHFWRP\ 
METHODS
Study design and cohort
This study is a retrospective large case series that took place 
from January 2011 to April 2011 at the following dermatology 
Throat Infections are Associated with Exacerbation in a Substantial 
Proportion of Patients with Chronic Plaque Psoriasis
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RXWSDWLHQW XQLWV LQ ,FHODQG WKH GHUPDWRORJ\ RXWSDWLHQW FHQWUH
DW/DQGVSLWDOL ±7KH1DWLRQDO8QLYHUVLW\+RVSLWDO RI ,FHODQG
Reykjavik; Hudlaeknastodin dermatology clinic, Kopavogur; 
DQGWKH%OXH/DJRRQJHRWKHUPDOFOLQLF*ULQGDYLN$WRWDO
RISDWLHQWVZLWKSVRULDVLVYLVLWLQJWKHVHFOLQLFVZHUHLQYLWHG
WR SDUWLFLSDWH  PHQ DQGZRPHQ DJUHHG 
UHVSRQVHUDWH$OOSDUWLFLSDQWVZHUHRYHU\HDUVRIDJHDQGKDG
been diagnosed with psoriasis by a dermatologist. The study was 
DSSURYHGE\WKH1DWLRQDO%LRHWKLFV&RPPLWWHHRI,FHODQGWKH
'DWD3URWHFWLRQ$XWKRULW\RI,FHODQGDQGSHUIRUPHGLQFRPSOLDQFH
ZLWKWKH'HFODUDWLRQRI+HOVLQNLDQGLWVODWHUDPHQGPHQWV
A self-report anonymous questionnaire, composed of 15 
PXOWLSOHFKRLFH DQG VKRUWDQVZHU TXHVWLRQV Appendix S11
was designed. Participants were asked to answer as accurately as 
SRVVLEOH7KHTXHVWLRQQDLUHDGGUHVVHGPDLQWRSLFViJHQHUDO
GHPRJUDSKLFViiSVRULDVLVVXEW\SHDJHDWRQVHWDQGZKHWKHU
psoriasis onset had been associated with a sore throat or strep-
WRFRFFDOWKURDWLQIHFWLRQiiiIUHTXHQF\RIVRUHWKURDWVGH¿QHG
E\DSDLQIXOLQÀDPPDWLRQLQIHFWLRQRIWKHPXFXVPHPEUDQHVLQ
the pharynx, and the frequency of streptococcal throat infections 
GLDJQRVHGE\DWKURDWFXOWXUHUDSLGDQWLJHQGHWHFWLRQWHVWVWUHS
WHVW RU E\ D SK\VLFLDQ )XUWKHU TXHVWLRQV FRYHUHG H[DFHUED-
WLRQRISVRULDVLVGXULQJRUZLWKLQZHHNVRIDVRUH WKURDWRU
VWUHSWRFRFFDOWKURDWLQIHFWLRQivSVRULDVLVDJJUDYDWLQJIDFWRUV
other than sore throat, including general malaise, cold climate, 
VWUHVVIXOOLIHHYHQWVDOFRKROLQWDNHGLHWDQGGUXJVvZKHWKHU
the participant had been subjected to tonsillectomy after the onset 
of psoriasis; age at time of surgery; and whether the tonsillectomy 
was associated with changes in the activity of their skin disease. 
Statistical analysis
3DWLHQWGHPRJUDSKLFVZHUHVXPPDUL]HGGHVFULSWLYHO\&DWHJRULFDO
YDULDEOHVZHUHFRPSDUHGZLWKȤ2DQG)LVKHU¶VH[DFWWHVW/HYHORI
VWDWLVWLFDO VLJQL¿FDQFHZDVVHWDWp $ ORJLVWLF UHJUHVVLRQ
model of sore throat aggravation was pursued. All variables with a 
p < 0.1 were entered into the logistic regression model. Odds ratio 
DQGFRQ¿GHQFHLQWHUYDOVZHUHWKHQHVWLPDWHG$OOVWDWLVWLFV
ZHUHSHUIRUPHGLQ5YHUVLRQ7KH5)RXQGDWLRQ$XVWULD
5(68/76
$OOUHFUXLWHGSDUWLFLSDQWVPHQDQGZR-
PHQFRPSOHWHGWKHVWXG\TXHVWLRQQDLUH6HH7DEOH,IRU
demographic information. The majority of responders 
KDGEHHQGLDJQRVHGZLWKSODTXHSVRULDVLV
ZLWK ERWKJXWWDWH DQGSODTXHSVRULDVLV DQGZLWK
JXWWDWHSVRULDVLV)RXUSDWLHQWVUHSRUWHG333EXWRI
the 275 study participants did not belong to any of the 
DERYHFDWHJRULHV(DUO\RQVHWSVRULDVLVGH¿QHGDVDJH
DWRQVHWRI\HDUVRUOHVVZDVUHSRUWHGE\WKH
PDMRULW\RIVWXG\SDUWLFLSDQWV
Psoriasis exacerbation associated with a sore throat was 
UHSRUWHGE\RISDWLHQWVZLWKSODTXHSVRULDVLVRI
SDWLHQWVZLWKJXWWDWHSVRULDVLVDQGRISDWLHQWVZLWKD
history of both guttate and plaque psoriasis. This was also 
WKHFDVHIRURXWRISDWLHQWVZLWK3330RUHRYHURIWKH
SDUWLFLSDQWVZLWKDKLVWRU\RIFRQ¿UPHGVWUHSWRFRFFDO
WKURDWLQIHFWLRQV7DEOH,,UHSRUWHGVWUHSWRFRFFDO
associated psoriasis exacerbation. This DSSOLHGWRRI
SDWLHQWVZLWKSODTXHSVRULDVLVRISDWLHQWVZLWKJXW-
WDWHSVRULDVLVDQGRISDWLHQWVZLWKERWKJXWWDWHDQG
SODTXHSVRULDVLV)XUWKHUPRUHSDWLHQWVZKRUHSRUWHGVRUH
throat-associated aggravation were more likely to report 
VWUHSWRFRFFDODVVRFLDWHGSVRULDVLVH[DFHUEDWLRQYV
p 7KLVDOVRDSSOLHGWRVXEJURXSVRISVRULDVLV
SDWLHQWVSODTXHSVRULDVLVYVp JXW-
WDWHSVRULDVLVYVp DQGSDWLHQWVZLWK
ERWKJXWWDWHDQGFKURQLFSODTXHSVRULDVLVYV
p $VLJQL¿FDQWO\KLJKHU UDWLRRISDWLHQWVZLWK
early-onset psoriasis reported psoriasis exacerbation as-
sociated with a sore throat, compared with patients with 
ODWHRQVHWSVRULDVLVYVp 
Sore throat-associated aggravation was notably 
PRUHFRPPRQDPRQJZRPHQWKDQPHQYV
p (YHQDIWHUDGMXVWPHQW IRU WKH LQÀXHQFHRI
DJHSVRULDVLVVXEW\SHVVHH7DEOH,DQGRWKHUSVRULDVLV
H[DFHUEDWLRQ IDFWRUV IHPDOHV VWLOO KDG D VLJQL¿FDQWO\
higher risk of sore throat-associated psoriasis aggrava-
WLRQRGGVUDWLR25 FRQ¿GHQFHLQWHUYDO&,
±p 3VRULDVLVH[DFHUEDWLRQDVVRFLDWHG
with general malaise, cold climate, stress, consumption 
RIDOFRKRORUYDULRXVGLHWVZHUHUHSRUWHGVLJQL¿FDQWO\
more often by patients who also reported sore throat-
DVVRFLDWHG SVRULDVLV DJJUDYDWLRQ 7DEOH ,,, DQG WKLV
GLIIHUHQFHZDV VWLOO VLJQL¿FDQW IRU FROG FOLPDWH DQG
general malaise, after adjustment for age, gender and 
SVRULDVLVVXEW\SHV25 DQG&,±
DQG±p UHVSHFWLYHO\7KHUHZHUHQR
differences between men and women in this respect. 
7DEOH, Baseline characteristics of the 275 participating patients 
with psoriasis 
&KDUDFWHULVWLFV
0HQn 
Age, years, mean ± SD ±
Age at psoriasis onset, years, mean ± SD ±
(DUO\RQVHWSVRULDVLVRQVHWEHIRUHRUDW\HDUVn 
/DWHRQVHWSVRULDVLVRQVHWDIWHUWKHDJHRI\HDUVn 
3VRULDVLVVXEW\SHn
Plaque psoriasis 
*XWWDWHSVRULDVLV 
*XWWDWHDQGSODTXHSVRULDVLV 
Psoriasis nail changes 
Psoriatic arthritis 
3DOPRSODQWDUSXVWXORVLVn 
SD: standard deviation.
7DEOH,,. Streptococcal-associated psoriasis exacerbations among 
SDUWLFLSDQWVZLWKFRQ¿UPHGa streptococcal infections 
n
3DUWLFLSDQWVZLWKFRQ¿UPHGVWUHSWRFRFFDOWKURDWLQIHFWLRQVa 
Streptococcal-associated psoriasis exacerbation 
Plaque psoriasis 
*XWWDWHSVRULDVLV 
*XWWDWHDQGSODTXHSVRULDVLV 
Palmoplantar pustulosis 
a&RQ¿UPHGE\WKURDWFXOWXUHUDSLGDQWLJHQGHWHFWLRQWHVWRUDSK\VLFLDQ1KWWSZZZPHGLFDOMRXUQDOVVHDFWDFRQWHQW"GRL 
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2I WKHSDUWLFLSDQWV  KDGEHHQ WRQVLO-
OHFWRPL]HGDIWHUWKHRQVHWRISVRULDVLV7DEOH,9DQG
RIWKHVHUHSRUWHGWKDWWRQVLOOHFWRP\ZDVDVVRFLDWHG
ZLWKLPSURYHPHQWLQWKHLUSVRULDVLV,QWHUHVWLQJO\
RISDWLHQWVZLWKSODTXHSVRULDVLVDQG
of guttate patients noted an improvement in psoriasis 
DIWHUWRQVLOOHFWRP\7KLVDOVRDSSOLHGWRRI
SDWLHQWVZLWKERWKJXWWDWHDQGSODTXHSVRULDVLV 7DEOH
,93DWLHQWVZKRQRWHGLPSURYHPHQWDIWHUWRQVLOOHFWRP\
more frequently reported sore throat-associated aggrava-
WLRQp $OOSDWLHQWVZKRUHSRUWHGLPSURYHPHQW
after tonsillectomy also reported early onset of psoriasis.
',6&866,21
Psoriasis is a heterogeneous disease with respect to 
ERWKJHQHWLF   DQGSDWKRORJLFDO FRPSRQHQWV 
DQGVHYHUDOH[WHUQDOIDFWRUVKDYHEHHQUHSRUWHGWR
contribute to the onset and exacerbation of psoriasis 
±+RZHYHU VWUHSWRFRFFDO WKURDW LQIHFWLRQ LV WKH
only environmental factor that has convincingly been 
connected to the immunological mechanisms thought 
WR RSHUDWH LQ SVRULDVLV   HVSHFLDOO\ LQ SDWLHQWV
FDUU\LQJ WKH+/$&ZDOOHOH:LWK WKH+/$&ZDV
WKHPDMRUSVRULDVLVVXVFHSWLELOLW\DOOHOHWKH&'+ T cells 
are thought to be the major effector cells in psoriasis, as 
they may respond to peptide antigens presented in the 
FRQWH[WRI+/$&Z)XUWKHUPRUHFKURQLFVWLPXODWLRQ
by streptococci in the tonsils gives rise to a set of patho-
JHQLFVNLQKRPLQJ&/$+7FHOOV7KHOLQNEHWZHHQ
streptococcal throat infections and psoriasis is supported 
by several lines of research, including increased T-cell 
UHVSRQVHV WR VWUHSWRFRFFDOGHULYHG SHSWLGHV ±
shared T cell receptor rearrangements in psoriasis tonsil 
DQGVNLQKRPLQJDQGVNLQUHVLGHQW7FHOOVLQFUHDVHG
VWUHSWRFRFFDOUHDFWLYH LPPXQRJOREXOLQ* ,J* WLWUHV
LQWKHEORRGRISDWLHQWVZLWKSODTXHSVRULDVLVDQG
increased throat carriage rate of streptococci among 
SDWLHQWVZLWKSVRULDVLV2QFHJHQHUDWHGLQWKH
tonsils, skin-homing T cells can migrate to the dermis 
and epidermis, where they are thought to cross-react 
ZLWKVNLQGHULYHGHSLWRSHVVXFKDVNHUDWLQV
PDVSLQH]ULQ35';KVSRUPHODQRF\WH
GHULYHG SHSWLGHV  GULYLQJ WKH FXWDQHRXV LQÀDP-
mation characteristic of psoriasis. Several studies have 
indicated that psoriasis can improve after tonsillectomy 
EXWLQGLFDWLRQVIRUVXFKWUHDWPHQWUHPDLQWREH
established. However, most of the patients who have been 
treated in this way had a history of psoriasis exacerba-
tion in association with sore throats and/or streptococcal 
throat infections.
:H UHSRUW KHUH WKDW  RI SDWLHQWVZLWK SODTXH
psoriasis experienced worsening of their disease in 
DVVRFLDWLRQZLWKVRUHWKURDW)XUWKHUPRUHRIWKH
SDUWLFLSDQWVZLWKSODTXHSVRULDVLVDQGFRQ¿UPHGVWUHS-
tococcal throat infections reported exacerbation of their 
skin lesions. This is a higher frequency than previously 
UHSRUWHGE\:DUGURSHWDOZKHUHRISDWLHQWV
with plaque psoriasis associated worsening of psoriasis 
ZLWKVRUHWKURDWFRPSDUHGZLWKRIPDWFKHGHF]HPD
FRQWUROV1RWHRXUVWXG\ZDVGHVLJQHGDVDUHWURVSHFWLYH
questionnaire and could therefore be limited by recall 
bias. Sore throat-associated psoriasis aggravation was 
PRUHFRPPRQDPRQJZRPHQp ,WLVQRWFOHDU
why this gender difference exists, but it has been obser-
ved that women are more frequently affected with recur-
UHQWWRQVLOOLWLVWKDQPHQ)HPDOHVH[KRUPRQHVRU
altered skin corticosteroid levels might be involved, but 
we are not aware of any reports on this issue. To that end, 
it might be interesting to assess prospectively whether 
postmenopausal women are less sensitive to psoriasis 
exacerbation after a sore throat and/or a streptococcal 
throat infection. Patients reporting sore throat-associated 
aggravation of psoriasis also noted worsening in relation 
to various other aggravation factors, such as general 
PDODLVHVWUHVVDOFRKRORUFROGZHDWKHU1RWDEO\VXFK
associations were not reported by those participants who 
did not associate sore throat with psoriasis exacerbation. 
&KURQLFSODTXHSVRULDVLVKDVSUHYLRXVO\EHHQVXEGLYLGHG
LQWR VWDEOHDQGG\QDPLF W\SHV 3DWLHQWVZLWK WKH
G\QDPLFW\SHKDYHDPRUHÀXFWXDWLQJFRXUVHDSSHDUWR
EHPRUHLQÀXHQFHGE\WKHYDULRXVH[DFHUEDWLQJIDFWRUV
OLVWHGDERYHDQGDUHPRUHRIWHQFDUULHUVRI+/$&Z
than patients with a relatively stable disease. This form 
of plaque psoriasis has even been considered somewhat 
VLPLODUWRJXWWDWHSVRULDVLV%HVLGHWKHDVVRFLDWLRQ
between sore throat-associated psoriasis aggravation and 
other psoriasis exacerbating factors, our data also show 
that patients with early-onset psoriasis are more prone to 
sore throat-induced psoriasis aggravation. This suggests 
that these patients have the dynamic phenotype of plaque 
7DEOH ,,, Associations between sore throat-associated exacer-
bations and other factors reported to aggravate psoriasis 
Psoriasis 
exacerbating 
factors n
Patients with sore 
throat-induced 
exacerbation 
n
Patients without 
sore throat-induced 
exacerbation 
n p-value
*HQHUDOPDODLVH   65   < 0.001
&ROGFOLPDWH 162   < 0.001
Stress    < 0.001
Alcohol   68   0.005
Dieta    0.01
Drugsb     9   n.s.
a1RWVSHFL¿HGb,QFOXGLQJOLWKLXPEHWDEORFNHUVSHQLFLOOLQDQGPHWKRWUH[DWH
7DEOH ,9Effects of tonsillectomy reported by 56 patients with 
psoriasis who were tonsillectomized after onset of their psoriasis
,PSURYHPHQWDIWHUWRQVLOOHFWRP\n 
Plaque psoriasis 
*XWWDWHSVRULDVLV 
*XWWDWHDQGSODTXHSVRULDVLV 
1RWVXUHRUQRLPSURYHPHQWn 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psoriasis, and thus might be appropriate candidates for 
tonsillectomy. However, our study cohort was limited to 
,FHODQGLFSDWLHQWVZLWKSVRULDVLVDQG,FHODQG¶VJHRJUD
SKLFDOLVRODWLRQPLJKWKDYHLQÀXHQFHGWKHGHYHORSPHQW
of patients more affected by environmental trigger fac-
tors, such as streptococcal throat infections.
The tonsils are a major target for streptococcal infec-
tions in humans, which are the most common cause of 
EDFWHULDOSKDU\QJLWLV7KHKLJKOHYHORIVWUHSWRFRF-
cal throat carriage and infections in patients with plaque 
psoriasis is noteworthy, with the carrier rate for groups 
$&DQG*VWUHSWRFRFFLDVKLJKDV/RQJWHUP
treatment with antibiotics has not been effective for pso-
ULDVLV6WUHSWRFRFFLFDQH[LVWLQERWKWKHH[WUDFHOOXODU
and intracellular spaces, forming intracellular reservoirs 
inside endothelial cells and macrophages within the 
WRQVLOV$WEHVWDQWLELRWLFWKHUDS\RQO\PDQDJHVWR
reduce the bacterial load in the tonsils, leaving quiescent 
intracellular streptococci in the tonsillar epithelia and 
PDFURSKDJHV 7KHVH VWUHSWRFRFFL FDQ UHDFWLYDWH
re-colonize and cause symptoms again, whereas tonsil-
lectomy might remove this pool of streptococci.
This, and a number of other studies, support the as-
VRFLDWLRQEHWZHHQSVRULDVLV DQG VWUHSWRFRFFL ±
'HVSLWHWKHODFNRIODUJHFRQWUROOHGFOLQLFDOWULDOV
tonsillectomy is commonly advocated for patients with 
UHFXUUHQWJXWWDWHSVRULDVLV)XUWKHUPRUHDFFRUGLQJWRD
European expert group consensus, tonsillectomy may 
now be indicated for juvenile psoriasis patients with a 
SRVLWLYHVWUHSWRFRFFDOFXOWXUHDQGPRUHWKDQUHFXU-
UHQWLQIHFWLRQV2XU¿QGLQJVPLJKWKHOSWRLGHQWLI\
SDWLHQWVZLWKSODTXHSVRULDVLVZKRFRXOGEHQH¿WIURP
WRQVLOOHFWRP\EXW WKH\QHHG WREHFRQ¿UPHG LQSUR-
spective and more structured studies. 
$&.12:/('*(0(176
7KHDXWKRUVDUHLQGHEWHGWRWKHVWDIIDW/DQGVSLWDOL±7KH1D-
WLRQDO8QLYHUVLW\+RVSLWDORI,FHODQGGHUPDWRORJ\RXWSDWLHQW
FHQWUH+XGODHNQDVWRGLQGHUPDWRORJ\FOLQLFDQGWKH%OXH/D-
goon geothermal clinic for their assistance during the study. 
7KLV VWXG\ZDV VXSSRUWHG LQ SDUW E\ WKH ,FHODQGLF5HVHDUFK
)XQGDQG/DQGVSLWDOL8QLYHUVLW\+RVSLWDO5HVHDUFK)XQG$-
LV VXSSRUWHGE\1,+.$5 WKH1DWLRQDO3VRULDVLV
)RXQGDWLRQ86$DQGWKH%DEFRFN0HPRULDO7UXVW7KHIXQGLQJ
institutions had no role in the study.
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Supplementary material to article by R. H. Thorleifsdottir et al. ”Throat Infections are Associated with Exacerbation in a Substantial 
Proportion of Patients with Chronic Plaque Psoriasis”
Appendix S1. Questionnaire on frequency of psoriasis exacerbation during or after a sore throat.
The frequency of exacerbation of psoriasis during or after a sore throat 
 
Please answer as accurately as possible by writing or ticking the appropriate boxes for each question 
 
1. How old are you:_________________  
 
2. What is your gender:  
  Male    
  Female    
 
3. How old were you when you first noticed you had psoriasis:_______________________________ 
 
4. Did the first signs of your psoriasis appear during or within 3 weeks of having a sore throat (painful inflammation or infection or in the 
throat) or a streptococcal throat infection (strep throat)? 
  Yes    
   No   
   Unsure 
 
5. Has a dermatologist confirmed that you have psoriasis? 
  Yes    
   No   
   Unsure 
 
6. Which of the following statements describe your psoriasis best? (You may tick more than one box) 
 I have plaque psoriasis with raised, circular-to-oval red patches covered with silvery scales, for example on my scalp and/or knees, elbows 
 and lower back 
 I have guttate psoriasis with small (1-10mm), dot-like, fine scaled rash, mostly on my trunk and/or upper arms and legs 
 I have palmoplantar pustulosis (PPP) that appears as white blisters (pustules) surrounded by red skin in my palms and/or soles 
 I have psoriasis in my nails (all or some of these changes);  
 Pitting (small nail depressions, less than 1 mm in diameter) 
 Discolouration (circular areas resembling an oil drop) 
 Subungual hyperkeratosis  (thickening of the nails) 
 Onycholysis (separation of the nail from the nail bed) 
 I have psoriasis arthritis diagnosed by a dermatologist or rheumatologist  
 None of the above applies to my psoriasis 
 
7. Have you experienced worsening of your psoriasis during or within 3 weeks after having a sore throat? 
  Yes    
   No    
   Unsure 
 
8. How many times during the past 12 months have you had a sore throat? 
  Never  4  8 
  1  5  9 
  2  6  >10 
  3  7 
 
9. Have you been diagnosed with a streptococcal throat infection (strep throat) by a physician, a throat swab or a rapid strep test? 
  Yes        
   No     
   Unsure 
 
10. If yes, how many times____________________________________________________________ 
 
11. Did you notice worsening of your psoriasis during or within 3 weeks after having a streptococcal throat infection (strep throat)? 
  Yes        
   No     
   Unsure 
 
12. Have you experienced worsening of your psoriasis in association to the following? (You may tick more than one box) 
  General sickness    
  Stress  
  Cold weather 
  Alcohol 
  Food, what food________________________________________________ 
  Pregnancy 
  Medication, which medication?____________________________________ 
  Other, what?___________________________________________________ 
 
13. Have you had your tonsils removed (had tonsillectomy)? 
  Yes    
   No    
   Unsure 
 
14. If yes, at what age were your tonsils removed_______________________________________________ 
 
15. Did your psoriasis improve after the tonsillectomy? 
  Yes    
   No    
   Unsure   
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